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Abstract

Grainyhead-like 2 Reverses the Metabolic Changes Induced by the Oncogenic
Epithelial-mesenchymal Transition: Effects on Anoikis

Joshua C. Farris
When deprived of connections to their extracellular matrix, normal epithelial cells
trigger a process of programmed cell death referred to as anoikis. The transcriptional
reprogramming event known as Epithelial-Mesenchymal transition (EMT) confers anoikis
resistance and ultimately, increased metastatic potential. Distant metastatic disease
contributes to the majority of deaths occurring in many cancer types, especially those
originating in breast tissue. The ability to metastasize depends critically upon a cancer cell’s
ability to evade anoikis. Heterogeneity of tumors containing anoikis, therapy resistant
populations likely explains the tendency of disease to reappear in distant locations after a
period of apparent remission. The wound healing transcription factor, Grainyhead-like 2
(GRHL2), has been previously demonstrated to play an indispensable role in the
maintenance of the epithelial phenotype through both suppression of EMT and promotion
of the reciprocal event, Mesenchymal-Epithelial transition (MET), accompanied by
suppression of the cancer stem cell (CSC) phenotype and re-sensitization to anoikis. Loss of
GRHL2 expression is associated with aggressive, metastatic breast tumor types such as
claudin low and basal B subclasses of tumor cell lines. Specifically, GRHL2 expression is lost
in the cancer stem cell-like compartment of tumors characterized by their enrichment in the
CD44hi/CD24low cell population and an EMT phenotype. Constitutive expression of the
epithelial enforcer GRHL2 results in increased anoikis sensitivity as well as reduction in
tumor initiating frequency. Here, the effects of GRHL2 upon intracellular metabolism in the
context of reversion of the EMT/CSC phenotype, with a view toward understanding how
these effects promote anoikis sensitivity were investigated. EMT resulted in enhanced
mitochondrial oxidative metabolism. While this was accompanied by higher accumulation of
superoxide, the overall level of Reactive Oxygen Species (ROS) declined, due to decreased
hydrogen peroxide. Glutamate Dehydrogenase 1 (GLUD1) expression increased in EMT, and
this increase, via the product α-ketoglutarate (α-KG), was important for suppressing

hydrogen peroxide and protecting against anoikis. GRHL2 suppressed GLUD1 gene
expression, decreased α-KG, increased ROS and sensitized cells to anoikis. These results
demonstrate a mechanistic role for GRHL2 in promoting anoikis through metabolic
alterations.
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Chapter 1
Introduction and Literature Review

1

Epithelial-to-Mesenchymal Transition

Epithelial vs. Mesenchymal Cell Adhesion/Polarity

The major role of epithelial tissues is to function as barriers to physiologically

separate compartments. Epithelial cells display a unique gene expression profile relative to

mesenchymal cells which endows them with the ability to achieve the two major

characteristics of epithelial tissues: cell-cell adhesion and cell polarity. Phenotypically,
epithelial cells have a tendency to exist as a monolayer in a classically described cobblestone
pattern appearance often seen in two-dimensional tissue culture.

These epithelial

monolayers are maintained due to the expression of specific epithelial proteins including E-

cadherin, occludins, desmogleins, claudins, and desmocollins located at cellular junctions (1-

3). In vivo, however, epithelial cells generally polarize resulting in one side of cells attaching
to extracellular matrix (ECM) with its basal side attached to the basement membrane, while
the apical surface is oriented toward the lumen of a vessel or duct. Epithelial cells rely on

basolateral membrane interactions in order to survive (see section on anoikis below). Cells

maintain polarity through organization of tight junctions via claudins and occludins, which
restriction the diffusion of integral membrane proteins from apical to basolateral

membranes (4). Rab25 and Ankyrin G are epithelial-specific proteins found in the cytosolic
compartment of cells which act to ensure proper localization of junctional proteins (5, 6). A
major example of how the epithelial architecture maintained by cell-cell adhesion molecules

contributes to the gene expression profile of epithelial cells is that of Epithelial-cadherin, or
E-cadherin. The extracellular domain of E-cadherin functions to interact homophilically with

the extracellular region of adjacent cell E-cadherin proteins. The intracellular domain acts
2

to orchestrate cortical actin assembly, cell polarity, and influences gene expression through
sequestration of β-catenin, all contributing to the epithelial phenotype (7, 8).

Conversely, mesenchymal cells either do not express, or express very low levels of

many of the previously mentioned junctional proteins. In fact, a microarray comparison of

epithelial vs mesenchymal gene expression profiles reveals that these two phenotypic cell
variants differ dramatically (9).

The inability to produce tight junctions, adhere with

neighboring cells, and thus establish apical-basolateral polarity results in failure to maintain

barriers like their epithelial counterparts. Mesenchymal cells tend to migrate as individual

cells, and they are generally significantly more invasive (10). Due to these features,
mesenchymal cells lack the same dependence on their extracellular matrix for survival as do

epithelial cells, resulting in their resistance to cell death when detached from their matrix

(see anoikis section below) (11-15). In addition to the loss of cell adhesion and polarity
associated proteins, mesenchymal cells gain expression of other mesenchymal markers such

as N-cadherin, vimentin, fibronectin, and upregulation of transcription factors associated
with repression of the epithelial phenotype (more on this in a later section).

Whereas epithelial cells tend to form linings of organs or ducts due to their ability to

establish strong barrier compartments, normal mesenchymal cells in adults tend to be
involved in establishment of the extracellular matrix, as is the case with normal adult

fibroblasts, or they give rise to other tissue types altogether, as is the case with Mesenchymal

stem cells (MSCs).
chondrocytes.

For example, MSCs can give rise to adipocytes, osteoblasts, and

Epithelial-to-Mesenchymal Transition: Role in Normal Physiology
3

The epithelial-mesenchymal transition (EMT), a process implicated in cancer

progression as well as other pathogenic processes such as fibrosis, describes a major shift

which endows epithelial cells with characteristics of mesenchymal cells including disruption

of cell-cell adhesion, acquisition of increased motility and invasiveness, chemotherapeutic
resistance, and resistance to anoikis. While cellular plasticity between these two states can

drive the progression of disease, in the context of normal physiological function, EMT and its

converse process termed mesenchymal-to-epithelial transition (MET), are indispensable to
events such as embryological development and wound healing (16).

Three separate

categories of EMT have been described which vary based on the tissue involved as well as

the resulting changes (17). Type 1 EMT refers to implantation, embryo formation, and organ
development. For example, both Snail1 and 2, well established EMT associated transcription

factors, are required in early embryogenesis, as it has been demonstrated that embryos

depleted of these factors fail to gastrulate as a result of unyielding epithelial junctions of
mesodermal cells, preventing formation of the primitive streak (18, 19). The importance of

EMT plasticity is also displayed soon after primitive streak formation, where strong

epithelial junctions are required for neural tube closure, which is followed immediately by

an EMT event which is required during neural crest delamination (20-22). These EMT’d

cells then migrate away from the neural tube only to MET in order to develop into structures
such as the somites and the notochord (23).

In adults, wound healing is a dynamic process that requires plasticity between

epithelial and mesenchymal states. Type 2 EMT refers to the cellular transitions that occur

during wound healing, tissue regeneration, and organ fibrosis. Epidermal wound healing
4

requires the activity of myofibroblasts both for wound contractility as well as restructuring
of the extracellular matrix. Keratinocytes at the wound border recapitulate the process of

EMT by exhibiting a partial EMT or “metastable” phenotype in which they are able to move,
advancing an attached epithelial sheet rather than invading as individual cells (23, 24). TGF-

β induced EMT of epithelial cells also occurs within an organ in some pathogenic states, and
this can contribute to the tissue fibrosis wherein fibroblasts generate excessive levels of

collagen (25).

EMT and Oncogenesis
Aberrant regulation of normal cellular processes such as cellular proliferation and

growth are common features to many malignancies. EMT is another example of a normal
process that is often employed inappropriately in the context of cancer progression. Type 3

EMT refers to plasticity between epithelial and mesenchymal states that results in metastatic

progression of malignant disease. A multitude of (epi)genetic changes can alter oncogene
and tumor suppressor expression resulting in neoplastic growth. This growth is typically
characterized by increased proliferation and angiogenesis.

Many cues in the

microenvironmental milieu can influence cell fate and result in induction of EMT such as

nutrient or oxygen starvation (26, 27). It is well established that oncogenes are known to
induce senescence in some contexts. There is evidence to suggest that cancer cell EMT

events may play a role in the escape of oncogene-induced senescence, thereby leading to the

acquisition of many deleterious traits by cancer cells (28-30). These traits will be detailed

below.

5

Migration, Invasion, and Chemotherapeutic Resistance
While aberrant epithelial cell proliferation and angiogenesis are indeed early

hallmarks in the initiation of epithelial cancers, the major event which signals the onset of

metastatic dissemination of these carcinomas is invasion, often conferred by EMT, leading to

cancer cells passing through the basement membrane (17, 31). A widely studied feature that

EMT induces in carcinomas is the gain of migratory and invasive properties, as this is
considered the final stages in the cascade of oncogenesis leading to metastatic dissemination
of disease. The association of EMT with invasion has been observed in many in vivo and in

vitro experimental models in which carcinoma cells acquire mesenchymal traits and
upregulate mesenchymal markers such as α-SMA, FSP1, vimentin, and desmin at the invasive

front of primary tumors – the ultimate result being the activation of the metastatic cascade

including intravasation, circulatory transport to a secondary site, extravasation and
formation of micrometastases (17). Generally speaking, one of the major alterations that

occurs as a result of EMT that influences this invasion is the loss of the cell-cell adhesion

intermembrane protein E-cadherin. Experimentally, enforced expression of E-cadherin

abrogates invasive properties in cancer cells, and clinically, expression of E-cadherin is

associated with lower risk of tumor invasion (32-35). E-cadherin may block these invasive
traits either physically, a result of homophilic interactions with the extracellular domain of

other E-cadherin molecules favored more highly than interactions with extracellular matrix.

This invasive phenotype is also influenced through other pathways that E-cadherin interacts

with such as polarity complex interactions, sequestration of pro-survival factors such as

NRAGE, β-catenin, YAP/TAZ (signaling molecules involved in HIPPO signaling), and Smad3
(critical for TGF-β signaling). These pathways will be discussed further in discussions of
6

anoikis below. In addition to the association with metastatic phenotype, EMT also confers

upon cancer cells the pro-survival effects of chemotherapeutic resistance to cytotoxic
chemical agents and radiation which have been extensively documented (36-39).

EMT confers Cancer Stem Cell Properties
It was long ago hypothesized in pioneering work, originally in the context of

hematological malignancies, that only a small subpopulation of the leukemic cancer cell lines
has the intrinsic ability to recapitulate the original disease (40-43). This notion has held true

in solid tumors as well, specifically in the context of breast and brain cancers (44, 45). This

subpopulation is known as cancer stem cells (CSC) or tumor initiating cells (TICs). There are

several explanations for the origins of these populations in tumors. For example, it was
demonstrated by Eric Landers group that phenotypic equilibrium between non-CSC and CSC

populations are the result of “stochastic state transitions” which is predictable given a
particular mathematic algorithm (46). It has also been reported that EMT results in the

acquisition of stem cell markers, an increased ability to form mammospheres as well as
increase in the ability to seed tumors in animal hosts, both well-established characteristics
of stem cells (47). Subsequent work has demonstrated that it is possible to physically

segregate two populations from a single tumor sample which differ in their cell-surface

antigen marker profiles (eg. CD24 and CD44 cell surface markers in the case of breast
cancer). Of critical importance is the observation that when re-implanted in vivo, these CSC

populations then produce tumors which are pre-dominantly not CSCs, demonstrating their
stem cell-like self-renewal properties. These observations present a unique challenge to

therapeutic intervention in that if any CSCs are not eradicated in the treatment of the
7

primary malignancy, they contain the ability to regenerate the entire disease in the form of
local recurrence or even drive the emergence of distant disease at metastatic nodes.

The field of CSCs/TICs is quite controversial, both in terms of their origin as well as

what percentage of the total malignancy they truly comprise (44). A common CSC surface
profile used in the case of breast cancer is the CD44HIGH/CD24LOW phenotype which has been

used to isolate the tumorigenic from the non-tumorigenic population (45). It was shown by

Mani et al. that normal immortalized human mammary epithelial (HMLE) cells display a

phenotypic conversion toward the CD44HIGH/CD24LOW phenotype following induction of the
EMT program (47). It has also been demonstrated that a distinct group of EMT’d cells exists

within the epithelial HMLE cell line termed MSP or mesenchymal-subpopulation which is

dependent on paracrine and autocrine signaling pathways including TGF-β, canonical as well
as noncanonical Wnt activation, as well as BMP pathway inhibition (10).

A recent

publication by Scheel et al. however, demonstrated that transient Twist1 activation

permanently alters cell state and primes epithelial cells for stem cell-like properties which
did not require permanent acquisition of the EMT phenotype (48). This finding informs the

intimidating reality that any tumor cell subjected to the proper conditions in the tumor

microenvironment may undergo EMT and thus potentially become a cancer stem cell
highlighting the need for targeted therapy to eradicate this subpopulation.

The extent of involvement of EMT/MET in the area of metastasis is an area of

controversy in the field currently. Reversion of mesenchymal to epithelial cells in some
contexts has been shown to enhance metastatic colonization (17).

This has led to the

establishment of a theory opposing the prevailing dogma that instead of EMT as a culprit for
metastasis, MET is the critical event which ultimately leads to the establishment of
8

secondary tumors and eventual death of cancer patients.

For example, it has been

demonstrated by Nieto and colleagues that downregulation of the EMT inducing homeobox

transcription factor Prrx1 is required for cancer cells to seed metastatic locations in vivo;

however, it was noted in this study that Prrx1 overexpression does not induce cancer stem
cell-like traits as does ZEB1, Twist, or Snail mediated EMT events as previously described

(47, 49-51). In fact, breast cancer metastases are typically epithelial and express E-cadherin

(52). However, it is undeniable that EMT invokes many traits in cancer cells associated with
aggressiveness, invasion, anoikis resistance, therapeutic resistance, and tumor recurrence.
A potential reconciliation of these views are that EMT/MET plasticity is in fact the major
force to endow cancer cells with their malignant properties.

An extension of this

interpretation would imply that either EMT or MET could be viewed as tumor suppressive

or oncogenic events depending on the stage of disease progression. This observation that
metastatic tumors often do not resemble the mesenchymal cells which gave rise to them is

likely a consequence of differing local microenvironmental stimuli encountered following

extravasation into distant organs, where the stress signals initially invoking EMT in the
primary tumor are no longer present (31, 53, 54). It is clear that a better understanding of

the major regulators of EMT and MET is critical in order to prevent the emergence of
treatment resistance metastases and recurrence.
Regulation of EMT

EMT Induction – Transcription Factors
Many factors are known to induce EMT. These factors far outweigh the number of

EMT inhibitory elements. A multitude of extracellular signals originating from the stromal

tissue associated with the primary tumor are known to stimulate the EMT program including
9

HGF, EGF, PDGF, and TGF-β. These growth factors activate a horde of receptors to ultimately
result in the induction of many proteins including major EMT inducing transcription factors
such as Snail, Slug, Twist, Goosecoid, FOXC2, and ZEB1. Many of these factors when
overexpressed alone, can lead to the orchestration of the EMT program, while the

mechanism varies. Snail and ZEB1, well established E-box binding transcription factors,
function as direct repressors of epithelial genes such as E-cadherin (55-58). Twist,

Goosecoid, and FOXC2 are inducers of EMT which coordinate through more indirect means,
typically through Snail or ZEB1 upregulation (9, 23). Supporting the view of the role of

oncogenic EMT, overexpression of these transcription factors leads to progression of
malignancy in multiple models.

Very well characterized signaling networks including PI3K, Akt, ERK, MAPK, Ras,

RhoB, β-catenin, LEF, c-FOS, and Smad are critical components of the implementation of the

EMT program (17). Cell surface integrins also play a role in the activation of EMT, enabled

by the disruption of cell-cell and cell-matrix adhesions (30, 47, 59). As previously mentioned,

YAP and TAZ, critical components of the Hippo signaling pathway, are examples of pro-

survival transcription factors that are also sequestered by cell-cell and epithelial cell polarity
complexes (9, 60). Homeoproteins such as HOXA5, LBX1 and SIX1 are further examples of

well-established TFs involved in developmental EMT which also play a role in the oncogenic
EMT, through direct transactivation of the ZEB1 promoter (61-63).

TGF-β superfamily ligands bind to TGF-βR1/R2 heterodimeric receptors resulting in

the serine phosphorylation of Smad2/3 (often referred to as R-Smads or receptor regulated
Smads), which then can bind Smad4, resulting in nuclear translocation and upregulation of

many genes ranging from growth inhibitory to EMT activating genes such as ZEB1 (64, 65).
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It is in large part this enormous range of regulated genes that gives the TGF-β-Smad2/3 axis

its context dependent, and seemingly paradoxical effects of either oncogenesis or tumor

suppression (66, 67). Recently published work by our lab shines some light on what

determines which response a cell line will have to TGF-β signals (ie. Growth arrest vs EMT).
This will be discussed further below in the section on Grainyhead-like 2.
Inhibition of EMT

As is evident above, many factors contribute to the induction of the EMT process;

however, there are relatively fewer inhibitors of oncogenic EMT. Included in this list are
BMPs, the mir200 family, ESRP1/2, and the human homologue of drosophila Grainyhead,

Grainyhead-like 2 (GRHL2). BMPs or Bone Morphogenetic Proteins, named for their ability
to induce formation of bone and cartilage, belong to the TGF-β superfamily (68). BMPs

represent a major class of EMT inhibitors which induce MET through inhibition of TGF-β

signaling. Overexpression of BMP family members has been shown to enforce the epithelial

phenotype, and pharmacologic studies have verified that TGF-β receptor inhibition results

in effects mimicking that of BMPs (10, 68-70). Further, the BMP functional inhibitors chordin
and gremlin are known to enhance TGF-β induced EMT (71). This signaling is accomplished

via BMP ligand binding to BMPR1A/R1B heterodimeric complexes resulting in R-Smad1/5
phosphorylation, which complete with R-Smad2/3 for binding to Smad4 (70).

EMT is further controlled by microRNAs, specifically those of the miR-200 family.

These small noncoding endogenous regulators of gene expression have been shown to be

downregulated during EMT, and their enforced expression inhibits TGF-β induced EMT and
is sufficient to initiate MET in mesenchymal populations (72). It has been well established

that the primary mechanism by which the miR-200 family acts to enforce the epithelial
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phenotype is through post-transcriptional repression of ZEB1/2, and in fact, a negative

feedback loop has been demonstrated such that ZEB transcription factors transcriptionally
repress miR-200 expression (64, 72-76).

Yet an additional example of post-transcriptional regulation of the EMT phenotype is that

of the mRNA splicing factors ESRP1 and ESRP2. These splicing regulatory proteins are

downregulated during EMT. Their depletion by shRNA results in EMT associated with loss
of cell polarity and characteristic upregulation of fibronectin, a mesenchymal associated

extracellular matrix glycoprotein, and the intermediate filament vimentin. Interestingly, it

has been reported that loss of ESRP1 and 2 contributes to the acquisition of EMT traits by
independent mechanisms. Stable knockdown of ESRP1 has been shown to result in change
in cell motility via induction of Rac1b, whereas loss of ESRP2 results in abrogated cell-cell

adhesion through induction of EMT associated transcription factors (77).

Finally, another major negative regulator of EMT is one of the three mammalian

homologues of drosophila Grainyhead, known as Grainyhead-like 2 (GRHL2 - also known as

TFCP2L3 or BOM). GRHL2 represses the oncogenic EMT through multiple mechanisms

including direct repression of the ZEB1 promoter, upregulation of miR-200b/c, upregulation

of BMP2, and inhibition of TGF-β-Smad2/3 mediated transcription (78, 79). These and other

findings have established GRHL2 as a master regulator of the epithelial phenotype and
repressor of EMT plasticity. A more detailed review of the functions of Grainyhead-like 2
transcription factor in the context of cancer will be presented in a later section.
Anoikis
Physiological Role of Anoikis
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Normal epithelial cells undergo a program of apoptosis when detached from their

ECM or when attached to an inappropriate matrix termed “anoikis”(11). Anoikis, the Greek
word meaning “homelessness,” is a normal apoptotic process which ensures epithelial cells,

which are often shed at a high frequency, are eradicated, such as in the case of skin or colonic

epithelium (15). The process of anoikis ensures that cells are unable to take up residence in

inappropriate locations. What factor(s) establish sensitivity vs resistance to anoikis has
been the major question in the field since its discovery.

This is of significant importance in the case of oncogenic transformation of cells.

Anoikis prevents the translocation of cells which have (epi)genetic changes from attaching

elsewhere and exploiting their growth/survival advantages at these secondary locations.

Metastasis of cancer cells requires the suppression of anoikis (80-83). The apoptotic

mechanism induced by detachment is not specific to this context, and is regulated by normal
death-effector machinery common to other forms of cell death signaling pathways (84).
Therefore, regardless of the exact mechanism of activation, these signals typically culminate
with mitochondrial outer membrane permeabilization (MOMP), resulting in the release of

cytochrome c generating a caspase-9 containing apoptosome, ultimately activating effector
caspases. Bcl-2 family proteins play anti/pro-apoptotic roles upstream of mitochondrial

membrane permeabilization, cytochrome c release, and apoptosome formation as in other

apoptotic settings. In this vein, BH3-only family genes (including Bim, Bad, Bmf, Noxa, and

Puma) are exquisitely sensitive to integrin-assisted signal transduction, and these pathways

have been widely characterized in the setting of anoikis (85). For example, Bim, a BH3-only

family protein, has been shown to act as a mediator of anoikis dependent on β1-integrin
engagement, EGFR downregulation, and inhibition of the Erk pathway in detached basal
13

mammary epithelial cell line MCF10a cells (86).

While the results do not appear

generalizable to all cell lines or contexts, death receptor signaling has been reported to be

involved in anoikis signaling such that the FAS-associated death domain protein (FADD) has
been shown to contribute to anoikis sensitivity, though the precise mechanisms are unclear
(87).

The influence of other inputs upstream of the apoptotic machinery which influence

anoikis such as reactive oxygen species and metabolism have been topics of significant

recent research. The contribution of these variables to differences in anoikis sensitivity

endowed by the epithelial-mesenchymal transition is poorly understood however, and will
be discussed further below.

The Oncogenic Epithelial-to-Mesenchymal Transition Confers Resistance to Anoikis
Among their many deleterious traits, metastatic tumor cells have a compromised

anoikis response (14, 88). As discussed previously, EMT is generally viewed as a major

contributory program driving metastasis. In addition to increasing migratory and invasive

properties, it has become well established that EMT also induces anoikis resistance in cancer

cells (14, 89, 90). As was alluded to earlier, many of the core cellular signaling pathways
involved in the implementation of the EMT program such as PI3K/Akt and MAPK activation
also contribute to cell survival in general, anoikis being no exception (91).

E-Cadherin: Ankryin-G, Wnt/β-catenin and TGF-β, and HIPPO Contribute to Anoikis
In the seminal work in which anoikis was first identified, epithelial cells, specifically

Madin-Darby canine kidney epithelial (MDCK) cells, were noted to be exquisitely sensitive
14

to this mode of apoptosis, especially when grown to confluence, an observation also reported
elsewhere (11, 92).

While the mechanism contributing to this phenomenon is not fully

explained, several points of evidence point to a major role of the cell-cell adhesion protein Ecadherin to explain these findings. In a p53-dominant negative tumor model, depletion of Ecadherin in a conditional knockout significantly increased tumor metastasis in vivo;

moreover, the resulting cell lines produced from this study were anoikis resistant compared

to their E-cadherin positive counterparts (93). These findings have also been further
generalized to include the Human Mammary Epithelial Cell line (HMLE) cells (94).

Interestingly, the major characterized pathways upstream of anoikis resistance observed in
mesenchymal cells have a common node emanating from the cell-cell junctional protein E-

cadherin. These pathways include the Ankryin-G/NRAGE/p14ARF, Wnt/β-catenin, and the

HIPPO/YAP/TAZ pathways. While these pathways contribute in individual ways to both

EMT, and its conferred anoikis resistance, they are highly interrelated, resulting in significant

cross talk between each pathway (95). Each of these pathways and their contribution to
anoikis resistance in the context of EMT will be outlined below.

Our lab previously reported the role in anoikis of the E-cadherin associated gene,

Ankyrin G (Ank-3), an epithelial cytoskeletal linker protein responsible for sequestration of
the transcription factor NRAGE.

NRAGE was found to be sequestered by Ankyrin-G,

preventing its nuclear translocation where it typically represses the pro-apoptotic gene
p14ARF; however, in the context of EMT, E-cadherin and Ankyrin-G downregulation result

in unhindered NRAGE to undergo nuclear translocation, repress p14ARF and contribute to
anoikis resistance (12). E-cadherin further influences anoikis sensitivity by way of the

Wnt/β-catenin signaling axis.

In the context of E-cadherin depletion, which by its
15

intercellular domain acts to sequester β-catenin, HMLE cells exhibited an increase in βcatenin phosphorylation, stability, and nuclear translocation, resulting in transactivation of
target genes and anoikis resistance (94).

Apical/baso-lateral polarity was described above as a major trait of epithelial cells -

one that is lost during EMT, either by downregulation of these components or failure of

proper localization (96-98). Crumbs, Par and Scribble are polarity complexes in normal
epithelial cells which contribute to apical, apical/basolateral border, and basolateral side

polarity, respectively (99). The HIPPO kinase pathway has previously been well established
as a critical regulator of organ size during development (100). Cell-cell contacts promote the
formation of the polarity complexes Crumbs, Par, and Scribble; interactions of the HIPPO
signaling pathway with these complexes results in phosphorylation and cytoplasmic

sequestration of the pro-survival factors YAP/TAZ (95, 101, 102).

When in their

unphosphorylated forms, YAP/TAZ are localized to the nuclear compartment, where they

interact with Smad proteins (TGF-β signal transducers discussed previously) to activate a

large variety of target genes. Loss of cellular polarity is thought to result in resistance to

anoikis, at least in part, through deficient HIPPO kinase cascade activation where

cytoplasmic retention of YAP/TAZ transcriptional co-activators is lost, resulting in nuclear

translocation and repression of pro-apoptotic protein Bim. Further evidence that cell
polarity established through HIPPO kinase cascade is linked to anoikis was shown where
luminal clearance, a process in which anoikis is required, was shown to be reliant on the cell
polarity complex Scribble assessed by MCF10a mammary morphogenesis assays (103).

Of note, the apoptosis stimulating protein of p53 effector protein, ASPP1, acts as an

activator of YAP/TAZ transcriptional activity through inhibition of kinases LATS1 or LATS2,
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which normally modify these survival co-activators such that they are tagged for nuclear

export and degradation. It has been reported that ASPP1 mediated downregulation of Bim
mediates cell survival, enhanced cellular migration, and anoikis resistance, indicating an

oncogenic role of this HIPPO associated protein, although the exact mechanism of Bim

downregulation is unclear at present (104). Further, EMT induced mislocalization of

scribble resulting in TAZ activation and increased anoikis resistant mammospheres (102).
Hippo signaling may explain the initial observations of increased sensitivity to anoikis of
confluent MDCK cells, as it has been reported that the Crumbs complex acts as a mode of

sensing cellular density, and these signals are relayed through YAP/TAZ interaction with the

TGF-β pathway (105).

Alternative to inhibition of direct transactivation of pro-survival target genes of YAP

and TAZ, the HIPPO pathway also functions to inhibit the Wnt and TGF-β pathways, both of

which contribute to EMT and anoikis resistance (described above). This is accomplished

through direct protein-protein interactions of phosphorylated forms of YAP/TAZ with the

Crumbs polarity complex and Smads, resulting in inhibition of both pathways. Therefore,

cellular polarity is able to regulate TGF-β signaling beyond E-cadherin direct sequestration

of β-catenin. This is accomplished through YAP/TAZ binding to Smad3, which relies on
receptor mediated phosphorylation through TGF-βR1/R2. LATS1/2 phosphorylation of
YAP/TAZ results in sequestration of these factors to the cytoplasm, effectively binding

Smad3 to this compartment as well (95, 106) . Therefore, upon loss of cell polarity, Smad
sequestration by YAP/TAZ is inhibited, allowing for further reinforcement of EMT through
TGF-β signaling. It has also been demonstrated that phosphorylation of YAP is regulated

through a integrin-matrix interaction involving actin-tubulin rearrangement where cell
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detachment activates LATS1 and LATS2 resulting in YAP sequestration (107). Cross talk of

the HIPPO pathway with Wnt activation is also present, as it has been demonstrated that

through Casein Kinase I (CKI), YAP and TAZ interact with the disheveled homologue Dvl,
inhibiting its activation, resulting in canonical Wnt inactivation (108). Thus, these findings
demonstrate the multiple levels of regulation on the HIPPO pathway and cross-talk between

other critical pathways for control of anoikis and demonstrates how these are influenced by
the EMT phenotype.

Interestingly, there are cellular polarity complexes whose role in contributing to

anoikis pathways seems limited or context dependent. Loss of scribble in keratinocyte

models have revealed alterations in cell invasion with very little effect on anoikis; however,
depletion of Dlg1 (disc large homologue 1) results in maintenance of cell polarity but
significantly suppresses anoikis (109).

Direct Influence of EMT regulatory Transcription Factors on Anoikis
Above, an indepth review of major transcription factor regulation of the process of

EMT itself was given. Here, the modification by these EMT associated transcription factors
to the core apoptotic machinery will be described. As was mentioned earlier, the major E-

box binding transcription factors Snail, Slug, Twist, and ZEB1/2 act predominantly as

transcriptional repressors of the major adhesion genes such as E-cadherin, and those

components contributing to the formation of tight junctions and desmosomes. Given the
known critical function of maintenance of cell polarity on preserving anoikis sensitivity, it

follows that these EMT factors which disrupt cell polarity will indirectly result in
suppression of anoikis due to dysregulation of the pathways described above.
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These transcription factors also contribute to the acquisition of anoikis resistance

through regulation of cell-survival factors as well. ZEB1 represses the pro-apoptotic gene

Tp73 through direct E-box binding to intron 1 (110). Snail has been described to contribute

to cell survival pathways through upregulation of MAPK and PI3K signaling pathways (111).

Both, Snail and Slug have been reported to promote resistance to cell death through direct
transcriptional repression of pro-apoptotic genes such as BID and caspase-6 (112). Snail also

has been shown to suppress genes associated with p53-mediated apoptosis, promoting cell

survival (113). The pro-apoptotic gene p14ARF was described above as the major target of

the Ankyrin-G sequestered transcription factor NRAGE, which is released following EMT

(12). Myc induced apoptosis has been shown to rely on formation of the pro-apoptotic Myc-

ARF complex (114). Twist mediates direct repression of p14ARF, preventing apoptosis by

interfering with the ability of Myc to form this complex, thereby collaborating with Myc to
result in a transformed phenotype rather than inducing cell death (115). The transcriptional

co-repressor CTBP is generally required for EMT induction and attenuation of anoikis (55).

Mechanistically, this may occur through ZEB1 co-repression of E-cadherin (15), but it has
also been demonstrated that CTBP can repress Bik (Bcl-2-interacting killer) resulting in
further repression of the anoikis response (116).

In some contexts, NF-κB is a critical component of EMT initiation in response to

inflammatory pathway activation (117, 118). This signaling pathway has also shown to be
critical for anoikis regulation in both the context of intestinal epithelial cells, as well as in

basal breast mammary epithelial cells where DBC1 was reported to stimulate NF-κB

pathway activation through direct interaction with IKK-β, stimulating its kinase activity,

which increased NF-κB transcriptional upregulation of c-FLIP and bcl-xl survival factors
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(119, 120). Other pro-survival target genes of this pathway include several members of the

IAP (inhibitor of apoptosis) family, bcl-2, CFLAR, survivin, and XIAP (15).

Survivin

specifically has been shown to mediate anoikis resistance via complex with XIAP which

activates transcriptional activity of NF-κB to result in fibronectin increase which maintains
clustering and β1-integrin signaling to rescue from anoikis (121).
FAK and ILK signaling pathways– Anoikis and EMT
Activation of FAK and ILK pathways results in suppression of anoikis (92, 122). This

is generally by promoting the epithelial-mesenchymal transition resulting in the repression
of epithelial adhesion genes such as E-cadherin through multiple pathways; however FAK

has been reported to influence expression of multiple E-box binding transcription factors

such as Snail, Twist, and ZEB1/2 (123). Co-localization of these proteins with integrins links

activation of these pathways with integrin-ligand cell-ECM interactions (124-126). FAK and

ILK are activated by attachment to matrix components such as collagen and influence EMT
inducing machinery as well as are activated by growth factor induced EMT (mediated by
TGF-β, EGF, HGF, etc.) (127-130).

While EMT linked anoikis resistance appeared to be an insurmountable obstacle to

cancer researchers for many years, the emergence of master regulators of the epithelial
phenotype (e.g. GRHL2) give hope to the possibility that EMT suppression and enhancement

of anoikis sensitivity in cancer cells might be a therapeutic possibility through determination
of pathways which suppress these important transcription factors (of significant interest are

the Wnt, TGF-b, and BMP pathways). This would inform treatment protocols and may
greatly reduce metastasis and disease recurrence usually associated with the EMT
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phenotype.

The mechanisms of GRHL2 induced MET and anoikis sensitivity will be

discussed in great detail in later sections. First, alternative contributors to the induction of
anoikis will be highlighted.
Reactive Oxygen Species
Reactive Oxygen Species and Intratumoral Cellular Metabolic Needs
It is not fully clear why cancer cells initially engage a program of phenotypic and

(epi)genetic alterations, such as EMT, that ultimately culminate with leaving their primary
site. This has pointed to the idea that a problem exists in their primary microenvironment.
Oncogenic mutations in tumors generally lead to properties that are advantageous to the

tumor in the short term such as increased proliferation; however, the primary site in which
they are located typically lacks the vasculature to support this activity, leading to challenges
such as lack of carbon source nutrients, hypoxia, and resulting reactive oxygen species
accumulation.

In some cases, oncogenic alterations may in fact be harmful and threaten cell survival.

As was mentioned earlier, c-Myc forms a complex with p14ARF, which, if not accompanied
by defects in the basic apoptotic machinery, will lead to devastating consequences. In the

case of oncogenic EMT, E-cadherin and the associated cytoskeletal linker protein, AnkyrinG, are downregulated, resulting in NRAGE nuclear translocation and suppression of p14ARF,

which is also directly suppressed by Twist activation (12).

Prior to an increase in

angiogenesis, the rapidly proliferating tumor cells can be exposed to hypoxic conditions.
This results in the need for tumor cells to increase their anabolic processes in the face of
anaerobic conditions.
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There is evidence that these challenges to the tumor microenvironment may be the

very driving force to invoke adaptive changes such as the EMT transcriptional program. This

is demonstrated by observations that in hypoxic conditions, HIF1α stabilization occurs,

resulting in the induction of a myriad of genes to combat the hostile environment. Hypoxia,
paradoxically, results in the generation and accumulate of reactive oxygen species (80).
Stabilization of HIF1α, usually targeted for ubiquitination by Von-Hippel-Lindau protein
(VHL) (131), results in the induction of multiple antioxidant genes (80) as well as EMT
inducing transcription factors including Twist, Snail, and ZEB1 (27, 132).

While high ROS levels are known to induce various types of cell damage, tumor cells

have been reported to have higher ROS relative to “normal” tissues, and are thought to

upregulate antioxidant enzymes in order to keep ROS within a “non-lethal” threshold limit.

Of importance, the observation that tumors generally have elevated ROS levels (133), comes

with the caveat that these comparisons normally compare bulk, predominantly epithelial
tumor samples to “normal” tissue which in the case of many cancer types, especially breast
cancer, is often stromal tissue containing an entirely different gene expression profile.

Therefore, comparisons of these tissue types which claim ROS as a survival factor in some
contexts, should be considered with caution. The true role of ROS is likely as not as simple

as either cell survival protagonist or antagonist. The maintenance of ROS within a crucial

range my aid in some cellular processes acting as a signaling molecule of sorts (134), while
rising beyond that range can be catastrophic, requiring safeguards such as antioxidant gene

expression. In fact, when totally quenched by pharmacologic intervention, ROS levels
plummet resulting in cell cycle arrest or even apoptosis (135). In light of these observations,

the evolving model posits that tumor cells react to changes in their microenvironmental
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signals by adopting particular metabolic adaptations which may include, but are not limited
to, changes in EMT status, migration, invasion, and importantly for survival distal to the
primary site, anoikis resistance (136).

Cellular Sources of Reactive Oxygen Species
There are a multitude of cellular sources of ROS which vary in their triggers, species

of ROS they produce, and their implications to biological processes.

Classically, ROS

generation has been considered to come from two chief sources including oxidative

phosphorylation in the mitochondria, and the NADPH oxidase (NOX) complex at the cell

membrane, both of which predominantly generate the superoxide species (137). While

these processes are important to consider as ROS sources, other major contributors and/or

regulators are emerging as critical players in the control of ROS-related anoikis induction.

Studies to show what fraction of ROS these pathways contribute to the overall pool are yet
to be carried out in most cases.

During normal oxidative phosphorylation, single electrons passed between

components of the mitochondrial electron transport chain (ETC) are shunted instead
directly to molecular oxygen at a fairly substantial frequency (0.1-2%). This superoxide
(O 2 .-) leak is generally quickly converted to hydrogen peroxide (H 2 O 2 ) by the mitochondrial

isoform of superoxide dismutase (SOD2), which can be further detoxified by catalase or
glutathione peroxidase (Gpx) to produce harmless water. Individual components of the

electron transport chain have differing contributions to ROS generated by this mechanisms
however. The majority of ROS contributed by the ETC comes from complexes I and III (137).

Experimental depletion of core components of the mitochondrial respiratory complex I
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(NDUFS-3 and GRIM-19) by siRNA transduction resulted in ROS reduction generated

through the NADH ubiquinone oxidoreductase complex (138). Alternatively, metformin has

been demonstrated to abrogate mitochondrial activity through complex I inhibition,
resulting in increased ROS level, sensitizing to radiotherapeutic approaches (139). These

findings demonstrate the complexity of ROS generation from the mitochondrial electron

transport chain as a source, signifying both positive and negative implications toward ROS
production.

Mitochondrial uncoupling proteins family members (UCP1-3) generally act to protect

cells from processes favoring ROS generation through uncoupling respiratory chain input of

substrates for oxidation from ADP phosphorylation output, with implications toward
longevity (140). The consequence of these uncouplers on ROS production toward regulation

of apoptosis is unclear as ANT (adenine nucleotide translocase) proteins, another major
uncoupling source resulting in proton leak in the mitochondrial membrane, have been

associated with transient opening of the MPTP (mitochondrial permeability transition pore),
but it is unclear at present whether this is a normal part of mitochondrial metabolism or

associated exclusively with apoptosis (134). The ROS generating activities of the NOX
complex, its regulation, and roles in cellular processes will be discussed in greater detail in a
later chapter.

Reactive Oxygen Species and their Reactivity
Oxyradicals are harmful when produced at high levels due to their propensity to

interact non-selectively with biomolecules disrupting their function, and this reactivity has
been implicated in a number of damaging processes including DNA strand breaks, direct
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oxidative damage to DNA bases, and can lead to peroxidation of lipid bilayer components,
altering membrane permeability (134, 137).

This disruption has a place in normal

physiological processes, such as in lysosomal or phagocytic ROS bursts intended to remove
unwanted cellular components or microbicidal killing. Overproduction of ROS however, can

result in the oxidation of critical cysteine residues, often in the active site of enzymes,

modulating or eliminating their activity seen in protein tyrosine phosphatases, lipid

phosphatases (e.g. PTEN), MAPK phosphatases, and can also result in disruption of ubiquitin

regulatory proteins altering proper protein degradation pathways (141-143). As was

alluded to earlier, maintenance of the proper cellular range of ROS is critical for many cellular

process, given that complete quenching of ROS results in global hyperactivation PTPs,
resulting in broad inhibition of signaling pathways requiring tyrosine phosphorylation
(135).

Mitochondria exists as the major source of ROS due to their reliance on aerobic

processes utilizing O 2 as the ultimate electron acceptor. Since O 2 is only capable of accepting

one electron at a given time, the reduction of O 2 to H 2 O can be somewhat muddled,
producing reactive intermediates including hydrogen peroxide (H 2 O 2 ), superoxide (O 2 .-),

and hydroxyl radicals (OH.-), which vary from least to most reactive, respectively. ROS is a

very broad term intending to encompass each of these species, including singlets, doublets,
and nonradicals such as hydrogen peroxide (144). While these species are all encompassed

by the ROS umbrella, they differ in properties such permeability to cellular compartments as
well as the targets with which they have a propensity to interact. For example, superoxide

is membrane impermeant; the results of which is restriction to the compartment in which it

is produced until it is converted to another, permeable form. Superoxide can be converted
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to H 2 O 2 , or can react with H 2 O 2 via iron sulfur centers to generate hydroxyl radicals via the

Fenton reaction. Hydrogen peroxide, relative to superoxide, is less reactive, more membrane
permeant, and tends to oxidize proteins with low-pK a cysteine residues, peroxidases, and

unsaturated lipids (145). Hydroxyl radicals on the other hand are highly reactive, and tend

to produce secondary radical species. Taken together, it is clear that a variety of reactive
oxygen species contribute to the damage of critical cellular components. How these effects
are believed to contribute to anoikis will be discussed below.
Reactive Oxygen Species Induce Anoikis
Detachment from ECM has been demonstrated to result in diversion of glucose

transporters from the plasma membrane, resulting in increased ROS which inhibits fatty acid
oxidation (FAO), resulting in loss of ATP (146). It is unclear at present, however, whether

low ATP induces anoikis, or whether production of a ROS burst somewhere in this process

is the crucial factor. Antioxidant enzymes such as superoxide dismutase and catalase have

been shown to prevent ATP loss following detachment (147). Compounds which act to
scavenge reactive oxygen such as α-lipoic acid and reduced glutathione have been shown to
inhibit caspase activation in suspension (148).

Consistent with these findings,

overexpression of antioxidant enzymes (e.g. SOD, catalase) protects from detachment
induced cell death while depletion of these enzymes both increases cellular ROS as well as
death (147).

Furthermore, ROS has also been shown to contribute to apoptosis directly through

mechanisms such as direct mitochondrial peroxidation of cardiolipin, a lipid which
sequesters cytochrome c, as well as direct inactivation of the anti-apoptotic Bcl-2 (149).
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Recently, ROS and metabolism have been under investigation highlighting their importance

in anoikis (80, 146, 147). From a particular isoform derived from an alternative promoter
of the SHC1 gene, p66Shc protein is produced in the mitochondria. Here it acts to form a
complex with cytochrome c and generates superoxide radicals resulting in mitochondrial
dysfunction (150).

While cytoplasmically located p66Shc appears to have antioxidant

functions, mitochondrial p66Shc has a clear positive link with ROS induction. It has been

demonstrated that depletion of p66Shc results in protection from anoikis, although this
effect appears to be independent of the cytochrome c interaction domain, but instead relies
on activation of RhoA (151). Interestingly, RhoA activation is implicated in ROS production

via activation of the NOX complex (152) (which will be described further in a later chapter).

Further, the anti-apoptotic protein Bcl-2, in addition to its roles in MOMP

suppression, acts to influence cellular redox balance via mitochondrial membrane proteins
where it interacts with complex IV and the small GTPase-Rac1 (153). The critical role of

maintaining a low ROS environment in cancer stem-like cells for evading cell death induced
by radiation and chemotherapy has been well documented (154-156).

The role of ROS

suppression in cancer stem-like cells in inhibiting anoikis is hypothetically also a critical

feature of this subclass of cells – a feature that appears to be intrinsically related to their
metabolic phenotype.

ROS can be produced in response to a number of extracellular stimuli including

growth factors, cytokines, and activation of G-coupled protein receptors (157). Further, it

has been reported that ROS perturbs a number of cell signaling pathways which (as
discussed above) are critical for maintaining anoikis resistance, especially in the context of
EMT including ERK, JNK, NF-κB, FAK, Ras, Rac, and Akt transduction pathways (158).
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There are multiple factors which further alter the production of ROS in tumor cells.

The importance of glucose and glutamine have been shown (through separate mechanisms

which will be discussed in more detail later) to dramatically affect not only cellular metabolic

pathways, but also influence the intracellular redox potential, principally through alteration
of ROS scavenging pathways. Enzymes which are involved in the processing of these carbon
sources thus greatly impact their utilization and shunting to different pathways. It has been

shown that in a non-small cell lung carcinoma model, EMT causes upregulation of the neural

isoform glucose transporter, GLUT3, via ZEB1 (159). The exact roles of these processes in

ROS generation will be detailed below.

Previous work indicates that glucose uptake in suspension declines due to relocation

of glucose transporters from the plasma membrane, and that glucose metabolism is integral

to maintaining an antioxidant environment through shunting to the pentose phosphate

pathway to produce NADPH (146). The result is a sharp increase in cellular ROS level.
Reduced glutathione (GSH) and thioredoxin pools (maintained by other processes) play a

significant role in neutralizing ROS and are critical for the maintenance of a reduced state

requiring the cofactor NADPH (160, 161). Along with the production of antioxidant enzymes

such as superoxide dismutase and catalase (discussed above), these are additional pathways
in which cells maintain a low ROS environment.

The ROS induced cell death described previously was reported to be caspase-

independent, thus non-apoptotic in nature, and was due to inhibition of FAO and ATP decline
(146).

Here, the authors proposed that this cell death was a consequence of ATP loss

resulting in low energy charge; however, it is unclear at present whether their findings are

causative or the result of cell death as they evaluate late stage time points in suspended
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culture after which caspase activation may have led to ROS pathway activation (e.g. caspase

cleavage of PKC resulting in activation of the NOX complex).

In light of these, as well as other studies showing ROS scavenging methods protect

from anoikis (148), it is clear that detachment induced ROS burst have clear role in induction

of cell death in suspended conditions. ROS can have even more upstream implications in cell
survival properties. It has been shown that AMPK activation occurs after cells detach from

their matrix (via activation through LBK1 kinase), which results in anoikis resistance
through MTORC1 suppression as well as inhibition of acetyl CoA carboxylase, resulting in
maintenance of NADPH (162). Also of note, pyruvate kinase isoform M2 (PKM2) tends to be
overexpressed in tumor cells. Interestingly, PKM2 is inhibited by high ROS level resulting in

a buildup of metabolites prior to the branch step converting pyruvate to acetyl CoA, resulting
in abundance of glycolytic intermediates supplying the PPP, increasing NADPH production
(163).

Various proliferation inducing oncogenes such as K-Ras, B-Raf, and Myc, described in

previous sections to lend survival traits to tumors including anoikis resistance, also result in

increased in Nrf2 gene expression. Nrf2 is a master regulator of the ROS cellular milieu when

released from its cytoplasmic negative regulatory sequestration partner Keap1. When redox

sensitive cysteine resides in Keap1 are oxidized due to oxidative stress, conformational

changes result in release of Nrf2, which undergoes nuclear translocation and dimerizing with

Maf to transactivate the antioxidant response element (ARE) (164).

Through this

mechanism, Nrf2 induces numerous antioxidant enzymes, including major targets such as
HO-1 and NQO1, the latter reported to have specific roles in ROS detoxification in NSCLC

models such that its depletion sensitizes cells to anoikis (165). In addition to antioxidant
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enzymes, Nrf2 also transactivates expression of genes related to the pentose phosphate

pathway, thereby aiding in maintenance of NADPH. In summary, evidence of the role of ROS
suppression in tumorigenesis and anoikis resistance is abundant.

Reactive Oxygen Species and the Epithelial-Mesenchymal Transition
While it appears that ROS and EMT share a paradoxical relationship in that ROS is

purported to result in the activation of the EMT program (e.g. hypoxia induced HIF1α

stabilization or NFκB activation) (166, 167), few studies have been done to examine the
eventual ROS environment in cells once they have undergone this transition. Rac1b, an

alternatively spliced Rac isoform, is reportedly activated by MMP-associated ectodomain
cleavage of E-cadherin, resulting in activation of NOX complexes (168).

However,

considering this as a source of ROS only takes superoxide species into account. Also, it is

unclear from the current reports if ROS induces the EMT phenotype, or rather, selects for
EMT subpopulations which are resistant to the harmful effects of ROS. A more global

description of ROS in mesenchymal vs epithelial cells is required. How EMT contributes to
anoikis through suppression of ROS and altered metabolic function will be discussed in detail
in Chapter 2.

Metabolism: Glycolysis, Oxidative Phosphorylation, and Glutaminolysis – Impact on Anoikis
Metabolism has been an area of intensive focus in the study of malignancy since Otto

Heinrich Warburg first described the concept of aerobic glycolysis, in which he defined
cancer cells as relying extensively on glycolytic metabolism regardless of the presence of
abundant oxygen which could be utilized to drive oxidative phosphorylation, a much more
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energy efficient means of carbon utilization (169). Through this process, cancer cells not

only act to fulfill their energy requirements, they also produce vital biosynthetic precursors
for anabolic processes such as fatty acid synthesis, ribose production, amino acid production,

and protein glycosylation (170). While these observations were groundbreaking in their

time, and brought attention to an extraordinarily important area of research in cancer

biology, his original idea has been dramatically oversimplified however, and are insufficient

to explain the complex metabolomics that occurs in cancer cells. Warburg’s original

observations have been widely misinterpreted to mean that cancer cells in fact suppress

their mitochondrial oxidative pathways in favor of glycolysis or that their mitochondria are

somehow defective. It is now understood that cancer cells even within a single tumors vary
dramatically from one portion to another in their reliance on these two primary means of

energy utilization (171, 172). Given this observed variety, it is no surprise that there is also

significant metabolic diversity when comparing primary tumor, circulating tumor, and

metastatic cells (173). The metabolic profile of tumors is likely far more dependent on the
regional oxygen/nutrient constraints, soluble factors from the tumor microenvironment
heavily influenced by nearby tumor associated stromal fibroblast cells, as well as the

infiltration of the tumor with immune cells. Given the great increase in efficiency of EMT
plasticity on the ability to migrate away from the primary site, survive in suspension, and

colonize a secondary site, it is most likely that the cellular metabolic needs of successful
tumor cells are also plastic, resulting in adaptation to their surroundings (136).

In

connection with this idea, the concept of “metabolic coupling” has emerged, and has been

reviewed eloquently by the Lisanti group (174), which has shown that in fact, the majority

of glycolysis occurs in the tumor stromal compartment. This is due to influence from
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secreted factors from tumor cells, resulting in the production of significant amounts of

pyruvate and lactate. It has even been postulated that tumor cells produce oxidative stress

to extract nutrients from surrounding stromal cells, resulting in induction of mitophagic
processes producing energy rich nutrients that “feed” the cancer cells (174). Tumor cells

have abundant monocarboxylate transporters (MCT) family proteins often overexpressed
on the cell surfaces of aggressive tumors. These glycolytic end products can then be

imported into the tumor cells where they are converted into carbon fuel sources for
oxidative metabolism.

In breast cancer cell line models, cancer stem-like cells have been reported to display

a shift in metabolism favoring oxidative phosphorylation as a means of ATP production, and

interestingly, more metastatic basal and claudin low cell lines show a more significant
increase in this population when compared to luminal subtypes (156). Given the metabolic
differences seen in these CSC subpopulation, it follows that EMT, which endows cancer cells

with properties of CSCs, would influence the oxidative phenotype. It has been reported EMT
in breast cancer cells supports increased oxidative phosphorylation, and a greater reliance

on alternative fuel sources to carbohydrate catabolism such as fatty acid oxidation is needed
to overcome the inefficient process of metastasis (170, 175).

Multiple changes in suspended culture can possibly result in alterations in fatty acid

oxidation. Pyruvate dehydrogenase kinase (PDK4), an enzyme which inhibits pyruvate

dehydrogenase, has been reported to increase in expression in suspension resulting in a
reliance on FAO and alternative fuels for oxidative phosphorylation; however ROS can inhibit

these alternate processes (146, 176, 177). The importance of EMT in regulation of these
critical metabolic pathways is evident as E-cadherin depletion in vivo, either by ZEB1
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overexpression or shRNA targeting E-cadherin, altered the metabolic profile of cancer cells
which favored oxidative phosphorylation over glycolysis (178).

Cancer cells have been reported to favor glutaminolysis as a carbon source in some

contexts, and even display a “glutamine addiction” in many cancer types (179, 180). In fact,
even though glutamine is a non-essential amino acid, most mammalian cells cannot

proliferate without exogenously supplied glutamine. Increased glutamine consumption is

essential for many cancer types during periods of excessive proliferation (181), and has even

been linked to aberrant regulation of oncogenes and tumor suppressors (182, 183).

Glutaminolysis is the processes by which cells metabolize the amino acid glutamine via its

conversion to α-ketoglutarate (α-KG), which proceeds through the tricarboxylic acid (TCA)
cycle to produce reducing equivalents for ATP production by means of the ETC. In highly
proliferative cancer cells, citrate (an earlier intermediate in the Krebs cycle) is shunted to
the cytoplasm where it is involved in the production of NADPH and fatty acids; however,
glutaminolysis replenishes this loss with α-KG, a process referred to as anaplerosis (184,

185). Glutaminolysis has been ascribed roles in various cellular processes aside from
anaplerosis, the implications of which in anoikis were previously unclear. In addition to

replenishing the TCA cycle, glutaminolysis has implications in autophagy and regulation of
ROS, the implications of which will be discussed below.

Through the process of glutaminolysis, glutamine undergoes deamidation through an

irreversible reaction catalyzed by glutaminase (GLS).

Mitochondrial Glutamate

Dehydrogenase I (GLUD1 or GDH1) is then responsible for the deamination of glutamate to
α-KG (186, 187). GLUD1 will be discussed in more detail as it relates to the induction of

anoikis resistance in the following chapter. Regulation of this process is complex and
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involves a series of positive and negative feedback regulation of these enzymes. The enzyme

glutaminase is inhibited by its product, glutamate by a direct negative feedback regulation.
Leucine on the other hand, is a potent allosteric activator of GLUD1. Activation of GLUD1

increases the glutamate to α-KG conversion, decreasing glutamate and removing GLS

inhibition. The glutamine bidirection antiporter SLC7A5-SLC3A2 extrudes glutamine and
imports leucine into the cell (188). Glutamine modulation of cellular leucine levels therefore
directly activates GLUD1 and increases the conversion of glutamate to αKG, further
removing GLS inhibition to signal the process forward.

Glutamine is a known regulator of autophagy, a process used by cells to degrade

proteins and organelles, replenishing energy charge (189). Activation of autophagy would

protect from anoikis by replenishing energy charge, a process inhibited by activation of
MTORC1, mammalian target of rapamycin complex I, which is a central regulator of cell

growth, translation of mRNA, and metabolic pathways (190-192). The exact mechanisms
regarding glutamine inhibition of MTORC, influences over autophagy, and exactly how this

impacts anoikis are unclear (193, 194). Pharmacologic inhibition of the major regulators

and antiporters involved in this process and their effects on cellular processes such as
autophagy, anapleurosis, and anoikis merits further study.

It has been reported that mouse embryonic stem cells, when grown in conditions

which maintain their naïve pluripotency, proliferate in the absence of exogenous glutamine;
however, when replaced, they utilize higher levels of glutamine and use this to maintain high

level of level of intracellular αKG (195). In this study, the authors proposed that embryonic

stem cells sustain an elevated αKG: succinate ratio, which maintains their pluripotency,
promoting histone/DNA demethylation (195).
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Conditions that favor elevated αKG:

succinate ratio (e.g. elevated rates of glutaminolysis), thus favor epigenetic changes
supporting the stem cell phenotype. As was discussed in detail in previous sections, EMT

induces the acquisition of stem cell features and flexible epigenetic state. Given the other
major characteristics innate to mesenchymal cells, such as anoikis resistance, the
involvement of the process of glutaminolysis and the role of αKG in its regulation in the
context of EMT is of critical importance.

The implications of these metabolic alterations on anoikis and EMT are described

here. Tumor cell coupling with associated stromal fibroblasts become reliant on these
carbon sources for energy production, meaning less flow through glycolytic pathways, and
thus less input into the PPP, hampering the production of NADPH. This could initially

increase ROS in these tumor cells causing EMT through mechanisms described above (HIF1α

stabilization, NFκB induction, etc). During the EMT process, in addition to other deleterious
features, cells upregulate defenses against this oxidative environment, through Nrf2 and

HIF1α transactivation of ARE, antioxidant defense systems are engaged, resulting in low
ROS. Tumor cells that are now reliant on oxidative phosphorylation as an energy production

source are now poorly suited to remain in the hypoxic primary tumor environment.
Considering these stimuli, cells are encouraged to undergo transient EMT processes,

increase invasiveness and anoikis resistance, and leave their primary site. In fact, breast

cancer cells recovered from metastatic sites have been observed to contain elevated
mitochondrial number and increased mitochondrial membrane potential (136, 196). These
findings all support the role of EMT in modulating ROS, metabolism and anoikis.
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Grainyhead-like transcription factor family: Roles in Cancer

The three mammalian homologues of Drosophila Grainyhead, termed GRHL1, 2, and

3 have each been demonstrated to play significant roles in carcinogenesis.

These

homologues share some common targets; however, like their distinct chronological
induction during embryogenesis and varied expression patterns in adult tissues, they have

unique target genes and effects on cellular processes. In the context of cancer, GRHL1 has

been demonstrated to act as a tumor suppressor in both squamous cell carcinoma (SCC) and
neuroblastoma (1). In the context of SCC, the tumor suppressive role of GRHL1 was

demonstrated in Grhl1-/- mice, which developed a higher number of malignant lesions
following treatment with topical carcinogen, DMBA as compared to wild type. In this study,
Mlacki et al., demonstrated that mechanistically, loss of GRHL1 resulted in a chronic

elevation of inflammatory factors as well as a faulty keratinocyte terminal differentiation

program (2). Interestingly, the closely related family member, GRHL3, has also been
demonstrated to have tumor suppressive functions in SCC via maintenance of its target gene

PTEN, where the expression of GRHL3 was demonstrated to be repressed by the proto-

oncogenic network mediated through miR-21 (3). The role of GRHL2 in oncogenesis remains

contested, and appears to play a role which at the very least might be context and/or tissue

specific in its tumor promoting or suppressing behavior. Highlighting the most critical
findings in regards to GRHL2 will be the focus of this review.

Suppression of the Oncogenic Epithelial-to-Mesenchymal Transition by Grainyhead-like 2

48

The epithelial-mesenchymal transition (EMT), has been strongly implicated in the

malignant progression of cancer, endowing subpopulations of tumors with enriched
metastatic potential as well as stem cell-like properties (4). This cellular event represents a

major shift within these epithelial subpopulations, resulting in characteristics reminiscent
of mesenchymal cells including disruption of cell-cell adhesion (5), increased motility and

invasiveness(6), chemo/radiotherapeutic resistance (7-10), and resistance to matrixdetachment induced cell death, a process referred to as anoikis (11-14). These features

represent the manifestations of cellular phenotypic plasticity conferred by passage between
these two distinct states. In the context of normal physiological function, EMT and its

converse process termed mesenchymal-epithelial transition (MET), are indispensable to
events such as embryological development and wound healing (5, 15). However, these

normal processes, when dysregulated, can have catastrophic consequences. Perturbations

of normal cellular functions such as proliferation and growth are extensively characterized
in the context of cancer progression, and an extensive body of evidence has now established
EMT/MET plasticity as a normal process employed inappropriately in the context of
malignancy.

In breast cancer specifically, loss of GRHL2 expression is seen specifically in the

aggressive claudin-low and basal B subtypes, which are known to exhibit a frank EMT
phenotype, and are often associated with resistance to therapeutic intervention and poor

prognosis (16-18). While a multitude of factors have been shown to induce EMT, these

factors far outweigh those which inhibit this event. GRHL2 has emerged as a master

regulator of the epithelial phenotype, the mechanisms of which are largely established (18-

20). Overexpression of GRHL2 is associated with MET resulting in downregulation of the
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mesenchymal markers vimentin, fibronectin, N-cadherin, and CD44S as well as E-cadherin

upregulation (18). Snail and ZEB1, well established E-box binding transcription factors,

function to directly repress epithelial genes such as E-cadherin (21-24), directly contributing

to loss of cell-cell junctional networks of epithelial cells, and further enhancing
transactivation of survival genes associated with Wnt signaling through loss of β-catenin

sequestration (25). A critical reciprocal feedback loop has been discovered between GRHL2

and ZEB1 such that in ovarian cancer, colorectal carcinoma, and breast cancer cell lines,
GRHL2 and ZEB1 expression levels have been found to inversely correlate (20, 26, 27). This

relationship is mediated at least partially through direct GRHL2 repression of the ZEB1

promoter as demonstrated through ChIP assay (18), and furthermore, it has also been
demonstrated that ZEB1 represses the GRHL2 promoter through direct binding as well (19).

Of note, in an superb study by Chung et al., the reciprocal feedback loop between GRHL2 and
ZEB1 was confirmed in epithelial ovarian cancer (27); however, they were unable support

previous findings (18) that demonstrated direct GRHL2 binding to the ZEB1 promoter. This
discrepancy is most likely the result of relative gain difference comparing ChIP-seq

technique to direct ChIP assay in which the sensitivity of interaction detected can be

significantly modified through DNA fragment input alteration. Further, support for direct

GRHL2 binding to the ZEB1 promoter was confirmed by repression of a luciferase tagged
ZEB1 promoter construct co-transfected with GRHL2 in a dose-dependent manner as well as
enhanced ZEB1 promoter activity in cells expressing stable GRHL2 knockdown (18).

Additionally, GRHL2 has been demonstrated to interfere with ZEB1 expression through
other mechanisms.

The homeoprotein SIX1 is a well-established transcription factor

involved in developmental EMT which also plays a role in the oncogenic EMT, through direct
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transactivation of the ZEB1 promoter (28, 29). Interestingly, GRHL2 further disrupts ZEB1

expression by altering the Six1-DNA complex resulting in further abrogated transcription at
this site (19).

In addition to suppressing ZEB1 transcriptional activity, GRHL2 further supports the

epithelial phenotype through suppression of TGF-β/Smad mediated transcription. TGF-β

has been extensively described to confer either tumor suppressive (through induction of
CDK inhibitor proteins) or tumor promoting (through transcriptional support of EMT)
properties dependent on tumor stage.

In fact, TGF-β signaling, along with

canonical/noncanonical Wnt signaling is upregulated and through autocrine signaling

pathways maintain the mesenchymal subpopulation present in Human mammary epithelial
lines (HMLE) (30). GRHL2 inhibits Smad mediated transcription, and depletion of GRHL2 is
permissive of EMT induction in HMLE cells (18), which are otherwise resistant to this

stimulus (due to high endogenous GRHL2 levels) (30). Further, it was confirmed that
depletion of GRHL2 in HMLE cells expressing low level K-Ras (HMLER) results in EMT, a

phenomenon shown to be dependent on autocrine TGF-β signaling (18). Additionally,

GRHL2 was shown to prevent TGF-β induced EMT in MCF10a cells constitutively expressing
GRHL2 (20). Notably, GRHL2 was reported to upregulate BMP-2, a member of the bone
morphogenetic protein family, belonging to the TGF-β superfamily, which are known to
inhibit TGF-β receptor signaling through competition with Smad2/3 for Smad4 binding and

nuclear translocation (18, 31).

It has been well established that the primary mechanism by which the miR-200 family

acts to enforce the epithelial phenotype is through post-transcriptional repression of

ZEB1/2, and in fact a negative feedback loop has been demonstrated such that ZEB
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transcription factors also transcriptionally repress miR-200 expression (11, 32-36). It is

now well established that GRHL2 positively regulates the transcription of this family of
microRNAs. Stable knockdown of GRHL2 resulted in a significant reduction in both miR-

200b/c transcript levels (18). Further, GRHL2 was shown to bind directly to the promoter
region regulating the polycistronic primary transcript of mi-R200b, miR-200a, and miR-429

(27), inducing their expression. Interestingly, it was shown here that stable overexpression

of either miR-200b or miR-200a was able to restore E-cadherin expression in OVCA429
ovarian cancer cells expressing stable knockdown of GRHL2, indicating a so-called “double

negative” regulatory feedback loop with the miR-200 family, GRHL2, and ZEB1. The positive

regulatory effect of GRHL2 on the miR-200 family has also been confirmed in other models

including oral squamous cell carcinoma (37, 38). The transcription factor p63 is a multiisoform relative of p53 critical for proper epidermal development (39). A recent report

showed a critical role in the maintenance of the epithelial phenotype for p63 and
demonstrates a positive regulatory loop between p63 and GRHL2. It was demonstrated here
that depletion of p63 results in loss of GRHL2 and miR-200 family gene expression as well as
other epithelial specific markers and resulted in an EMT phenotype (38).

Several of the aforementioned pathways have regulatory control of endogenous

GRHL2 expression as well. As previously stated, TGF-β is only able to induce EMT in

particular contexts or stages of tumor progression. For example, in the setting of HMLE cells,
EMT is only induced by TGF-β in conjunction with either stable GRHL2 knockdown (18) or

activation of Wnt signaling (30). It is now clear that activation of the Wnt and TGF-β
pathways work in concert to downregulate endogenous GRHL2 expression.

Neither

activation of the Wnt pathway via BIO compound (GSK3 inhibitor) or stably expressed S33Y
52

β-catenin nor long term TGF-β treatment resulted in significant downregulation of GRHL2
alone; however, in combination, these pathways downregulated GRHL2 considerably (19).

BMP2, which was significantly upregulated in GRHL2 expressing cells (18), acts as an

inhibitor of TGF-β signaling. Treatment of cells with BMP2 prevented downregulation of
GRHL2 and ZEB1 upregulation in response to Twist mediated EMT (19).

As will be

demonstrated below, it is clear that a better understanding of how to inhibit these pathways

successfully in vivo could be a crucial step in inhibition of EMT plasticity and preventing
mortality from chemotherapeutic resistance, recurrence, and metastasis.

Anoikis, Cancer Stem Cell Phenotype, Recurrence and Metastasis: Reversal by GRHL2

Among the various deleterious traits of metastatic tumor cells, one especially

important for their ability to survive beyond their primary site is a compromised anoikis
response (14, 40). Along with increasing migratory and invasive characteristics, it is well

established that EMT induces anoikis resistance in cancer cells (14, 41, 42). Many of the core
cellular signaling pathways involved in the implementation of the EMT program such as

PI3K/Akt and MAPK activation also contribute to cell survival in general, anoikis being no
exception (43). Ectopic GRHL2 expression was shown to restore sensitivity to anoikis in
MDA-MB-231 breast cancer cells as well as the mesenchymal subpopulation of HMLE cells

(18). Accordingly, depletion of GRHL2 by shRNA in HMLE+Twist-ER and MCF10a neoT cells

also decreased sensitivity to anoikis (44). While many signaling pathways are aberrantly

activated during EMT (e.g. FAK, ILK, TrkB; refer to (13) for an indepth review), and

contribute to anoikis resistance, our lab recently showed GRHL2 at least partially enforces
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anoikis sensitivity through downregulation of the mitochondrial enzyme glutamate
dehydrogenase I (GLUD1) (44). GLUD1, an enzyme shown to have pro-tumorigenic roles in
orthotopic models, has been demonstrated to influence the cellular oxidative milieu via

production of α-ketoglutarate (α-KG), increasing fumarate production in the citric acid cycle,
stabilizing the antioxidant enzyme glutathione peroxidase 1. Further, in this study, Jin et al.

demonstrated by IHC that GLUD1 expression correlates with progressive stages of both
breast and lung carcinomas (45). Our lab found that overexpression of GRHL2 resulted in a

decline in α-ketoglutarate levels, elevating reactive oxygen species (ROS), and impacting

mitochondrial metabolism; further, stable knockdown of GLUD1 increased ROS and anoikis
sensitivity, while replacement of α-KG in these cells resulted in decreased ROS and enhanced

resistance to anoikis (44).

Luciferase assays showed that the GLUD1 promoter was

significantly repressed by GRHL2 in cotransfection experiments. Here, it was demonstrated

that GRHL2 acts to repress the GLUD1 promoter as well as the EMT program in HMLE cells

and further suppresses tubulogenesis in MDCK cells via inhibition of the histone
acetyltransferase co-activator, p300 (Pifer et al., 2016; in review).

Resistance to anoikis is a pre-requisite for tumor metastasis. In order for cancer cells

to escape their primary microenvironment, they must be able to shed their connections to

the surrounding extracellular matrix in their primary environment and survive
intravasation into the vasculature or lymphatic system.

Experimentally, enforced

expression of E-cadherin abrogates invasive properties in cancer cells, and clinically,

expression of E-cadherin is associated with lower risk of tumor invasion (46-49),

highlighting the importance of the EMT program in these early stages of metastasis. EMT
thus endows subpopulations of tumor cells with anoikis resistance allowing them to survive
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dissemination after invading out of their primary niche. In a p53-dominant negative tumor
model, depletion of E-cadherin in a conditional knockout mouse transgenic line significantly

increased tumor metastasis in vivo; moreover, the resulting cell lines produced from this
study were anoikis resistant compared to their E-cadherin positive counterparts (50).

However, despite these findings, the role of EMT/MET in metastasis is an area of

controversy.

Reversion of mesenchymal to epithelial cells in some contexts has been shown to

enhance metastatic colonization (5). In fact, breast cancer metastases are often, but not

always, epithelial and express E-cadherin (51). As such, it was demonstrated by Nieto and
colleagues that depletion of the EMT inducing homeobox transcription factor Prrx1 is

required for cancer cells to seed metastatic locations in vivo; however, it was noted in this

study that Prrx1 overexpression does not induce cancer stem cell-like traits as does ZEB1,

Twist, or Snail mediated EMT events as previously described(52-55). This contradicts

findings showing that tumor metastases, at least in some cases, are mesenchymal or contain

a mixture of mesenchymal and epithelial cells, indicating that the EMT phenotype likely still
exists in metastases, at least in early stages of metastatic colonization. This observation that
metastatic tumors often do not resemble the mesenchymal cells which gave rise to them is

likely a consequence of differing local microenvironmental stimuli encountered following

extravasation into distant organs, where the stress signals initially invoking EMT in the

primary tumor are no longer present (6, 56, 57). Some studies have posited that following

Twist activation and EMT induction, in order for circulating tumor cells to colonize distant

sites, it must be silenced (58). While it may be true that MET confers proliferative

advantages in metastatic settings, a major flaw with this reasoning is evidenced by the
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inhibition of proliferation which occurs due to activation of exogenous Twist in these
settings, which may result in misinterpretation of these results.

A potential reconciliation of these views is that EMT/MET plasticity is in fact the

major force to endow cancer cells with their malignant properties. An extension of this
interpretation would imply that either EMT or MET could be viewed as tumor suppressive

or oncogenic events depending on the stage of disease progression. A recent publication by

Scheel et al. however, demonstrated that transient Twist1 activation permanently alters cell

state and primes epithelial cells for stem cell-like properties which did not require

permanent acquisition of the EMT phenotype (58). This finding informs the intimidating

reality that any tumor cell subjected to the proper conditions in the tumor
microenvironment may undergo EMT even transiently, and thus potentially attaining cancer

stem cell-like properties highlighting the need for targeted therapy to eradicate this

subpopulation, or rather, prevent its emergence. It is clear that a better understanding of

the major regulators of EMT and MET is critical in order to prevent the emergence of
treatment resistant metastases and recurrence. Regardless of the seemingly contradictory

evidences, it is undeniable that EMT invokes many traits in cancer cells associated with
aggressive malignancies, invasion, and anoikis resistance, and that these features are

ameliorated by expression of the epithelial enforcer GRHL2. Of critical importance, it was

demonstrated through a comprehensive IHC analysis of primary breast tumors that a
striking loss of GRHL2 expression occurs at the invasive front of primary tumors, and a

significant inverse correlation exists between GRHL2 expression and the presence of lymph

node metastases (20). Also, it was noted by the authors in this study that while correlative
evidence, basal cell carcinomas, which nearly never metastasize, as well as non-invasive
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urinary bladder cancer both showed incredibly strong expression of GRHL2. Conversely,

other reports have associated GRHL2 expression with increased risk of metastasis and poor
relapse free survival (59, 60). However, these studies do account for that fact that tumors of

epithelial phenotype enrich for genes such as GRHL2 or E-cadherin relative to “normal”
tissue (which is often predominantly fibroblastic stromal tissue).

This provides the

implication that the more rapidly an epithelial tumor grows, the more “epithelial” it will
appear to techniques such as RNA-seq due to expansion of this compartment. In addition to
this, as mentioned previously, the most relevant sub-compartment of the tumor to driving

therapy resistance, recurrence and metastasis is a very small proportion of the overall tumor
which downregulates GRHL2, therefore this population is masked by techniques that

consider the entire tumor.

Disease recurrence several years following initially successful treatment of primary

disease is a frequent reality, and is the most common cause of death from cancer. It has been

extensively demonstrated that in these settings, plasticity conferred by EMT benefits small

populations of cells, bestowing CSC-like and chemoresistant properties to these primary
tumor cells, which persist, only to resume growth after a period of dormancy (41, 61-66). In

breast cancer, these populations are often identified by a shift in surface expression toward
a CD44HIGH/CD24LOW phenotype. In culture, treatment of HMLE cells with taxol derivatives
selects for this CSC-like population; conversely, stable expression of GRHL2 significantly
sensitizes these, as well as MDA-MB-231 cells, to this therapy. Most importantly, ectopically

expressed GRHL2 prevents the chemotherapy-induced emergence of this population capable
of tumor initiation (19). In a study by Singh et al, it was demonstrated that epithelial SUM149
cells subjected to metabolic stress such as glutamine deprivation resulted in the emergence
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of a “metabolically adaptable,” glutamine independent population, termed SUM149-MA or

MA2. It was demonstrated here that in addition to having undergone EMT, these cells now
displayed chemotherapeutic resistance to taxol, Erlotinib, doxorubicin, and a number of

other both targeted and cytotoxic agents. Upon global gene expression analysis, it was

discovered that MA2 cells had significantly downregulated GRHL2 and upregulated ZEB1.

The authors noted a significant decrease in histone activation marks H3K4 trimethylation

and H3K14 acetylation in the MA population previously reported to be associated with the

drug resistant state (67), which when reversed using HDAC inhibitor pretreatment,
significantly sensitized cells to chemotherapy (68). Interestingly, it has also been reported
that while H3K4me3 marks remain largely unchanged following GRHL2 depletion with

shRNA, repressive mark H3K27me3 significantly increased in the promoter regions of genes

positively regulated by GRHL2 including CDH1, MIR-200B/200A and 429(27). These findings
strongly point to a potential role for GRHL2 in epigenetic modification as a mechanism of

transcriptional regulation. Observations such as these support a role in both sensitization
to chemotherapy by GRHL2, as well as a critical role in abrogating CSC emergence crucial for

the initiation of recurrent disease.

Mouse models recapitulating recurrence following regression of primary tumors

driven by doxycycline inducible neuNT, Wnt1, or c-myc have shown that in comparison to
the primary tumors, recurrent disease that emerges following withdrawal of the oncogenic
driver have undergone EMT (64, 69, 70). Analysis of tetO-neuNT and tetO-Wnt1 primary vs

recurrent RNA expression revealed a striking decrease in GRHL2 expression in recurrent

tumors (19). These findings strongly support the hypothesis that GRHL2 is a tumor

suppressor, is specifically silenced in the tumor initiating subpopulation of the primary
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tumor, and is a major suppressor of disease recurrence. Further evaluation is needed in
order to more clearly define the precise role of GRHL2 in preventing recurrence in vivo.
GRHL2: Tumor Suppressor or Oncogene?
Despite the extensive evidence reporting GRHL2 as a tumor suppressor and inhibitor

of the EMT phenotype, there are contradictory reports in both breast and other malignancies
supporting a role of GRHL2 in oncogenesis (1).

It is clear that the expression pattern of

GRHL2 in adult tissues is immensely complex. GRHL2 is found almost exclusively in tissues

of the body that are predominantly epithelial (71), correlating with expression of junctional
proteins such as E-cadherin and CLDN4 (72); however, its expression is diversely regulated,

showing up and downregulation often within the same tissue type, highlighting its potential
for tumor suppressive or oncogenic roles, depending on the context .

It was reported that in oral squamous cell carcinoma, GRHL2 interacted directly with

the promoter of hTERT (human telomerase reverse transcriptase) as assessed by promoter
magnetic IP (PMP assay). In this model, telomerase, which is required to maintain the

malignant phenotype, had higher activity in tumor lines expressing high GRHL2 expression,
and depletion of GRHL2 reduced telomerase activity and cell viability, as well as resulted in

hypermethylation of the hTERT promoter (73, 74). The precise rationale for this GRHL2-

mediated regulation of cellular immortalization in this context is unclear at present. In
agreement with these findings, Chen et al demonstrated that depletion of GRHL2 abrogated
tumorigenesis and was necessary for maintenance of stemness in a model of oral squamous

cell carcinoma (37). Another study reported that the 8q22 gene cluster was involved in

death receptor-mediated apoptosis. Here, GRHL2 was identified in a whole-genome RNAi
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screen which indicated that it suppressed death receptor signaling (75); however, unlike
other target genes identified in this screen, the authors were unable to rescue the RNAi

associated phenotype resulting from GRHL2 depletion, therefore an off-target effect could
not be eliminated. Also noteworthy, the shRNA pool used in the study was conducted in
HT1080 fibrosarcoma lines which have minimal expression of endogenous GRHL2.

Many of these findings can be rationally explained, such as studies which knocked

down GRHL2 expression in already mesenchymal HT1080 fibrosarcoma cells (75), or

overexpressing GRHL2 in NIH3T3 fibroblast lines (20), whose cancer relevance, as noted by

the authors, is questionable. Still other studies contain discrepancies not fully understood

at present. For example, while it was reported by Xiang et al that highly invasive 4T1 cells
orthotopically injected into the mammary fat pad would metastasize in a period of about 4

weeks, and that the resulting metastases recovered from the lungs displayed an EMT

phenotype, they observed a counterintuitive increase in metastasis when injecting 4T1 cells

overexpressing GRHL2 (59). Further, GRHL2 was confirmed in this study to enforce the

epithelial phenotype. These results are in direct opposition to those showing a direct role of
EMT in promoting metastases, rather than inhibiting it (12, 76-83). In our hands, we have

found that GRHL2 does not retain several critical functions in some murine cell lines such as
4T1 cells (unpublished observations); therefore, it is possible that in some restricted murine
settings, GRHL2 fails to inhibit metastasis.

As detailed above, GRHL2 expression is lost in recurrences which often display EMT

phenotype (19); however, other studies have shown that gain of GRHL2 (via amplification of

GRHL2 gene at chromosome 8q22.3) was demonstrated to be a marker of early recurrence

in hepatocellular carcinomas (84). However, unlike in the context of basal-B breast cancer
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cell lines, where GRHL2 was reported to have no effect on proliferation (18, 20), in the HCC
lines studied by Tanaka and colleagues, GRHL2 knockdown resulted in decreased cell

proliferation, indicating that in this context, either GRHL2 significantly impacts tumor cell
growth and proliferation which may contribute to earlier detection of apparent recurrent

disease in some tissue types (84). Likewise, colorectal carcinomas, which have been

reported express high levels of GRHL2, have been described to show enhanced proliferation,

larger tumor size, and more advanced clinical stage in this setting (85). These findings were
verified by depletion of GRLH2 in colorectal cell lines HCT116 and HT29 cells (26);

conversely, in our hands, HCT116 cell lines were found to express very low levels of

endogenous GRHL2 (unpublished observations). A potential explanation of the role of

GRHL2 in regulating cellular proliferation may be found in examination of the reported

target gene Erbb3 by GRHL2. Erbb3, with known roles in carcinogenesis and proliferation,
was identified as a GRHL2 target gene by Werner et al, and furthermore, was found to contain
a single conserved GRHL2 DNA binding site (AACCGGTT) upstream of the transcriptional

start site. Binding to this site was demonstrated by EMSA and activation was shown through
luciferase cotransfection experiments (20). Importantly, this upregulation was originally
noted in NIH3T3 cells overexpressing GRHL2, and the authors noted that in the triple
negative breast cancer line MDA-MB-231 cells, where GRHL2 has no reported effect on

proliferation, there was no upregulation of Erbb3 (20). It is possible that differential gene
regulation in different cell lines may therefore contribute to findings demonstrating

alterations in proliferation by GRHL2. Of note, it has been demonstrated that GRHL2 copy
number gain, reported in several cancer types including gastric (86) and hepatocellular

carcinoma (84) does not necessarily translate to an increased expression of GRHL2 (71).
61

However, in a directly conflicting report, it was demonstrated by Xiang et al, that gastric

cancer cell lines contained significantly downregulated GRHL2 mRNA and protein levels;

moreover, expression of exogenous GRHL2 in this setting significantly inhibited
proliferation and promoted apoptosis (87). Further, the authors of this study demonstrated
that GRHL2 negatively regulated the pro-survival factors c-myc and Bcl2.

In a finding that has since been discredited in multiple models, Yang et al, reported

that in wound healing scratch assays, MDCK and MCF7 cells overexpressing GRHL2

displayed increased invasion relative to vector only expressing cells (60). As these results
were not confirmed using assays more specific to migration and invasion such as Boyden
chamber assays, the most likely interpretation of these data is that in this cell lines,

overexpressing of GRHL2 increased proliferation as it has been reported to do in other

models rather than enhanced migration as discussed previously (26, 85). Opposed to this
view, it was reported that overexpression of GRHL2 in both MDA-MB-231 and BT549 cells

result in MET and significantly suppressed migration in Boyden chamber assays (20).

Further, it was demonstrated that depletion of GRHL2 in ovarian cancer cells enhanced
migration, invasion, and motility using a matrigel embedded gap invasion assay, a more
specific approach for analysis of invasion (27). In fact, this report demonstrated that

shGRHL2 cells migrated as individual cells rather than a collective front, and further verified
that differences were not due to proliferation differences.

The discrepancies in the reported roles of GRHL2 in tumor progression could

resemble that of the TGF-β pathway which has reported roles in both processes. This theory
is certainly is conceivable given the well-established interaction of GRHL2 in the inhibition

of the TGF-β pathway. Given the critical role of EMT in metastasis and establishment of CSC62

like populations, a better understanding of pathways regulating expression of master
regulatory transcription factors such as GRHL2 is crucial for improving patient survival, both
in terms of sensitizing to initial chemotherapy as well as preventing the emergence of
treatment resistant secondary disease.
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Abstract
Resistance to anoikis is a pre-requisite for tumor metastasis. The epithelial to

mesenchymal transition (EMT) allows tumor cells to evade anoikis. The wound healing

regulatory transcription factor Grainyhead-like 2 (GRHL2) suppresses/reverses EMT,
accompanied by suppression of the cancer stem cell (CSC) phenotype and by re-sensitization
to anoikis. Here, we have investigated the effects of GRHL2 upon intracellular metabolism in

the context of reversion of the EMT/CSC phenotype, with a view toward understanding how
these effects promote anoikis sensitivity. EMT enhanced mitochondrial oxidative
metabolism. While this was accompanied by higher accumulation of superoxide, the overall

level of Reactive Oxygen Species (ROS) declined, due to decreased hydrogen peroxide.
Glutamate Dehydrogenase 1 (GLUD1) expression increased in EMT, and this increase, via the

product α-ketoglutarate, was important for suppressing hydrogen peroxide and protecting
against anoikis. GRHL2 suppressed GLUD1 gene expression, decreasing α-ketoglutarate,
increasing ROS and sensitizing cells to anoikis. These results demonstrate a novel role of
GRHL2 in promoting anoikis through metabolic alterations.
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Introduction
When deprived of connections to their extracellular matrix, normal epithelial cells

trigger a process of programmed cell death referred to as anoikis (1). The ability to
metastasize depends critically upon a cancer cell’s ability to evade anoikis (2-4). The
transcriptional reprogramming event known as the Epithelial to Mesenchymal transition

(EMT) confers anoikis resistance and ultimately, increased metastatic potential (5). The

increased phenotypic plasticity underlying transitions between epithelial and mesenchymal
states is thought to be epigenetically driven (6-10). One additional manifestation of this

increased plasticity, aside from EMT, is that cancer stem cell subpopulations emerge, that,
like cells resulting from EMT, are resistant to anoikis; these contribute crucially to both
metastasis and disease recurrence.

The wound healing regulatory transcription factor, Grainyhead-like 2 (GRHL2), plays

an indispensable role in the maintenance of the epithelial phenotype and branching

morphogenesis (11-14). Previously, we reported that GRHL2 suppresses the oncogenic EMT,

i.e., promotes MET (15-17). The loss of GRHL2 expression is associated with aggressive,
metastatic breast tumor types that contain an unusually large fraction of EMT-like
subpopulations, and in the cancer stem cell-like subpopulation of tumors resulting from EMT

and/or drug resistance. Interestingly, the constitutive expression of GRHL2 invariably led
also to anoikis-sensitivity (15, 16). The mechanism underlying this effect was unclear,
however.

Reactive oxygen species (ROS) are ubiquitously important in apoptosis through

mechanisms such as direct mitochondrial peroxidation of cardiolipin, a lipid which
sequesters cytochrome c, as well as direct inactivation of the anti-apoptotic Bcl-2 (18).
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Accordingly, ROS contributes to anoikis as well as the non-apoptotic cell death of detached
cells accompanying ATP loss (19, 20). It is unclear at present, however, whether changes in

ROS levels occur in EMT or cancer stem cell transitions, and, if so, what drives these changes.

The HMLE cell line is an immortalized mammary epithelial cell line that contains a

CD44hi/CD24low subpopulation referred to as the Mesenchymal Sub-Population (MSP) that

co-expresses EMT and cancer stem cell phenotypes (21, 22). Previously, we reported that
MSP cells have low GRHL2 expression, and are resistant to anoikis (15, 16). Forced
expression of GRHL2 in MSP suppressed their cancer stem cell-like as well as EMT

phenotypes and sensitized them to anoikis. The possibility that GRHL2 achieves the latter
effect by altering intracellular metabolism has not been explored.

Glutaminolysis is a critical metabolic pathway on which tumors rely as a major

alternate carbon source to glucose, with significant ramifications for cell proliferation,
metabolic adaptability and cell survival (23-25). Following deamination of glutamine to
produce glutamate, glutamate dehydrogenase-1 (GLUD1 or GDH1) generates the Krebs cycle

intermediate α-ketoglutarate (α-KG), which is converted by the Krebs cycle to fumarate, an

important cofactor for glutathione peroxidase enzymes. Accordingly, α-KG is an important

protective factor against oxidative stress, and GLUD1 is over-expressed in breast and lung

carcinomas (26, 27).

In this paper, we report that, in reversing EMT, GRHL2 suppresses GLUD1 expression,

elevating H 2 O 2 ROS levels and promoting anoikis-sensitivity. GRHL2 also reversed the
cancer stem cell-like shift to oxidative phosphorylation-based ATP production and cell

survival. These results inform a novel connection between EMT, metabolic pathways, ROS
and anoikis-sensitivity, regulated by GRHL2.
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Materials and Methods

Cell lines
HMLE, and HMLE+Twist-ER cells and generously provided by R. Weinberg (The

Whitehead Institute, Cambridge, MA); MCF10A neoT cells were provided by F. Miller

(Karmanos Cancer Center). HMLE and HMLE+Twist-ER cells were maintained in Advanced

Dulbecco’s Modified Eagle’s Medium (DMEM): Ham’s F-12 (Gibco) + 5% horse serum + 1X

penicillin-streptomycin-glutamine (PSG) + 10 μg/mL insulin, 10 ng/mL EGF, 0.5 μg/mL
hydrocortisone. MCF10A neoT cells were maintained in the same media as HMLE cells with

the addition of 0.1 μg/mL cholera toxin. If indicated, HMLE+Twist-ER cells were growth in
the presence of 4-hydroxytamoxifen (10 ng/mL) in order to activate the ER inducible Twist
construct.

MSP cells were obtained from HMLE cells by sorting for CD44-APC high

population/CD24-Cy5.5 LOW. HMLE cells were sorted according to CD24-Cy5.5 high and

CD44-APC low.

Generation of stable cell lines by retroviral transduction
The template for Human GRHL2 was purchased from Open Biosystems (MHS4426-

99625903). GRHL2 was subcloned by standard molecular biology protocols into the pMXS-

IRES-puro retroviral vector in frame with the C-terminal 3X-FLAG tag (vector contribution

of Russ Carstens, University of Pennsylvania). Retroviral packaging and amplification was
done in GP2+293T cells by transfection of 4.5 μg of retroviral plasmid and 2.5 μg of pCMV-

VSV-G on collagen coated 60 mm2 dishes that were pre-coated for >1 hr with 50 μg/mL
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collagen using Lipofectamine 2000 (Invitrogen). Plates were refed 4-6 hours following
transfection and viral supernatants were harvested approximately 36 hours following
refeed. Viral stocks were filtered through 0.45 μm filters (Whatman) and 1 mL of
supernatant was used to infect 1 well of target cells. This was followed by 1,400 RPM

centrifugation for 1 hour at room temperature followed by 6 hour or overnight incubation.
Infected cells were passaged to 100 mm dishes, and incubated for 48 hours following

infection. Cells were then selected for puromycin (2 μg/mL for HMLE or MCF10A neoT cells).
Generation of stable cell knockdown cell lines by lentiviral transduction
Lentiviral GLUD1 short hairpin RNA (shRNA) was purchased from Open Biosystems

in the pLKO vector. ShRNA #1 was Open Biosystems catalogue number RHS3979-

201758959 and shRNA#2 was RHS3979-201758962. pLKO scramble control vector was

generously contributed by the laboratory of Dr. Scott Weed (WVU). Lentiviral constructs
were packaged and amplified in 293T cells by transfection of 3.5 μg shRNA vector, 2.3 μg
sPAX2, and 1.2 μg CMV-VSV-G on 60 mm2 dishes that were pre-coated for >1 hr with 50

μg/mL collagen using Lipofectamine 2000. GRHL2 shRNA was described previously and
was shown to duplicate the biologic effects of transfected siRNAs (15).
Western Blotting
SDS-PAGE was conducted using 4-20% gradient Tris-Glycine gels (Invitrogen).

Proteins were electrophoretically transferred to polyvinylidine difluoride filters
(Immobilon) in 5% methanol Tris-Glycine transfer buffer. PBS + 0.1% Tween-20 + 5% nonfat

milk were used for blocking filters, primary antibodies were incubated in PBS+0.1% Tween76

20 + 5% nonfat milk. Primary antibodies were typically incubated between 2 hours at room

temperature or overnight at 4 degrees C. Primaries used were: E-cadherin, ms (BD
Biosciences), CD44 (HCAM) ms [Santa Cruz Biotech (SCBT)]; GRHL2, rb (Sigma), Akt or pAkt,
rb (Cell Signaling); GLUD1, rb (Abcam 168352), α-tubulin, Rb (Cell Signaling), Fibronectin,
ms (BD Biosciences), GAPDH, ms (Origene), β-actin, ms (Thermo-pierce), SOD2, Rb (Cell

Signaling), HIF1α, ms (BD Biosciences), p110, ms (BD Biosciences), TOMM20, ms (BD
Biosciences), VDAC1, Rb (Cell Signaling). Secondary antibodies for chemiluminescence were

either anti-mouse or anti-rabbit, conjugated to horseradish peroxidase (HRP) enzyme (BioRad). Secondary antibodies (Biorad) were used at 1:3000 dilution and filters were incubated
for approximately 1 hour at room temperature. Western blots were developed via ECL Super
Signal West Pico (Thermo-Pierce).
Anoikis Assays
For anoikis assays, caspase activation was measured using the Caspase-Glo 3/7

assay kit (Promega). Cells were dissociated using TrypLE Express (Invitrogen) and a fixed

number of cells (1.5 x 105 cells) were placed per 6 well poly-(2-hydroxyethyl methacrylate)
(poly-HEMA) coated low attachment plates in 2.0 ml of normal growth medium + 0.5%

methylcellulose for the indicated time. Aliquots of cells were mixed 1:1 with caspase glo

reagent at indicated time points and assayed for luminescence utilizing a Wallac Envison
Perkin Elmer plate reader according to manufacturer’s instructions. Where indicated,

time-zero cell death values were subtracted from the data presented to normalize for small
loading variation.
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ROS Assays
For ROS assay, cells were seeded as above and attached for 48 hours. Cells were

detached by trypsinization, and equal numbers of cells were placed in a 15 mL centrifuge

tube. Cells were assayed immediately by flow cytometry after staining for 15 min at 37
degrees with 1 uM CM-H 2 DCFDA (Invitrogen) protected from light. If indicated, 24 hr ROS
was examined after plating cells in low attachment polyHEMA (2 mg/mL) coated 100 mm

dishes in 5 mL of 0.5% methylcellulose to prevent excess cell clumping. Cells were harvested

by diluting well with 10 mL DME/F12 + 10% Horse Serum containing media. Cells were

centrifuged at 2000 RPM for 2 minutes. Pellets were washed 2X with HBSS and stained in 1
uM CM-H 2 DCFDA as indicated previously. In some cases, Amplex Red (Invitrogen) assays

were used to measure ROS in order to compare attached and suspended conditions and were
used according to manufacturer’s instructions.

For measurement of general cellular

superoxide, cells were processed as above and stained with 5 uM dihydroethidium (DHE)
(Invitrogen) for 15 minutes at 37 degrees C protected from light followed by flow cytometric

analysis at 605 nm fluorescence. Mitochondrial specific superoxide was measured using

mitoSOX (Invitrogen) dye by staining cells with 5 uM mitoSOX solution for 10 minutes at 37
degrees C protected from light. Samples were analyzed by flow cytometry at 580 nm
fluorescence using a BD LSRFortessa Cell analyzer.
ATP Assays

For the measurement of ATP in attached cells, Cell Titer Glo (Promega) reagent was

added to 96 well plates. Luminescence was read after 10 minute incubation at room

temperature. Values were normalized based on BCA protein assay (Pierce). To measure ATP

in detached conditions, cells were detached and placed in 6 well poly-HEMA dishes. Aliquots
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were mixed 1:1 with Cell Titer Glo reagent. Values were normalized based on BCA protein
assay (Pierce).
JC1 Assay

ug/mL

Cells were seeded on poly-d-lysine coated MatTek dishes. Cells were incubated in 2
JC1

(5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine

iodide)

(Invitrogen) at 37 degrees for 30 minutes protected from light. After incubation, dye was

washed off of cells and replaced with normal growth medium. Cells were analyzed using an

Axiovert 100M LSM510 Zeiss Confocal microscope. Cells were excited with an argon-ion
laser source at 488 nm. JC1 monomer emission was observed at 529 nm and J-aggregate
emission was observed at 590 nm. Images were acquired using 20X/0.75 Plan-Neofluar
objective. Software used was Zeiss AIM software, version 3.2.
Oxygen Consumption and Extracellular Acidification Rate
The oxygen consumption rates (OCR) and extracellular acidification rate (ECAR) of

adherent cells were measured utilizing the Seahorse XF Extracellular Flux Analyzer
(Seahorse Biosciences Inc., North Billerica, MA). This method of analysis allows for real time
monitoring of extracellular acidification rates and oxygen consumption based on two

fluorimetric probes inserted into the small volume well. Equal numbers of cells (7500 cells
per well) were seeded in a defined small volume in Seahorse XF-96 well plates. The following

day, wells were refed with fresh HEPES buffered media approximately 1 hour prior to assay.

In short, the sensor cartridge was loaded with metabolic inhibitors to target specific
components of the electron transport chain at specific times, while monitoring pH change as
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well as oxygen consumption. The metabolic inhibitors used are oligomycin (ATP synthase
inhibitor), followed by the protonophore FCCP (an uncoupler of oxidative phosphorylation),
and finally a combination of rotenone (complex I inhibitor) and antimycin A (complex III

inhibitor). Basal OCR and ECAR measurement during time course treatment with the

inhibitors listed above allow for calculations of basal OCR, maximum mitochondrial
respiratory capacity, OCR due to proton leak, ATP production, spare respiratory capacity,
and non-mitochondrial derived OCR. Fatty acid oxidation study was done by treating cells

overnight prior to assay with substrate limited media (DME/F12 media + 1% horse serum,
0.5 mM carnitine hydrochloride [pH adjusted], 1X PSG, 0.5 mM D-(+)-Glucose, 5 mM HEPES

buffer). On day of assay, substrate limited media was replaced with FAO medium 45 minutes
prior to the start of the assay (Homemade Krebs Henseleit Buffer modified with CaCl 2 : To

500 mL sterile water the following was added: 111 mM NaCl, 5.7 mM KCl, 1.25 mM CaCl 2 , 2.0

mM MgSO 4 , 1.2 mM Na 2 HPO 4 ; This buffer was supplemented with 2.5 mM glucose, 0.5 mM

carnitine, 5 mM HEPES, pH adjusted to 7.4 with NaOH). 15 minutes prior to start of assay, 40

μM Etomoxir was added to the appropriate wells. At the beginning of the assay, either
palmitate:BSA or BSA control was added to appropriate wells. Mitostress test was the
conducted according to manufacturer’s instructions. For glycolytic stress test, cells are

deprived of glucose for approximately 1 hour prior to the beginning of the assay. ECAR is

measured and glucose is re-introduced to the media. The increase in ECAR is attributed to
glucose conversion to pyruvate through glycolysis. Oligomycin is then added to shunt all

metabolic function to glycolysis, which results in a large increase in ECAR indicating the
glycolytic reserve. Following addition of 2-deoxy-glucose (competitive inhibitor of
hexokinase), the non-glucose derived OCR can be calculated.
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Flow Cytometry Sorting
Trypsinized cells (1 x 106) were stained with APC tagged mouse anti-human CD44

(BD Biosciences 560890), and PerCP-Cy5.5 tagged mouse anti-human CD24 (BD Biosciences

561647) in 100 uL of flow sorting buffer (1X PBS, 2.5 mmol/L EDTA, 10 mmol/L HEPES, and
2% horse serum) on ice protected from light for 30 minutes. Following staining, cells were

washed with 1X HBSS and resuspended in flow sorting buffer. Cells were analyzed and sorted
using a FACS-Aria.

Cell Culture Antioxidant Treatments
For suppression of reactive oxygen species, the following antioxidants were used.

Where indicated, HMLE cells were treated with N-acetyl cysteine (NAC) at the concentration

indicated for 1 hr prior to assay. Reduced glutathione (GSH) was added to HMLE cells after
pH correction to 7.4 and incubated for approximately 1-2 hours depending on experiment at

the indicated concentration. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid

(Trolox) was added to cells at the indicated concentration for overnight pretreatment of
HMLE or HMLE+shGLUD1 cells. HMLE or HMLE+shGLUD1 cells were treated with cell

permeable di-methyl-α-ketoglutarate (Sigma) which was pH corrected to 7.4. Cells were
treated at the indicated concentration between overnight and 2 hour pre-treatment.
RNA Sequencing
RNA was isolated in triplicate from both MSP cells expressing vector alone or stably

expressing GRHL2. For RNA isolation, the RNeasy Plus Kit (Qiagen) was used and was
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quantified using Nanodrop (Fisher Scientific). The RNA quality check was performed on

Bioanalyzer (Agilent). RNA quality check and libraries builds were done by the WVU
genomics core. RNA samples were then sent to the University of Illinois Core Facility for

100BP single end data RNA sequencing. FastQC was used to visualize quality of sequencing.

After it was determined that no filtering was needed, the reads were mapped to hg38 using
STAR. The data was then quantified with featureCounts with the following flag set: —ignore
dup—primary. This count data was used as input into DEseq2 to produce a list of

differentially expressed genes with some visualizations also included. The list of genes with
FPKM was also acquired and was produced from the count data with a simple custom script.
Kinetic α-KG assay
HMLE, MSP, or MSP+GRHL2 cells were seeded in 6 well dishes in duplicate wells and

allowed to attach for 24 hours. Wells were washed 2X with PBS, followed by lysis in 300 uL

RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton-X100, 1% Sodium Deoxycholate,

0.1% sodium dodecyl sulfate, + pierce miniprotease inhibitor table per 10 mL lysis buffer).
Lysates were scraped into microfuge tubes and cleared in cold centrifuge at 4ºC at full speed
for 10 minutes. Supernatants were saved and assayed in 100 uL reaction buffer (100 mM

KPO 4 pH 7.2, 10 mM NH 4 Cl, 5 mM MgCl 2 , and 0.15 mM NADH added immediately prior to

assay). 10 uL of sample were added to 100 uL reaction buffer. Immediately prior to the
beginning of the assay, 0.7 uL (0.5 units) of L-Glutamate Dehydrogenase enzyme (bovine

liver, sigma G2626) was added to each of the wells using a multi-channel pipettor. Positive
control samples were done to ensure linear range of α-KG concentration in samples. OD was

read kinetically at 37 ºC at 340 nm reading the sample every 10-20 seconds depending on
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the number of samples in the assay. Depending on the level of α-KG in the sample, the
reaction would proceed more quickly or more slowly. The slope of the line created by

monitoring the decline in NADH absorbance as it was used up in the reaction was calculated

and indicated the relative concentration of α-KG. Calculated slopes were normalized to
protein in the samples as determined quantitatively by BCA assay (Pierce).
Extraction of Cells for LC-MS Analysis
All solvents used were high quality HPLC gradient grade and sterile milliQ grade

water was used. Cells were plated in triplicate per condition in 6 well dishes. Cells were
seeded for at least 24 hours prior to extraction. Wells were washed 3X with PBS. Extract

solution was made up of 50% methanol, 30% acetonitrile, and 20% milliQ water. Extraction

buffer was pre-chilled in a dry ice ethanol bath. Eppendorf tubes were pre-chilled in a dry
ice/ethanol bath placed in a metal heating block for maximum cooling. Intracellular extracts

were made by adding 500 uL of pre-chilled extraction buffer to wells and placing plate on a
shaker in the cold room for 10 minutes. The solution was then transferred into pre-chilled

Eppendorf tubes. Samples were centrifuged at 0 ºC at full speed for 10 minutes. Supernatants
were transferred to HPLC vials and stored at -80 ºC. For LC-MS method, Column was the
sequant Zic-pHilic (150 mm × 2.1 mm i.d. 5 μm) with the guard column (20 mm × 2.1 mm i.d.

5 μm) from HiChrom, Reading, UK. Mobile phase A: 20 mM ammonium carbonate plus
0.1% ammonia hydroxide in water. Mobile phase B: acetonitrile. The flow rate was kept at
100 μl min−1 and gradient as follow: 0 min 80% of B, 30 min 20% of B, 31 min 80% of B, 45 min
80% of B. The mass spectrometer (Thermo Exactive Orbitrap) was operated in a polarity switching
mode.
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Immunofluorescence
Cells were plated on chamber slides (LabTek154526) using ~0.5 ml medium per

chamber. Wells were pre-coated with sterile 0.5 mg/ml poly-lysine or 20 ug/ml collagen for
~1 hour, and washed off prior to plating. Cells were washed in HBSS or D-PBS, and fixed

in EM grade 4% formaldehyde in 1X PBS for 20 minutes at room temperature. Cells were
washed 2X with PBS. Samples were then permeabilized in 0.5% TX100 in PBS at 4 degrees

for 10minutes. Permeabilization solution was washed 2X with PBS. Cells were incubated in
100mM glycine in PBS for 10 minutes to quench the formaldehyde. Cells were blocked for
one hour in PBS+10% goat serum+0.1% Tween-20+0.1%BSA for 1 hour. Primary antibody

was diluted in blocking solution, and incubated 1 hr/RT or overnight/4 degrees (TOMM20,
ms; BD Biosciences). Primary antibody was typically diluted 1:250. After probing, cells were

washed with PBS+0.1% Tween-20, 3X. Secondary antibody (Anti-mouse Alex Fluor 555;

Invitrogen) was diluted in blocking solution, and incubated 1-2 hr/RT (typically 1:1000
dilution). Cells were washed again with PBS+0.1% Tween-20, 3X. Samples mounted in
ProLong Gold+DAPI.
Statistical Analysis
Error bars in graphs represent SDs. P-values were calculated using a Student’s two-

tailed t-test.
Results
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EMT shifts metabolism from glycolysis to oxidative phosphorylation, which is reversed by
GRHL2.

MSP and TGF-β-induced MCF10aneoT cells result from EMT that requires GRHL2

down-regulation (15, 16, 28), accompanied by a CD44highCD24low marker profile (figure 1A).
Re-expression of GRHL2 sensitized these cell lines to anoikis significantly, as assessed by a

caspase activation assay (figure 1B, 1C, figure S1A). Conversely, the stable knockdown of

GRHL2 using shRNA conferred anoikis-resistance in HMLE+Twist-ER cells as well as
MCF10A neoT cells (figure 1D, S1B). We first endeavored to characterize the effect of EMT

and, conversely, the effect of GRHL2-induced MET on metabolism in our system. We found
that the ATP level in attached MSP cells was elevated significantly compared to HMLE cells.

When cells were suspended, ATP level declined significantly in HMLE cells, but was

maintained in MSP cells, even at twenty-four hours of suspension (Figure 2A). GRHL2

reduced the level of ATP in both suspended and attached MSP cells (figure 2B). In light of the

higher efficiency of mitochondrial oxidative phosphorylation compared to glycolysis in the

production of ATP, these results suggested that EMT perhaps caused a shift to the former.
MSP cells had a higher mitochondrial membrane potential (ΔΨ), reflecting increased
oxidative phosphorylation. Conversely, GRHL2 overexpression resulted in decreased ΔΨ in
MSP cells (Figure 2C). These results, and the marked ATP differences, indicated that EMT

shifted cells toward an increased utilization of mitochondrial oxidative phosphorylation to
increase basal ATP levels and sustain ATP even in suspended cells.

In order to test the effect of EMT or GRHL2-induced MET on regulation of oxidative

metabolism specifically, we compared oxygen consumption rate in HMLE, MSP, and
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MSP+GRHL2 cells using the Seahorse mitochondrial stress test. The Seahorse XF assay
system measures extracellular acidification rate (ECAR) as well as oxygen consumption rate
(OCR) in order to determine fluxes in metabolic parameters that occur upon addition of

various inhibitors and stimulators of the electron transport chain. Our results indicated that
MSP cells had greater ATP, maximum respiration, as well as spare oxidative capacity relative

to HMLE cells, and re-expression of GRHL2 reversed these effects (figures 3A,B). The
increased mitochondrial activity of MSP and reversal by GRHL2 were not limited to cells
utilizing glucose and glutamine as carbon sources, as similar effects were seen with the fatty

acid carnitine as the sole carbon source (figures S4A,S4B). Moreover, HMLE cells had higher
glycolytic activity than MSP cells (figure S2A). Stably depleting GRHL2 in both HMLE+TwistER and MCF10A neoT cells partially reversed the mesenchymal metabolic phenotype,
increasing ATP and maximum respiration (figure S2B, S2C, S2D).

To determine whether the increased OCR observed was due to elevated

mitochondrial number, cell lines were stained for a mitochondrial structural protein,
TOMM20. Surprisingly, we found that MSP cells had lower mitochondrial staining than HMLE
cells (figure S2E, S2F). This may indicate that HMLE cells partially compensate for low

mitochondrial activity by up-regulating mitochondrial biogenesis. Taken together, these

results confirmed that mesenchymal cells enhanced oxidative phosphorylation, and partially

suppressed glycolysis, both of which are counteracted by GRHL2. Confirming this
observation, we found that treatment with 2-deoxyglucose (2-DG) resulted in greater

decrease in ATP level in HMLE cells (58% of no treatment control) and MSP+GRHL2 cells

(59.1% of no treatment control) than in MSP cells (72.1% of no treatment control) (figure
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S3A). GLUD1 depletion did not directly affect ATP levels, as reported (29). The loss of GLUD1
did, however, result in a decrease in mitochondrial membrane potential (figure S3B).
EMT suppresses the accumulation of ROS; reversal by GRHL2

To identify genes regulated by GRHL2 underlying its metabolic effects, we conducted

RNA-seq analysis. Surprisingly, we did not find that major ETC components or Krebs cycle
metabolic enzymes were significantly affected by GRHL2 expression, with the possible

exception of pyruvate dehydrogenase kinase 4 (PDK4), but its levels were highly sensitive to

the initial conditions of each individual experiment, precluding definitive conclusions as to

its regulation (data not shown). GRHL2 did, however, regulate several genes that participate

in reactive oxygen species (ROS) regulation (Table 1). Interestingly, GRHL2 expression did
not significantly affect expression of the major ROS regulatory enzymes superoxide
dismutase or catalase (Table 1).

We compared endogenous ROS levels in HMLE, MSP, and MSP+GRHL2 cells. We found

that the MSP cells display a significant reduction in ROS by fluorigenic reporter assay (CMH 2 DCFDA) in both 0 hour and 24 hour suspended conditions, and that GRHL2 increased

ROS to the approximate level detected in HMLE cells (figure 4A). Inducing EMT in the basal
mammary epithelial cell line, MCF10A neoT, with TGF-β treatment resulted in decreased

ROS; further, overexpression of GRHL2 elevated ROS level (figure S5A). Conversely, shRNA
depletion of GRHL2 suppressed ROS levels both in HMLE+Twist-ER cells and MCF10A
neoT cells (figures 4C, S5D).
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To identify the species of ROS present, we analyzed cells with a variety of fluorometric

dyes with varying species selectivities. CM-H 2 DCFDA staining is a general ROS indicator that
responds well to hydrogen peroxide (H 2 O 2 ). In order to verify that this was the predominant
species, we stained cells with MitoSOX red, dihydroethidium (DHE), and Amplex red-

hydrogen peroxide reporter. Amplex Red, which reports hydrogen peroxide specifically,
indicated ROS trends similar to those obtained by CM-H 2 DCFDA staining in both attached

and suspended conditions (figure 4B). MitoSOX red and DHE staining report mitochondrial
and generalized superoxide, respectively. These probes showed that HMLE cells had lower

mitochondrial and general superoxide (O 2 .-) levels than MSP cells and that overexpression

of GRHL2 resulted in a decreased O 2 .- level (figure S5B, S5C). Mitochondrial electron
transport is the major source of cellular superoxide (30). In this light, our superoxide data
correlated well with our data on mitochondrial oxidative phosphorylation. These data

indicated clearly that mitochondria are not the major source of higher ROS in normal
epithelial cells or GRHL2-reverted epithelial cells, as this ROS was hydrogen peroxide, not

superoxide, and mitochondria were more active in mesenchymal cells, which had lower
overall ROS.

We further sought to examine the role played by ROS in contributing to anoikis

sensitivity. HMLE cells were treated with two common antioxidant compounds including

reduced glutathione and the vitamin E derivative, Trolox. We found that these compounds
reduced ROS level in cells and significantly reduced both ROS and sensitivity to anoikis

(Figure 4D). In figure S5A, we show that MCF10a neoT cells experience a large ROS burst
between 0 and 24 hours. Speculatively, this burst may occur much earlier in HMLE cells,

resulting in little difference between 0 and 24 hours. It is also plausible that in HMLE cells
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at 24 hours, enough cell death has occurred to obscure the ROS burst. These findings
support the crucial role of ROS in triggering anoikis.

We have previously reported that CD44S, which is upregulated in MSP cells, contributes

to anoikis resistance (31). CD44 was shown elsewhere to decrease ROS by shifting
metabolism from oxidative phosphorylation toward glycolysis and pentose phosphate
pathways, thereby increasing reduced glutathione levels (32). Consistent with this, the

stable knockdown of CD44 resulted in increased ROS, and increased sensitivity to anoikis
(figure S7A, S7B). Our metabolic findings were inconsistent with the mechanism proposed
in (32) because we observed a shift toward oxidative phosphorylation in MSP cells (figure
3) and because reduced glutathione levels in HMLE and MSP cells were similar (figure S8).

Interestingly, neutralizing cellular ROS in HMLE cells with the scavenger N-acetyl

cysteine (NAC) resulted in a significant increase in ΔΨ (Figure 4E). Neutralizing ROS in
MSP+GRHL2 cells replicated this effect (figure S6A), indicating that the low-ROS cellular

environment could play a role in sustaining the elevated mitochondrial function that we
observed in mesenchymal cells (figure 2).

EMT up-regulates glutamate dehydrogenase-1; reversal by GRHL2

Our RNA-seq data indicated that GRHL2 down-regulated several genes that have well

established effects on ROS in other systems (Table 1). Manipulation of the levels of
NCF2/p67PHOX, ALOX15, FAT4 and NQO1, however, produced no significant change in ROS

in our cells (data not shown). GRHL2 also down-regulated Glutamate Dehydrogenase 1
(GDH1 or GLUD1), an enzyme implicated in the suppression of ROS (27). By western
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blotting, we found that GLUD1 protein was upregulated in MSP cells relative to HMLE cells,
and downregulated in MSP by GRHL2 expression, in agreement with our RNA-seq data
(figure 5A). Similarly, EMT that was generated by transient activation of Twist-ER protein
also up-regulated GLUD1, which was prevented by GRHL2 (figure 5B); similar effects were

found in TGF-β-induced MCF10a neoT cells (Figure S8). Conversely, GLUD1 expression
increased following depletion of GRHL2 in both HMLE+Twist-ER and MCF10A neoT cells

(figure 5C), indicating that GRHL2 is an important repressor of GLUD1.

Depletion of GLUD1 was previously shown to reduce α-ketoglutarate (α-KG) levels,

indicating that GLUD1, through glutaminolysis, is a major source of α-KG (27). Interestingly,
we found that MSP cells have an elevated α-KG:succinate ratio relative to HMLE cells and that
GRHL2 decreased α-KG, using both enzymatic and liquid chromatography/mass

spectrometric assays, consistent with the expression levels of GLUD1 (Figure 5D, 5E, 5F).
GLUD1 suppresses ROS and anoikis

Next, we tested the effects of altered GLUD1 and α-KG levels on ROS and anoikis. The

stable knockdown of GLUD1 enzyme using shRNA transduction resulted in both an increase
in ROS level as well as increased sensitivity to anoikis (figure 6A). A similar effect of GLUD1
knockdown was observed in HMLE+Twist-ER cells (figure S8C).

To confirm that the GLUD1 effect on ROS was mediated by α-KG, we tested the effect

of α-KG supplementation using the cell-permeable di-methyl-α-ketoglutarate derivative in
GLUD1-depleted cells. This resulted in a dose dependent protection from anoikis as well as
a reduction in ROS in HMLE cells (figure 6B). Moreover, the excess anoikis observed in HMLE
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cells as well as MSP+GRHL2 cells was suppressed by α-KG replacement, demonstrating that
the loss of GLUD1 promoted anoikis through ROS (figure 6C, 6D, S10). Neutralizing ROS with

antioxidants or α-KG partially protected HMLE+shGLUD1 cells against anoikis as well (figure
6E, 6F).

These data indicate the critical role of GLUD1 up-regulation during EMT, resulting in

protection from anoikis by suppressing ROS, and the converse role of GRHL2 in promoting
anoikis through GLUD1 down-regulation (summarized in figure 7).
Discussion

The role and mechanism of the Warburg-like shift to aerobic glycolysis in tumor cells

has received extensive investigation, but this effect is now known to be highly context
dependent. In fact, recent studies indicate that cancer stem cells (related, in some instances,
to EMT) develop an enhanced capacity for and dependence on oxidative phosphorylation

((33),see (34) for an excellent review). Moreover, oxidative phosphorylation can contribute

to tumor metastasis (35, 36). This is thought, counter-intuitively, to have advantages for
slow-cycling cancer stem cells, such as better maintenance of ATP in nutrient-poor tumor

environments due to the higher efficiency of the TCA/ETC pathway (using fatty acids or
glutamine as carbon sources); moreover, the tumor microenvironment is rarely, if ever,
hypoxic enough to inhibit oxidative phosphorylation (34). Our metabolic results comparing
MSP vs. HMLE cells are highly consistent with this new understanding, and they show that

GRHL2 reverts MSP cells back to an epithelial type metabolism (higher glycolysis, lower
oxidative phosphorylation), accompanying re-sensitization to anoikis.
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Metabolic changes due to oncogenic transformation, EMT or transition to cancer

stem cells have been reported extensively, with unique effects in each system (35, 37-40).
In this paper, we provide a mechanism by which EMT/cancer stem cell transition lowers
ROS so at protect cells against anoikis. Under this model, GRHL2 reverses EMT,

suppressing mitochondrial oxidative function by repression of the critical enzyme

regulating glutaminolysis, GLUD1, resulting in loss of glutamine utilization, increased ROS
level, ultimately shifting metabolism resulting in anoikis sensitivity (Figure 6).

There may be multiple mechanisms of ROS neutralization downstream of α-

ketoglutarate. First, it can act synergistically with other compounds (e.g., ascorbic acid) as

a co-antioxidant (41). Secondly, the reverse GLUD1 reaction yields glutamate, contributing
to glutathione synthesis. Thirdly, α-ketoglutarate is a co-factor for both histone

demethylase and DNA demethylase enzymes. Changes in the level of this co-factor could
affect gene expression epigenetically, as observed in other settings (42), with effects on
metabolism and ROS. Finally, a recent report shows that up-regulated GLUD1 in tumor

cells led to increases in α-ketoglutarate, increasing fumarate, in turn, through Krebs cycle

enzymes. This contributed to the neutralization of cellular ROS, because fumarate

activated glutathione peroxidase activity. GLUD1 up-regulation was, accordingly, shown to

be pro-tumorigenic, and this effect was mediated by decreased ROS levels (27). In renal cell

carcinoma, fumarate hydratase (FH) deficiency was increased fumarate to millimolar

levels, contributing to oxidative stress rather than alleviating it (43). However, the major

ROS in that study was superoxide rather than hydrogen peroxide, and GRHL2 did not affect
FH level in our cells (data not shown). We speculate that the contradictory effects of
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fumarate in FH-deficient vs. GLUD1-over-expressing tumor cells may be reconciled by

these considerations.

Interestingly, autophagy, which may play positive or negative roles in anoikis and

non-apoptotic cell death after detachment, is regulated by glutaminolysis as well, through

mTORC complexes (25). Speculatively, GLUD1/ α-ketoglutarate alterations due to EMT or
GRHL2 may affect cell survival through these additional pathways.

The upregulation of GLUD1 would have multiple advantages for EMT/CSC cells,

including increased use of glutamine or glutamate as alternative carbon sources in glucosepoor environments, protection against ROS, and the increased ETC/oxidative

phosphorylation capability afforded by less ROS-induced mitochondrial damage.
Interestingly, the aspartate/glutamate transporter SLC1A6 was down-regulated

dramatically by EMT, and, conversely, up-regulated by GRHL2 (table 1). Recently, SLC1A6
was found to act primarily as a glutamate exporter (44). EMT/CSC cells are predicted,

therefore, to have increased accumulation of intracellular glutamate, contributing to the
pathway that we have emphasized here.
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Table 1. Effect of GRHL2 on expression of ROS-regulatory genes
Gene ID

Fold Change

Significance in ROS or Metabolism

(MSP+GRHL2/
MSP+vec control)
ALOX15

+236.0

Can reportedly generate lipid peroxide radicals from

ALOXE3

+21.0

arachidonic acid substrates

ALOX12P2

+18.3
Glutamate/Aspartate transporter which may alter α-KGDH

SLC1A6

+165.7

activity resulting in H 2 O 2 radicals and reduce its TCA
activity

NCF2
PHOX)

(p67-

+23.4

Cytoplasmic subunit of NADPH-Oxidase (NOX) Complex
Human homologue of Drosophila Fat. Potentially contains

FAT4

-19.6

Ft mito fragment which binds complex I and stabilizes it to
reduce ROS/increase mitochondrial activity
Soluble superoxide dismutase enzyme involved in

SOD1

-1.4

cytoplasmic O 2 .- detoxification. Not significantly by GRHL2
overexpression
Mitochondrial isoform of superoxide dismutase involved in

SOD2

+1.2

conversion of mitochondrial O 2 .- into diffusible H 2 O 2 . Not
significantly altered by GRHL2 overexpression

SOD3

NA

Extracellular superoxide dismutase
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Catalase enzyme involved in detoxification of H 2 O 2 ROS
Cat

-1.3

species. Appears to be slightly regulated by EMT, but not
significantly altered by GRHL2 overexpression

NQO1

-1.9

ROS detoxifying enzyme which reduces quinines to
hydroquinones – major Nrf2 target gene
Reported be the primary source of cellular regulation of α-

GLUD1

-2.5

KG which feeds to TCA cycle to increase Fumarate and
stabilize GPx1

Figure Legends
Figure 1. MSP cells are an anoikis resistant subpopulation of HMLE cells which have
undergone EMT and lost GRHL2 expression. A. (upper panel): HMLE cells were sorted for

CD44 and CD24 by FACS (insert shows up-regulated CD44S in MSP cells); B: Resulting sub-

populations were assayed for anoikis sensitivity by caspase 3/7 activation assay; C. MSP cells
in which GRHL2 was re-expressed were assayed for anoikis compared to vector control (24
hour time point with zero time subtracted). (lower panel):

confirmation of GRHL2

expression by western blotting. D. HMLE+Twist-ER cells depleted of GRHL2 by shRNA

transduction were assayed for anoikis; the confirmation of GRHL2 knockdown is shown as
part of figure 5C.

Figure 2. ATP levels are elevated in mesenchymal relative to epithelial cells due to
increased mitochondrial membrane potential (ΔΨ) A. HMLE and MSP cells were

analyzed for ATP level under attached or suspended (16 h, 24 h) conditions. (The line

indicates that the attached level cannot be directly compared to the suspended levels due to
proliferation in attached condition). B. GRHL2 suppresses ATP level in MSP cells in both
attached and suspended conditions. C. ΔΨ is elevated in MSP cells, which is reduced by

GRHL2 overexpression (JC1 fluorescent probe; green=monomers to indicate free JC1,
orange=aggregates of JC1 proportional to ΔΨ); (right panel): Image J quantification and ratio
calculation of raw intensity pixel density for single phase red and green images.
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Figure 3. Shift from glycolysis to oxidative phosphorylation accompanies EMT;
reversal by GRHL2 A. MSP cells have higher ATP production, maximum respiration, and
higher spare capacity for oxidative phosphorylation than HMLE; B. Reversal by GRHL2

Figure 4. Epithelial cells have higher ROS than mesenchymal cells, and the excess ROS
promotes anoikis. A. HMLE cells have higher ROS compared to MSP cells, which is elevated
by GRHL2 expression in MSP cells: CM-H 2 DCFDA fluorescence at the indicated times of

suspension. B. Hydrogen peroxide is the major regulated ROS type (Amplex Red assay); C.

shRNA depletion of GRHL2 decreases ROS in HMLE+Twist-ER cells. D. Antioxidant
compounds protect against anoikis. MSP+GRHL2 cells were pre-treated overnight with
reduced glutathione (GSH, 5 mM) and Trolox (100 uM) followed by ROS and anoikis assay;
E. Suppression of ROS resulted in increased JC1 aggregate formation and elevated ΔΨ. HMLE

cells were treated with N-acetyl cysteine (NAC) at 0.25 and 0.5 mM for 1 hr before staining
with JC-1 fluorimetric dye. (right panel): Image J quantification and ratio calculation of raw
intensity pixel density of single phase red and green images.

FIGURE 5. GRHL2 regulates Glutamate dehydrogenase-1 and α-ketoglutarate levels.
A, GLUD1 is downregulated by GRHL2 in MSP cells (upper panel: RNA-seq data lower
panel: western blot); B. GLUD1 expression is upregulated during EMT and is

downregulated by GRHL2 in HMLE-Twist cells; C. shRNA depletion of GRHL2 results in

increased GLUD1 protein. D. α-KG is higher in MSP cells relative to HMLE cells, and GRHL2
overexpression decreases it (enzymatic assay measuring loss of NADH absorbance); E. α-

KG:succinate ratio is higher in MSP than in HMLE or MSP+GRHL2 cells (mass spectrometric
assay). F. α-KG:succinate ratio is decreased by GRHL2 in HMLE cells induced to undergo
EMT by Twist-ER activation (mass spectrometric assay).

FIGURE 6. GLUD1 and α-KG regulate anoikis through ROS. A. (upper panel): Western
blot analysis of HMLE+shGLUD1 cells. (lower panel): GLUD1 knockdown elevates ROS

level; (B) GLUD1 knockdown promotes anoikis as assessed by CM-H 2 DCFDA assay and

caspase 3/7 activation assay (respectively); C. Dimethyl-α-KG lowers ROS; (D) Dimethyl100

α-KG protects HMLE cells against anoikis; E. DM-αKG and Trolox lower ROS level; (F) DM-

αKG and Trolox protect GLUD1 knockdown cells against anoikis.

FIGURE 7. GRHL2 suppresses EMT and results in the loss of GLUD1. This decreases α-KG,
suppressing oxidative metabolism, increasing ROS, and sensitizing cells to anoikis.
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Supplemental Figure Legends
Figure S1. GRHL2 sensitizes MCF10A neoT cells to anoikis. A. Caspase 3/7 activation

assay on 24 hour anoikis assay (zero hour subtracted). B. shRNA depletion of GRHL2
decreases anoikis sensitivity in MCF10A neoT cells.

Figure S2. EMT causes a metabolic shift from glycolysis to oxidative phosphorylation, that
is partially reversed by GRHL2. A. Elevated glycolysis in HMLE cells relative to MSP cells

(Seahorse XF-96 glycolysis stress test); (B) shRNA depletion of GRHL2 increases ATP and
maximum respiration (Seahorse XF-96 mitostress test) in HMLE+Twist-ER cells; (C) shRNA
depletion of GRHL2 increases ATP and maximum respiration in MCF10A neoT cells.

D.

Graphical representations of Seahorse assays showing OCR measurements prior to and

following addition of stimulators and inhibitors of oxidative phosphorylation. E. MSP cells

(derived from HMLE+Twist-ER cells, not treated with 4-OHT) have decreased mitochondrial

structural protein TOMM20 when compared to HMLE+Twist-ER (not treated with 4-OHT)

epithelial subpopulation. F. MSP cells have lower expression of the mitochondrial structural
proteins TOMM20 and VDAC1 by western blotting.

Figure S3. MSP cells are able to maintain ATP in spite of inhibition of glucose
utilization with 2-deoxyglucose; reversal by GRHL2. A. Cells were treated with 5 and 10
mM 2-DG for 24 hours and evaluated for ATP level (Cell Titer Glo). Error bars are SD of mean.

B. Knockdown of GLUD1 in HMLE cells decreases mitochondrial membrane potential (JC1

aggregate formation) (lower panel): Image J quantification and ratio calculation of raw
intensity pixel density of red and green images.

Figure S4. Multiple carbon sources, including fatty acids, contribute to the elevated
mitochondrial function in MSP cells. A. Elevated FAO in MSP cells relative to HMLE cells

(Seahorse XF-96 FAO assay test; Eto = Etomoxir fatty acid oxidation inhibitor); B. GRHL2 re-

expression decreases ATP production and maximum respiration in response to a fatty acid
substrate (carnitine).
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Figure S5. EMT decreases overall ROS and results in anoikis resistance, but elevates
superoxide levels. A. (left and middle panels): Treatment of MCF10A neoT cells with TGF-

β (5 ng/mL) induced irreversible EMT resulting in decrease in ROS and anoikis; (right panel):
Overexpression of GRHL2 increased ROS in MCF10A neoT cells; B. Mitochondrial superoxide
was increased by EMT and diminished by GRHL2 overexpression (MitoSOX); C. GRHL2

overexpression also decreased general superoxide level (DHE). D. Depletion of GRHL2 in
MCF10A neoT cells decreases ROS by CM-H 2 DCFDA staining.

Figure S6. Treatment of MSP+GRHL2 cells with antioxidant compounds results in
elevated ΔΨ. (left panel): Representative images of treated cells. (right panel): Image J

quantification and ratio calculation of raw intensity pixel density of single phase red and
green images.

Figure S7. Depletion of CD44 with stable shRNA transduction increases anoikis and
ROS. A,B. shCD44 cells are more sensitive to anoikis (caspase 3/7 activation assay) and have
increased ROS level (CM-H 2 DCFDA fluorescence).

Figure S8. HMLE and MSP cells have similar levels of reduced glutathione.
Figure S9. GRHL2 downregulates GLUD1 in MCF10A neoT cells and depletion of
GLUD1 from HMLE+Twist-ER cells increases ROS and anoikis. A. 4OHT was added to
HMLE+Twist-ER cells for 9 days, causing EMT; 4-OHT was then removed (+/-), causing

cells expressing exogenous GRHL2 to revert to an epithelial state, while the control cells

remained mesenchymal (15). Lysates were made 9 days after 4OHT removal and analyzed
for the indicated proteins by western blotting. B. GRHL2 down-regulates GLUD1 in
MCF10aneoT cells induced with TGF-β. C. Stable knockdown of GLUD1 by shRNA

transduction increases ROS (left panel) and anoikis (right panel) in HMLE+Twist-ER cells
to a similar level as in HMLE cells.
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Figure S10. Treatment of MSP+GRHL2 cells with DM-αKG (10 mM) results in decreased
ROS and protection from anoikis.
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Chapter 3
The Effect of GRHL2 on Tumor Recurrence
following Chemotherapy or Oncogene
Withdrawal

The following represents unpublished data. Select portions of this work are ongoing projects
in the Frisch Lab.
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Project Overview
Grainyhead genes play an important role in embryogenesis in the context of neural

tube closure, wound healing, and carcinogenesis. For a more thorough discuss on the role
of Grainyhead-like 2 in cancer, chemotherapy resistance, and tumor recurrence, refer to

Chapter 1, part 2 of this dissertation. The major aims of this project were to investigate the
effect of GRHL2 overexpression on prevention of either chemotherapy induced recurrence
in an orthotopic injection model or oncogene independent recurrence in a transgenic
mouse model. These will be detailed below.
Introduction/Project Design
Disease recurrence several years following successful treatment of primary tumors

is a frequent reality, and is the most common cause of mortality from cancer. It has been

extensively demonstrated that in these settings, plasticity conferred by EMT benefits small
populations of cells, bestowing CSC-like and chemoresistant properties to these primary
tumor cells, which persist, only to resume growth after a period of dormancy (1-7). In

breast cancer, these populations are often identified by a shift in surface expression toward
a CD44HIGH/CD24LOW phenotype. In culture, treatment of HMLE cells with taxol derivatives

selects for this CSC-like population; conversely, stable expression of GRHL2 significantly
sensitizes these, as well as MDA-MB-231 cells, to this therapy. Most importantly,

ectopically expressed GRHL2 prevents the chemotherapy-induced emergence of this

population capable of tumor initiation (8). It is well accepted that EMT is generally

associated with a heightened propensity for metastasis as well as a decreased sensitivity to
conventional cytotoxic chemotherapeutics. Further, it has been demonstrated by
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Chakrabarty et al. that treatment of cancer cells with the anti-cancer chemotherapeutic

agent paclitaxel enriches for CD44 and ALDH expression as well as CD24 downregulation,
all features associated with cancer stem cells (9).

In order to elucidate the role of GRHL2 in prevention of chemoresistant CSC-like

subpopulations in vivo, we designed a doxycycline inducible ectopic GRHL2 construct. This

GRHL2 inducible vector has prevented EMT in HMLE-Twist-ER cells when subjected to 4-

hydroxytamoxifen induction, further supporting the importance of GRHL2 in suppression of
EMT. Work shown here proposed injection of tumor lines containing GRHL2 inducible

constructs into syngeneic mice followed by treatment with chemotherapy and subsequent

analysis of recurrent populations. In order to determine the role of GRHL2 in protection
from EMT/chemotherapy induced CSC enrichment, we planned to develop stable mouse
tumor cell line expressing a doxycycline inducible GRHL2 construct, inject these tumor cells

orthotopically into the mammary fat pad of syngeneic mice allowing tumors to form to sizes
of greater than 5 mm. We would then treat with chemotherapy (approved therapies include

Cisplatin, Cyclophosphamide, Doxorubucin, and Paclitaxel), dividing therapy groups further

into +/- DOX groups in order to induce GRHL2. We would observe the effect on GRHL2 tumor

sensitivity, tumor recurrence, and metastasis. To examine the role of EMT in the generation

of the CSC fraction in vivo, a murine breast cancer cell line referred to as Py2T was evaluated
for potential use in murine syngeneic orthotopic injection experiments. This cell line,

derived from a polyoma middle-T antigen mouse transgenic model, has been previously
described to undergo EMT either by addition of TGF-β in vitro or spontaneously by

orthotropic injection in vivo (10). Considered together with previous studies, our data

indicate a significant role for GRHL2 in the context of prevention of recurrence post125

therapeutic intervention. This section will highlight the technical difficulties experienced in
this project and future aims.

An additional focus of this project is to determine the effect of constitutive Grhl2

expression in a murine model of recurrence. Mouse models recapitulating recurrence

following regression of primary tumors driven by doxycycline inducible neuNT, Wnt1, or c-

myc have shown that in comparison to the primary tumors, recurrent disease that emerges
following withdrawal of the oncogenic driver have undergone EMT (4, 11, 12). Analysis of
tetO-neuNT and tetO-Wnt1 primary vs recurrent RNA expression revealed a striking

decrease in GRHL2 expression in recurrent tumors (8). These findings strongly support the

hypothesis that GRHL2 is a tumor suppressor, is specifically silenced in the tumor initiating

subpopulation of the primary tumor, and that it is major suppressor of disease recurrence.
Further evaluation is needed in order to more clearly define the precise role of GRHL2 in

preventing recurrence in vivo. We hypothesized here that constitutive GRHL2 expression

abrogates the emergence of the CSC population enriched for by chemotherapy or EMT,
thereby preventing therapy resistant recurrence in vivo. The search for a tumor suppressive

type transcription factor that might alter this transition from chemosensitive “normal”

tumor cell to the chemoresistant CSC could prove critical in producing improved outcomes
for patients with breast cancer.
Methods and Materials
Cell Lines
Py2T cell lines were generously donated from the lab of G. Christofori (Department of
Biomedicine, University of Basel – Switzerland). Py2T cells were grown in Dulbecco’s
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Modified Eagle’s Medium (DMEM) + 10% Fetal Bovine Serum (FBS) + 1X Penicillin-

Streptomycin-Glutamine (PSG). Clonal isolation of the mixed population (epithelial +

mesenchymal cells) was done in order to generate a purely epithelial colony of cells. These

cells were titled “Py2T C7” (clone 7). HMLE+Twist-ER cells were a generous contribution

from R. Weinberg (The Whitehead Institute, Cambridge, MA). HMLE+Twist-ER cells were
grown in Dulbecco’s Modified Eagle’s F12 Media (DME/F12) + 5% horse serum + 1X

penicillin-streptomycin-glutamine (PSG) + 10 ug/mL insulin + 10 ng/mL EGF + 0.5 ug/mL
hydrocortisone. 4T1 mouse mammary carcinoma cells were ordered from ATCC and

maintained in RPMI 1640 Complete media supplemented with 10% FBS + 1X PSG. Where
indicated, 4-hydroxytamoxifen (10 ng/mL) was added to the HMLE+Twist-ER cells to

activate the Twist-ER protein. Where indicated, Transforming Growth Factor-β (TGF-β)

was added to the HMLE+Twist-ER cells (5 ng/mL).

Generation of Stable Cell Lines by Retroviral Transduction
Mouse GRHL2 was amplified from a template purchased from Open Biosystems (MHS442699625903) and subcloned via standard molecular biological methodology into pcDNA3.1+3XF expression vector in order to generate a flag tagged mGRHL2 plasmid (cloned into SalI

site using Xho1 compatible enzyme). It was further subcloned into the doxycyline inducible
expression vector pLUT (cloned into Not1 and NheI sites). Separately, GRHL2 was

subcloned previously into MSCV-IRES-puro retroviral vector (Cieply et al., 2012). Also

cloned human GRHL2 into pLUT vector for verification of findings in human cell lines as

well as mouse lines. Lentiviruses of mGRHL2-pLUT plasmids were packaged and amplified
into 293T cells by transfection of 3.3 ug mGRHL2-pLUT, 2.2 ug psPAX, and 1.2 ug of pCMV127

VSV-G (plasmids obtained from Addgene) with Mirus TransitLT transfection reagent onto

60 mm2 dishes. GRHL2-MSCV-IRES-puro retroviral was packaged and amplified into GP2 +
293T cells by transfection of 4.5 ug of retroviral vector, 2.5 ug of pCMV-VSV-G per 60 mm2

dish of cells, with Mirus TransitLT transfection reagent. Cells were refed with Dulbecco’s
Modified Eagle’s Medium (DMEM) + 10% Fetal Bovine Serum (FBS) + 1X Penicillin-

Streptomycin-Glutamine (PSG) media after incubating with DNA/transfection medium

overnight. Viral supernatants were harvested 48 hrs later, filtered through 0.45 micron

filters (Whatman), and stored at -80°C. In subsequent infections, 0.6 mL of viral stock was
used to transduce cells with plasmid per 1 well of a 6 well dish, and dish was subjected to
centrifugation at ~1,400 rpm for 1 hr followed by 6 hours to overnight incubation with

viral supernatant. Infected cells were subsequently refed and passaged to larger dishes for
selection by puromycin. Following puromycin selection, cells were examined for protein
content by Western Blot analysis probing for GRHL2 protein in order to verify protein
overexpression in lentivirally transduced lines.
Animal Models
Animal work involving tumor injection and subsequent chemotherapy has all been

approved by the West Virginia University Animal Care and Use Committee (ACUC # 110706.4, approved 10-31-12). We generated MMTV-GRHL2 transgenic mice by embryo

transfer of a GRHL2-flag-MMTV fragment with the help of the WVU animal transgenics core
facility. Founders were found to express GRHL2 constitutively in the mammary gland and
developed normally (data not shown), as described previously. We crossed these

transgenic mice with a double transgenic tetO-neuNT/MMTV-rtTA mouse line in a FVB
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background provided by the laboratory of L. Chodosh. At six weeks of age, oncogene

expressing transgenic mice either containing the GRHL2 transgene, or GRHL2 negative

littermates were induced using 2 mg/mL doxycycline 5% sucrose water. Within 6-7 weeks,

primary tumors emerged in both groups and were allowed to grow to approximately
15x15 mm2. Tumors were monitored using caliper measurements weekly.
Immunofluorescence
For further evaluation as to the percentage positivity of GRHL2 within Py2T C7 cell

populations expressing lentivirally transduced mGRHL2-pLUT, immunofluorescence was

carried out in order to confirm ~100% cellular expression. Collagen coated chamber well
microscope slides (20 ug/mL) were used to plate cells for IF experiments. 40,000 cells

were plated at least 24 hrs prior to fixation. Cells were fixed with 4% paraformaldehyde
(PFA) in sterile PBS. PFA was quenched with 100 mmol/L glycine in PBS. Cells were

permeabilized with 0.5% Triton X-100 in PBS at 4 degrees for 10 minutes, followed by PBS
washing twice. Were blocked for 1 hr in PBS + 10% goat serum + 0.1% Tween-20 + 0.1%

BSA. The primary antibodies were used as follows: GRHL2, rb (Sigma) 1:250; Flag, ms
(Sigma) 1:250. The secondary antibody was rb or ms Alexaflour 555 (red), 1:1000.

Mounting media: Prolong Gold w/ DAPI (Invitrogen). Coverslips were mounted in Prolong
Gold. Images were produced with the Axiovert 200M microscope, AxioCam MRM camera,
and Axio Vision 4.3.1 software (Zeiss).
Western Blotting
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SDS-PAGE was performed with pre-cast 4-20% gradient Tris-Glycine gels (Invitrogen).

Proteins were immobilized by electrophorectic transfer to polyvinylidene difluoride filters
(Immobilon) in 5% MeOH containing Tris-Glycine transfer buffer. Transfer was done

running at either 80V for 3 hours or 50V for 14 hour overnight transfer. Filters were

blocked in TBS + 0.1% Tween-20 + 5% nonfat milk. Primary antibodies were incubated in

blocking solution either overnight at 4°C or for two hours at room temperature. Secondary
antibodies were incubated in blocking solution for 1 hour at room temperature. Primary

antibodies were used as follows: E-cadherin, ms (BD Biosciences) 1:1000; Fibronectin, rb

(BD Biosciences) 1:1000; GRHL2, rb (Sigma) 1:1000; β-actin, ms (Millipore) 1:1000;

Secondary antibodies for ECL chemiluminescence were either anti-mouse or anti-rabbit,

conjugated to horse-raddish peroxidase (Bio-Rad) and were used at a 1:3000 dilution.
Western blot membranes were developed using (ECL-West Pico, Pierce).
Statistics

GRHL2 expression data was obtained via NCBI Gene Expression Omnibus (accession
number GSE10885; ref 3) to compare log expression of GRHL2 among tumor types

including normal, luminal, Her2, claudin, and basal in order to develop an appropriate

model system to evaluate. Previous work by our lab showed by Tukey HSD tests which

compared these tumor lines for statistical differences in GRHL2 expression (Cieply et al.,
2012). Any statistical analyses were conducted by R version 2.13.1 (www.r-project.org).
Data for gene expression not shown.
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Results and Discussion
The Py2T cell line was originally generated by the Christofori laboratory as a model

cell line for examining the effects of EMT due to its ability to undergo EMT in vitro upon

addition of TGF-β, and spontaneously in vivo upon orthotopic injection into the mammary
fat pad (10). This murine breast cancer line thus seemed a model platform for examining
the effects of GRHL2 on EMT in the context of CSC marker enrichment in vitro as well as
sensitivity to chemotherapy, recurrence, and metastasis in vivo.

TGF-β induction

resulted in EMT in Py2T cells (figure 1). This EMT was accompanied by a striking

reduction in GRHL2. Analysis of common markers of EMT (E-cadherin and fibronectin)

revealed expected regulation showing downregulation of the epithelial cell-cell junctional
marker E-cadherin as well as upregulation of the mesenchymal marker Fibronectin.

Next, we attempted to overexpress human-GRHL2 in multiple murine cell lines

(figure 2a, b). These results showed that human-GRHL2 protein was not overexpressed by
lenti- or retroviral transduction in mouse cell lines. mRNA analysis by qPCR showed that
human GRHL2 was significantly elevated in 4T1 cells expressing h-GRHL2-MSCV-IRES-

puro, indicating a defect in protein translation (figure 2c). Based on these findings, it was
determined that mouse-Grhl2 would be needed to overexpress Grhl2 protein in murine
models.

Murine Grhl2 was successfully overexpressed in the Py2T C7 mouse breast cancer

cell line (figure 3) in a doxycycline inducible lentiviral vector (pLUT). Overexpression was

confirmed by western blot analysis (figure 3a). However, as was evident by IF analysis, the

resulting population had significant heterogeneity in Grhl2 expression showing strong

nuclear expression in a majority of cells, while others either lacked nuclear localization of
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Grhl2 or lacked even cytoplasmic expression (data not shown). It has been previously

observed in our laboratory that injection of heterogenous clones results in failure of GRHL2
to prevent tumorigenesis due to tumor initiation from the GRHL2-neg subpopulation.

Analysis of tumors that result shows that cells are devoid of GRHL2 expression indicating
selection for GRHL2 negative cells (data not shown). Based on this, we attempted to

isolate more homogenous expressers of Grhl2 by cloning out individual cell populations.

We isolated a cell population that contained a higher number of Grhl2 positive cells than

the parent population (figure 3b). However, upon treatment with TGF-β, these cells failed

to undergo EMT, regardless of the presence of Grhl2 (figure 4). It was concluded that the

lack of effect of TGF-β was due to overpassaging of the cells or selection against the TGF-β

responsive population during passaging. The cells did form protrusions at the leading edge
of colonies, but this occurred in both + and – GRHL2 cells. In 4T1 murine breast cancer

cells, Grhl2 was insufficient to prevent TGF-β induced EMT (data now shown). In order to

verify that the DOX inducible GRHL2 construct resulted in sufficient GRHL2 induction to

prevent EMT in our previously characterized models, human-GRHL2 pLUT was transduced
into HMLE+Twist-ER cells. The resulting line was confirmed by immunofluorescence to

contain a homogenous, nuclear localized GRHL2 positive population. Simultaneous GRHL2
induction and treatment with 4-hydroxytamoxifen confirmed that GRHL2 overexpression
protects against EMT in the context of activation of the Twist-ER fusion gene (figure 5b).

These results indicate that there may be restricted murine cell line settings in which

perhaps Grhl2 lacks appropriate co-factors required for enforcing the epithelial phenotype.
It was determined that experiments utilizing Grhl2 overexpression in murine models in
order to achieve syngeneic implantation of primary tumors would not be practical.
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Elucidating the effect of chemotherapy on emergence of recurrent disease in orthotopic
injection of human tumors in immunocompromised NSG mice will be an area of future
research.

Primary mammary tumors induced by doxycycline driven by a tetO-neuNT gene

regress upon doxycycline withdrawal, but recur at a high rate, forming tumors that have an
EMT signature which are no longer reliant on the initiating oncogene (4, 11, 13). While the
primary tumors are epithelial and express high levels of GRHL2, recurrent tumors have
significantly lower expression of this transcription factor and are morphologically

mesenchymal. This is a highly clinical relevant model of disease recurrence in HER2positive breast cancer populations whose tumors contain EMT-like subpopulations

conferring resistance to targeted therapies such as trastuzumab (5), resulting in emergence

of treatment resistance recurrent disease. We tested the supposition that enforced Grhl2

expression in this murine model would prevent recurrence of oncogene-independent EMTlike tumors. GRHL2 positivity in GRHL2-transgenic mice was confirmed by genotyping

using Taqman expression array designed to amplify exogenous GRHL2-flag (figure 6a).

GRHL2-MMTV expression was confirmed in mammary tissue of founder pups by qPCR

using trans-exonic primers to identify exogenous GRHL2 only (figure 6b). We induced 6
week old transgenic mice (tetO-neuNT/tetO-rtTA with GRHL2 transgene or littermate

negative controls) to drive the development of the primary tumor. Following withdrawal
of doxycycline, tumors regressed rapidly within around 17 days. The tumors recurred at
varying times such that 5 out of 17 control mice (29.4%) developed recurrences while 0

out of 13 Grhl2-positive mice developed recurrent tumors (0%) (figure 7). These tumors

were verified to be EMT-like and have lost GRHL2 expression in the control tumor (figure
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8). While the recurrence frequency of control mice with primary HER2 driven tumors was
significantly lower than previously reported (14), recent findings suggest that primary

tumors must reach a larger size (>25 x 25 mm2) before discontinuing oncogene activation.

An area of future research will be to induce a larger number of GRHL2-positive and control

mice, allowing primary tumors to grow to greater primary size in an attempt to achieve a
greater frequency of recurrence so that greater statistical significance can be reached.
The findings presented here preliminarily support the conclusion that GRHL2

contributes to the prevention of CSC enrichment in EMT subpopulations or following

chemotherapeutic intervention. These findings highlight the potential clinical relevance of
determination of pathways which might influence endogenous GRHL2 expression and
prevent the emergence of GRHL2negative subpopulations enriched for CSC-like

characteristics. Further study is needed to better characterize the role of GRHL2 in
preventing these recurrences in vivo.
Figure Legends
Figure 1: The Effect of TGF- β on EMT Markers in Py2T Cell Line. Py2T cells (mixed

population) treated for 11 days with TGF-β (5 ng/mL). Lysates were made on day 11 of

TGF- β induction, and were analyzed by western blot analysis. Samples were probed with
antibodies for GRHL2, E-cadherin (E-cad), Fibronectin, and β-actin as a loading control.

Figure 2: Ectopic human-GRHL2 expression in mouse mammary cancer cell lines. A)

Inducible human GRHL2-pLUT was transduced into mouse mammary carcinoma cell line

Py2T had no effect on GRHL2 protein level. B) Attempt to express an alternate GRHL2 form
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in MSCV-IRES-puro vector in mouse mammary carcinoma cell line 4T1. No increase in
GRHL2 expression was observed. C) mRNA expression human-GRHL2 in 4T1 mouse
mammary carcinoma cell lines by RT-qPCR.

Figure 3: Expression of mouse-GRHL2-pLUT in Py2T C7 cell line. A) mGRHL2-pLUT

expression induced by doxycycline (western immunoblot analysis). B)

Immunofluorescence data of Py2T C7+mGRHL2-pLUT +/- DOX probed with Flag antibody.
Figure 4: TGF-β failed to induce EMT in Py2T clone 7 cells. After isolation of higher GRHL2

expressing colonies from Py2T + mGRHL2 heterogenous populations, control cells were now
resistant to TGF-β induced EMT.

Figure 5: HMLE+Twist-ER + hGRHL2-pLUT +/- doxycycline. A) Immunofluorescence
data of HMLE+Twist-ER+hGRHL2-pLUT cells either induced with DOX or control cells

probed with Flag antibody. B) Cells were simultaneously treated with 4OHT (10 ng/mL)
and doxycycline (1 ug/mL) and were passaged for 14 days with continued 4OHT/DOX
induction.

Figure 6. Confirmation of MMTV-GRHL2 transgenic. (a) represents qPCR amplification plot
using trans-exonic GRHL2 primers and DNA from GRHL2-MMTV founder vs. control

mouse; (b) represents qRT-PCR using GRHL2-FLAG specific primers using RNA from F1

mouse mammary tissue derived from founder (6G) or control mice.

Figure 7: GRHL2 suppresses recurrence of neuNT-driven tumors in the MMTV-GRHL2 Tg;
MMTV-rtTA Tg; tetO-neuNT model.

135

Figure 8: GRHL2 is lost in recurrent tumors of MTB/TAN current mice. Right panel:

Confirmation of GRHL2 expression from primary tumor of GRHL2-MMTV+ transgenic

mouse (probed for flag).
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Chapter 4
EMT ROS Mechanisms: A brief description
of the NOX complex and FAT cadherins
The following represents unpublished data.
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Overview and Preliminary Findings

As discussed extensively in Chapter 2, GRHL2 overexpression alters the ROS, ATP,

and mitochondrial membrane potential in MSP cells. In order to characterize the specific

mechanism by which GRHL2 promotes anoikis and generates ROS in our model system, we
analyzed the expression of specific genes involved in ROS scavenging, mitochondrial

metabolism, NADPH oxidase (NOX) complex genes, as well as FAT atypical cadherin proteins.
ROS generation is known to paradoxically accompany hypoxia, a factor commonly resulting
from and influencing the poorly vascularized portions of tumors, which stabilizes HIF1α (1).
HIF1α is thought to contribute to the induction of EMT through upregulation of several EMT

associated transcription factors (e.g., ZEB1, Twist, and Snail) (2, 3). HIF1α transcriptional

activity can serve to ameliorate ROS through upregulation of antioxidant response genes (1).
The NADPH oxidase complex is made up of multiple isoforms which are differentially

expressed in a variety of tissues. The catalytic subunit, NOX, found in the plasma membrane,
binds to its dimeric partner p22phox, resulting in the assembly of several cytoplasmic

regulatory factors such as p67phox and p47phox, which are responsible for generation of a ROS
burst, commonly occurring in the setting of immune function (4, 5).

The potential

contribution of the NADPH oxidase complex to tumorigenesis has even been linked to a
specific role in EMT regulation of the NOX complex through Rac1b (5).

Another emerging mechanism of ROS production and metabolic control relates to the

FAT atypical cadherin protein family. FAT cadherins are enormous cell adhesion molecules

(>500 kDa) which have been demonstrated to play a critical role in regulation of planar cell

polarity (PCP) as well as Hippo pathways for tissue organization and organ size regulation
respectively (6, 7). It was recently shown by Sing et al that in Drosophila, the mitochondrial
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electron transport chain relies critically on an imported intracellular cleaved peptide

originating from FAT protein (termed FtMito) which localizes to the mitochondria to stabilize

the holoenyzme NADPH dehydrogenase ubiquinone flavoprotein (Ndufv2), a core

component of complex I, which results in increased mitochondrial function, and
interestingly, decreases production of reactive oxygen species (8). FAT4 is the most closely
related human homologue of drosophila FAT protein (9). Recent evidence has indicated that

FAT4 protein expression is significantly upregulated in human triple-negative breast cancer

(9), specifically in the claudin low subclass in which GRHL2 expression is lost (10). The role

of antioxidant gene expression, NOX complex activation, and FAT protein on ROS as well as
the involvement of GRHL2 in regulating these pathways was explored here.

Preliminary evidence indicates that differential antioxidant gene expression, the NOX

complex, and/or FAT atypical cadherins may play specific roles in the resistance to anoikis
seen in MSP cells. Suppression of reactive oxygen species using pharmacological ROS
scavengers protects cells from anoikis (refer to Chapter 2 published manuscript). Before

discovering the regulation GLUD1 by GRHL2, we first reasoned that if EMT or GRHL2
expression leads to altered antioxidant gene expression, as is known to accompany EMT, this
may explain why ROS is significantly different between HMLE and MSP cells. While we

confirmed that overexpression of SOD2 (mitochondrial isoform of superoxide dismutase)
did somewhat decrease sensitivity to anoikis in HMLE cells, we found that this effect was

very minor (figure 1). Also, we were also able to confirm that several antioxidant genes are
upregulated during EMT including catalase, SOD2, and NQO1, which were upregulated in

MSP cells relative to HMLE cells (Figure 2). We further confirmed protein upregulation in

MSP cells of both catalase, SOD2, and HIF1α by western blot analysis (figure 2). However,
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these proteins were not downregulated following GRHL2 re-expression (data note shown).
This indicated that while EMT may upregulate antioxidant response elements to ameliorate
ROS accumulation which may occur in their microenvironments, this was likely not the
mechanism by which GRHL2 increases ROS.

Through analysis of publicly available microarray data (11), we have discovered that

multiple important components of both the NADPH oxidase as well as the atypical cadherin
FAT protein family are differentially expressed in MSP relative to HMLE cells.

Overexpression of GRHL2 significantly upregulates a major cytoplasmic binding partner of

NOX involved in producing ROS bursts known as p67phox (figure 3), but does not appear to
significantly regulate p22phox, or any of the catalytic NOX isoforms analyzed (data not

shown). Further, stable knockdown of GRHL2 resulted in decreased expression of the

cytoplasmic regulator of the NOX complex. We reasoned that if alternate regulation of one
of the major components of the NOX complex in cells which have undergone EMT or GRHL2
induced MET contributes to ROS bursts in suspended culture, this might elucidate the
mechanism of GRHL2 induced ROS accumulation.

However, we found that transient

depletion of neither p22phox nor p67phox by siRNA transfection had any significant protective
effect on anoikis (figure 4) and did not alter the ROS observed in our system (data not
shown). The primary assay used in ROS determination was CM-H 2 DCFDA which is a

fluorescent probe for general ROS, being most sensitive to cellular hydrogen peroxide. We
later conducted assays to determine the precise ROS species being overproduced in our

model which we determined to be predominantly hydrogen peroxide (H 2 O 2 ) (see Chapter
2). Since ROS produced via the NADPH oxidase system is predominantly that of superoxide

(O 2 .-), which was in fact elevated in MSP cells relative to HMLE cells (reflective of their
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heightened mitochondrial activity), we reasoned that the NOX complex was likely not the
source of ROS contributing to the GRHL2 mediated ROS burst observed in our system.

The FAT cadherin family of proteins have been shown recently to alter mitochondrial

activity through intracellular cleavage (8). Despite the tumor suppressor role described of
FAT proteins (Ft protein) in drosophila (8, 12), FAT protein homologues have been shown

to potentially play roles in tumor suppression as well as oncogenesis in several cancer types

(9). We planned to examine the effect of FAT4 atypical cadherin expression on regulation of
metabolism, ROS, and anoikis (JC1, Seahorse, ATP Cell Titer assays, Caspase 3/7 activation
assays) after targeted shRNA knockdown of FAT4 protein. FAT4 is significantly upregulated

in MSP cells (figure 5a). This could increase FtMito protein, and consequently, lead to an

increase in mitochondrial activity seen in MSP cells. GRHL2 expression in MSP cells
downregulated FAT4 mRNA expression (figure 5b). Given the extraordinarily large size of

FAT cadherin proteins, this precluded detection by western blot analysis. We attempted
shRNA stable knockdowns in MSP cells; however, given the inability to analyze protein

expression by western blotting, we were unable to verify these knockdowns by western blot.
Further, depletion of FAT4 had no effect on ROS or anoikis in our model.

Analysis of our RNA-seq data revealed regulation of a mitochondrial enzyme referred

to as glutamate dehydrogenase 1 (GLUD1 or GDH1) which upon further pursuit proved to
decrease hydrogen peroxide level as well as anoikis – a mechanism dependent on the
production of α-ketoglutarate as described in more detail in Chapter 2 (13).

The

mechanisms described in this chapter were promising molecular pathways regulated by
GRHL2, but proved to have no effect on ROS or anoikis in our model.
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Chapter 5
The Role of Tubulins in Regulation
of Anoikis through Mitochondria
The following represents unpublished data which reflected our views of ROS
mechanisms and contributions to anoikis at the time. Since these observations were
made, our views on the links between ROS, metabolism, and anoikis have been updated
by more recent findings (see Chapter 2).
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Introduction

Detachment from extracellular matrix induces an apoptotic program or non-

apoptotic cell death process collectively called “anoikis” (1). For a more complete

review of this topic, refer to Chapter 1. The anoikis response is compromised in cells
that undergo the oncogenic Epithelial-Mesenchymal Transition (EMT), facilitating

tumor metastasis. Tumor metastasis is critically dependent upon mechanisms that
allow tumor cells to evade anoikis, such as EMT (2-5). The basic mechanisms of

anoikis regulation are critical to our understanding and therapeutic development,

and while the core machinery influencing anoikis is identical to that of apoptosis,
much is unknown regarding the aberrant activation of pathways allowing
mesenchymal cells to escape this process.

Many signaling mechanisms are engaged in the activation of the anoikis

response of normal epithelial cells, a subset of which are clearly defective in tumors,

a result of epigenetic, genetic or other modifications. These findings have been
demonstrated in tissue culture as well as animal models of metastatic tumor
progression (3-5).

Other matrix-dependent cell death events likely closely related

to anoikis, but non-apoptotic (caspase-independent) in nature, have been
demonstrated as well (“metabolic cell death”) (6, 7).

Both caspase-dependent and caspase-independent forms of anoikis are

critically regulated through cellular metabolic pathways (6, 7). These effects may be

the result of ATP depletion and/or excessive generation of reactive oxygen species
(ROS). For example, the three-dimensional acinar morphogenesis of MCF10a cells in
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matrigel, imitating terminal end bud clearance in vivo, relies on both caspase-

dependent and caspase–independent processes. The latter is likely the result of

inhibition of glucose transport due to sequestration of transporters, and partly
because fatty acid oxidation (FAO), which generally acts as a backup for ATP

maintenance when carbohydrate sources are lacking—is inhibited by ROS. In this

context, ROS accumulates to high levels due to lack of pentose phosphate pathway
input, which then fails to produce NADPH reducing equivalents. ErbB2 specifically,

has been reported to rescue these phenotypes, protecting from anoikis (8). The early

events connecting cytoskeletal changes to these downstream effects are not yet
understood, however.

For an indepth discussion of ROS, its cellular sources, reactivity, and

consequences, refer to the Reactive Oxygen Species section of Chapter 1. Under

normal conditions, ROS is generated in the process of normal mitochondrial function
as electrons are shunted directly to oxygen from components of the electron
transport chain during oxidative phosphorylation. ROS levels have been shown to

increase dramatically in detached cells (8). This suggests that suppression of ROS in
detached cells could be a means of anoikis evasion for tumor cells. For example, in

detached cells, pyruvate dehydrogenase kinase 4 (PDK4) is upregulated, inactivating
pyruvate

dehydrogenase

(PDH)

and

attenuating

mitochondrial

oxidative

phosphorylation; further, experimental depletion of PDK4 stimulates ox-phos, ROS

production, and promotes anoikis (9). Many tumor cells have been observed to over-

express antioxidant enzymes, resulting in ROS neutralization in detached cells,
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rescuing these cells from anoikis (10). These observations powerfully demonstrate
the pro-anoikis effect of ROS.

Integrin engagement results in basal stimulation of ROS at least in attached

cells, permitting anoikis resistance, through the ubiquitous increase of tyrosine
phoshorylation (including Src) due to tyrosine phosphatase’s exquisite sensitivity to

inactivation by ROS (11). In summary, mitochondrial oxidative phosphorylation

affects anoikis, both of caspase-dependent and –independent types, through both ATP
(protective) and ROS (protective or promoting, depending upon context). The precise
mechanisms by which cells generate ROS and maintain energy charge is unclear and
requires further examination.

Voltage Dependent Anion Channels (VDAC1-3) transport ADP, ATP, NAD(H)

and various metabolic intermediates across the outer mitochondrial membrane

(MOM), thereby regulating metabolic flux of the mitochondria, earning them the title
of “governators” of metabolism (12). VDACs are the most abundant channel of the
mitochondrial outer membrane. At low transmembrane voltage, VDACs are fully

open to anion transport. They are closed to anions/selective for cations at higher
voltages. VDAC greatly affects ∆ψ (mitochondrial outer membrane potential) (13)

which affects ATP, ROS generation, and may even be part of the MPT (mitochondrial

permeability transition) pore, although this idea is somewhat controversial and
evidence for this idea is not uniformly expressed in the literature (14).

Importantly, VDACs are regulated by several signaling inputs, including

protein kinase A (PKA) or GSK-3β (which phosphorylate VDACs), or via direct

interactions with Bcl-2 protein, hexokinases, or free tubulin dimers (12, 15, 16).
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Phosphorylation of the VDAC channel itself occurs on the “cis” (cytosolic) side of the
channel by kinases such as GSK3β and PKA, activities of which have been reported to

be altered during suspension (17, 18). This phosphorylation greatly (by orders of

magnitude) affects the sensitivity of VDAC to tubulin dimers, which affects their

propensity to close. Given their dramatic effects on mitochondrial metabolism, which
may affect ATP and ROS level, VDACs affect cell survival vs. apoptosis cell fate
decisions (19).

In fact, VDACs control cell survival in a number of settings. Persistent closure

of VDAC has been shown to compromise the integrity of the outer mitochondrial
membrane, leading to cytochrome c release and apoptosome-mediated apoptosis (20,

21). There are multiple methods of VDAC modulation to simulate physiological
opening or closing of VDAC channels. A VDAC-specific compound, erastin, induces

non-apoptotic cell death specifically in Ras-transformed cell lines via VDAC-2 and
VDAC-3 inhibition (22). Conversely, a bacterial pillus protein, FimA, enters host cells,

where it binds and stabilizes the fully open, hexokinase-interacting conformation of
VDACs, resulting in protection of host cells against apoptosis (23). Opening and
closure of VDAC clearly is more complicated in its regulation of cell survival as in
other contexts, opening of VDACs can trigger apoptosis (24).

Microtubules make up the internal structure of both cilia and flagella, form the

framework for secretory vesicles, and organelles. They play a major role in mitosis

during cytokinesis. Microtubules shift back and forth between soluble and insoluble
pools rapidly, free dimer and microtubule polymers respectively. α and β tubulin
dimers, but not microtubules, interact with the VDACs, stabilizing the closed
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conformation of the membrane channel. This interaction occurs through the C-

terminal tail of tubulin, which is extensively modified (15). Heterodimers combine to
form rows of protofilaments, which then make up microtubules. These microtubules
are the basis of cell shape and movement. Under stable conditions, heterodimers

attach to both ends of microtubules, thereby increasing microtubule length.
Destabilization of microtubules causes a greater loss of tubulin dimers from the
microtubules, leading to a higher concentration of free dimers.

In vivo, pharmacologic agents which act by stabilizing microtubules (e.g.,

paclitaxel) decrease free tubulin levels, which increases mitochondrial membrane
potential.

Conversely, drugs which destabilize microtubules (e.g., nocodazole),

increase free tubulin dimers, decreasing mitochondrial membrane potential (25).

The free to polymerized tubulin ratio may act as a metabolic programmer of
mitochondrial function through regulation of VDAC channels (12). The role of tubulin

may be rationalized because non-polymerized free tubulin, which tends to be

elevated in cancer cells (e.g., potentially due to the overexpression of stathmin/Op18
in some contexts, a microtubule-destabilizing factor), may aid in the maintenance of
the glycolytic phenotype, maintaining the Warburg effect. Mechanistically, Op18
binds two molecules of αβ dimers into a T2S complex which it sequesters away from

the polymerized pool of tubulin, thus decreasing microtubules and increasing free
tubulin (26). Physiologically, Op18 protein aids in rapid dissociation of microtubules

to allow better control of microtubule-tubulin dynamics during processes like
chromosome segregation in mitosis. Patient data suggests that Op18 (which is
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expressed in various subtypes of breast cancer and several other malignancies)
negatively impacts response to microtubule targeting drugs.

Most studies have focused on cell death in the context of matrix detachment

related to alteration of signaling pathways regulated through cell-cell adhesion

molecules and integrins that are transduced by the actin cytoskeleton. An area of
increasing research involves metabolic alterations which occur after cells are placed

in suspension, and how those changes contribute to cell death. The connection

between cytoskeleton networks and metabolism is presently unknown.

In this project, we hypothesized that cell-matrix detachment and/or EMT

alters the microtubule cytoskeleton. This alters the pool of free tubulin dimers
available for interaction with and regulation of the conductivity of the Voltage
Dependent Anion Channels (VDACs) on mitochondria. VDACs regulate cellular

metabolism, in numerous ways, including ATP levels and reactive oxygen levels,
which together determine cell survival vs. cell death. A better understanding of this

pathway may reveal the importance of microtubule cytoskeleton in anoikis for the

first time, integrating cytoskeletal and metabolic mechanisms of cell death, and will
indicate the novel ramifications of the use of microtubule drugs in the treatment of
cancer.

Methods
Microtubule Stability Assays
To prepare the lysates, aliquots of D-PBS and MST buffer were equilibrated to

37°C in a water bath. MST buffer consisted by 85 mM PIPES, pH corrected to 6.9, 1

mM EGTA, 1 mM MgCl 2 , 2M Glycerol, 0.5% TX-100. Microcentrifuge tubes were
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labeled and pre-warmed to 37°C. Cells were plated in 6 well dishes and allowed to
attach for 36hours. Cells were trypsinized, spun at 1200 RPM at room temperature,
followed by placement 1.5mL of 1% methylcellulose containing MCF10a medium in

low attachment polyHEMA dishes (2 mg/mL). At the indicated time of suspension,
cells were transferred to a pre-warmed microfuge tube and spun down for 15 seconds
at 7,000rpm. The supernatant was discarded, washing of the pellet in 1mL of 37° D-

PBS. After spinning, the supernatant was discarded and cells were resuspended in

300uL of 37° MST (microtubule stabilization buffer) buffer containing 4uM taxol and

Roche protease inhibitor. Samples were centrifuged at full speed for 10 minutes.
Supernatant was saved in pre-warmed microfuge tube and mixed with an equal
volume of 2X SDS sample buffer. After careful removal of the remaining supernatant,

the pellet was resuspended in 500uL of 1X SDS sample buffer. Samples were boiled
at 95° C for 3 minutes. To prepare attached samples, cells were washed twice with

approximately 1mL of 37° D-PBS. The cells were then scraped into 300uL of 37° MST

buffer containing 4uM taxol and Roche protease inhibitor. Lysates were centrifuged,
and supernatant and pellet were retained as described previously.
Western Blotting
SDS-PAGE was conducted using 4-20% gradient Tris-Glycine gels (Invitrogen).

Proteins were electrophoretically transferred to polyvinylidine difluoride filters
(Immobilon) in 5% methanol Tris-Glycine transfer buffer containing 5% methanol.
PBS + 0.1% Tween-20 + 5% nonfat milk were used for blocking filters, primary
antibodies were incubated in PBS+0.1% Tween-20 + 5% nonfat milk. Primary
158

antibodies were typically incubated between 2 hours at room temperature or

overnight at 4 degrees C. Primaries used were: β-tubulin, Rb (Cell Signaling), VDAC1,

Rb (Cell Signaling); . Secondary antibodies for chemiluminescence were either antimouse or anti-rabbit, conjugated to horseradish peroxidase (HRP) enzyme (Bio-Rad).

Secondary antibodies (Biorad) were used at 1:3000 dilution and filters were
incubated for approximately 1 hour at room temperature. Western blots were
developed via ECL Super Signal West Pico (Thermo-Pierce).
Anoikis Assays
For anoikis assays, caspase activation was measured using the Caspase-Glo

3/7 assay kit (Promega). Cells were dissociated using TrypLE Express (Invitrogen)
and a fixed number of cells (1.5 x 105 cells) were placed per 6 well poly-(2-

hydroxyethyl methacrylate) (poly-HEMA) coated low attachment plates in 2.0 ml of

normal growth medium + 0.5% methylcellulose for the indicated time. Aliquots of

cells were mixed 1:1 with caspase glo reagent at indicated time points and assayed

for luminescence utilizing a Wallac Envison Perkin Elmer plate reader according to
manufacturer’s instructions. Where indicated, time-zero cell death values were

subtracted from the data presented to normalize for small loading variation.
ROS Assays
For ROS assay, cells were seeded as above and attached for 48 hours. Cells

were detached by trypsinization, and equal numbers of cells were placed in a 15 mL
centrifuge tube. Cells were assayed immediately by flow cytometry after staining for
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15 min at 37 degrees with 1 uM CM-H 2 DCFDA (Invitrogen) protected from light. If

indicated, 24 hr ROS was examined after plating cells in low attachment polyHEMA
(2 mg/mL) coated 100 mm dishes in 5 mL of 0.5% methylcellulose to prevent excess

cell clumping. Cells were harvested by diluting well with 10 mL DME/F12 + 10%

Horse Serum containing media. Cells were centrifuged at 2000 RPM for 2 minutes.
Pellets were washed 2X with HBSS and stained in 1 uM CM-H 2 DCFDA as indicated
previously. In some cases, Amplex Red (Invitrogen) assays were used to measure ROS

in order to compare attached and suspended conditions and were used according to
manufacturer’s instructions. For measurement of general cellular superoxide, cells

were processed as above and stained with 5 uM dihydroethidium (DHE) (Invitrogen)

for 15 minutes at 37 degrees C protected from light followed by flow cytometric
analysis at 605 nm fluorescence. Mitochondrial specific superoxide was measured

using mitoSOX (Invitrogen) dye by staining cells with 5 uM mitoSOX solution for 10
minutes at 37 degrees C protected from light. Samples were analyzed by flow
cytometry at 580 nm fluorescence using a BD LSRFortessa Cell analyzer.
JC1 Assay
Cells were seeded on poly-d-lysine coated MatTek dishes. Cells were incubated

in 2 ug/mL JC1 (5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine

iodide) (Invitrogen) at 37 degrees for 30 minutes protected from light. After
incubation, dye was washed off of cells and replaced with normal growth medium.

JC1 monomer emission was observed at 529 nm and J-aggregate emission was
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observed at 590 nm.

Samples were analyzed by flow cytometry using a BD

LSRFortessa Cell analyzer.
siRNA transfections

MCF10a PG2 cells were grown to ~70% confluence and transfected with

siRNA (5 nM) targeting either non-target control siNT (Ambion, Austin TX), VDAC1,

VDAC2, or VDAC3. siNT was Silencer Select Negative control #1 siRNA (Cat
#4390844). siRNAs targeting VDACs were Silencer select siRNAs: VDAC1 (Cat #

4390824; ID:s14769), VDAC2 (Cat # 4392420; ID:s14771), VDAC3 (Cat # 4392420;
ID: 230730). siRNAs were transfected using Lipofectamine RNAiMAX (Invitrogen,
Carlsbad, CA) according to manufacturer’s instructions.

Quantitative reverse transcription PCR analysis
MCF10a PG2 cells were plated on collagen coated 60mm2 dishes and treated

as indicated. Cells were harvested using RNAeasy Plus mini kit (Qiagen), analyzed

using Nanodrop, and converted to cDNA using SuperScript III First-Strand Synthesis
SuperMix (Invitrogen) with oligo dT primers and 1ug of RNA. cDNA was analyzed

using SYBR Green PCR Master Mix on an Applied Biosystems 7500 Real Time PCR
System. Primers were as follows: VDAC1 (F: GGGTGCTCTGGTGCTAGGT; R:

GACAGCGGTCTCCAACTTCT),
TTTAGCTGCAATGCCAAAAC)

TGTTACTCCCAGCTGTCCAA).

VDAC2

VDAC3

(F:

CBX1-F

(F:
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CCAAATCAAAGCTGACAAGGA,
TTGACACAGCCAAATCCAAA,

(AAGTATTGCAAGGCCACCCA),

R:

R:

CBX-

R(TTTTCCCAATCAGGCCCCAA). Values reported were determined using the ∆∆CT
VDAC primer sequences were amplified as follows using CBX1 as an internal control
Results
The findings presented in this chapter were preliminary data of my previous

work. This project proposed to determine the effect of cell-matrix adhesion on the

tubulin/VDAC/mitochondrial axis in normal epithelial cells or in cells resulting from
epithelial-mesenchymal transition (EMT). To this end, we evaluated the effects of

EMT on free vs polymerized tubulins, VDACs, and mitochondrial function. We also

planned to test the function of components of the tubulin/VDAC/mitochondrial axis
on anoikis in normal epithelial cells or in cells resulting from EMT, including the
effects of altered VDACs, and the effects of altered tubulins/microtubules. Here, our
preliminary findings that led us to these hypotheses will be discussed, and how the

findings contributed to our current views of metabolism, ROS, and anoikis (which was
previously discussed in Chapter 2). Ultimately our findings were that manipulation of
VDACs had minimal impact on metabolic function, ROS, and anoikis.

Polymerized tubulin and free tubulin levels were determined through lysis in

microtubule stabilizing buffer (containing paclitaxel) followed by western blotting of

soluble vs. insoluble fractions, as described previously (25). We found that free
tubulin shifts to polymerized microtubules rapidly following cell-matrix detachment
of the normal epithelial cell line MCF10a (figure 1a); however, the microtubule

stability assays were highly inconsistent and given the start conditions, in some

experiments we were unable to see this effect (figure 1b). We next assayed MCF10a
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neoT +/- TGF-β, which induces a stable EMT event in this context, in order to
determine the effect of EMT on the response of tubulin polymerization in detached
culture.

While it was expected that EMT would result in stabilization of the free

tubulin dimer pool (closing VDAC, decreasing ROS, and protecting from anoikis), we

were unable to show this expected phenomenon in our cells. We decided to shift our
focus to that of the microtubule associated proteins Op18 and Tau.

Free tubulin dimers have been reported to interact with VDACs, causing

closure of the anion channel activity (12, 15). Overexpression of the microtubule

destabilizing protein Oncoprotein 18 (Op18; otherwise known as Stathmin)

increased free tubulin dimers levels (Figure 2a). We expected that an increase in free
tubulin dimers would close VDAC channels, decreasing mitochondrial activity,

decreasing ROS and protection from anoikis. However, we found that overexpression
of Op18 in MCF10a PG2 cells resulted in increased cell death in suspended culture
(figure 2b). Our original assumption was that this increase in the free pool of tubulin

would result in increased VDAC binding, resulting in their closure, but this may not

be the case. It is quite possibly that binding of tubulin dimers in the T2S quaternary
complex with Op18 prevents their binding to VDAC channels, effectively

competitively inhibiting free tubulin binding, resulting in a paradoxical opening of
VDAC channels.

Alternatively, if free tubulin dimer binding and closing VDAC

channels results in decreased ATP, this may negatively influence cell survival in

suspension, resulting in increased anoikis as shown here.
Further

manipulation

of

tubulin

dynamics

was

accomplished

via

overexpression of the Alzheimer associated neural protein, Tau (also known as MAP4
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or Microtubule associated protein 4). Tau primarily tends to bind to microtubules
and stabilize them, leading to a decrease in the total tubulin dimer pool,

hypothetically resulting in increased mitochondrial activity through lack of tubulin

induced VDAC closure. We found that increasing the polymerized pool results in
significantly lower colony formation by the same assay (figure 2c). We hypothesized

that decreased tubulin would result in removal of VDAC suppression opening the
channel to increase ROS and lead to oxidative stress potentially causing cell death.
We extended these findings to the MDCK cell line (Madin-Darby canine kidney).

When Tau was overexpressed in this model, we found that MDCK cells were more

sensitive to anoikis at 4, 8, and 24 hours, assessed by caspase 3/7 activation assay

(figure 2d). However, this effect was not reinforced when cell death was assessed
more generally by colony formation assay (figure 2e).

Given that modification to proteins involved in microtubule polymerization

could have multiple, even paradoxical effects, we next reasoned that if tubulin binding
to VDAC results in VDAC closure, removal of VDAC by siRNA transfection would be
equivalent to closing the channel. VDAC knockdown was confirmed by western blot

analysis and RT-qPCR (figure 3a, b; VDAC3 antibody was not specific for this isoform
but rather detected Pan-VDAC – data not shown). Utilizing isoform specific siRNA
transfection targeting VDAC1, 2, and 3 individually, we found that cells depleted of

VDAC1 protected somewhat against anoikis; however, this effect was very small
(figure 3c). Conversely, depletion of VDAC2 appeared to further sensitize cells to

anoikis (figure 3c). VDAC3 depletion did not have a consistent effect on anoikis as

average fold change (relative to siNT control) showed that depletion of this isoform
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had no significant effect on caspase activation when averaged between two
independent experiments (figure 3d).

In order to determine the role of VDAC channels in ROS regulation in our

system, ROS bursts were measured by CM-H 2 DFCDA fluorescence by flow cytometry.

Independent depletion of VDAC1, 2, and 3 all ameliorated ROS generated by
incubation in suspension relative to non-target control cells (figure 3e). While this
result is consistent with the view that VDAC closure decreases mitochondrial activity,
hampering ROS generated by oxidative phosphorylation, VDAC knockdown did not

correlate with loss of mitochondrial activity in excess of that seen in the control
samples however as assessed by JC1 fluorimetric assay (figure 4). If ROS were in fact

coming from loss of mitochondrial oxidative phosphorylation activity, we would have
expected to see a greater decrease in JC1 signal in suspended VDAC knockdown

samples. Further, we found no significant effect of either microtubule stabilization

alteration (through Op18 or Tau) on ATP level or basal JC1 signal (data not shown).
Given the results presented here, we concluded that the Tubulin/VDAC/ROS axis was
not playing a significant role in the induction of anoikis in our model.
Discussion
The results of this study were largely inconclusive or counter to our original

hypothesis. We attempted to show whether the open or closed state of VDACs is more
favorable for anoikis, and, whether the primary outcome is a reprogramming effect
that occurs prior to detachment vs. a more significant effect during the

detachment/suspension phase. Given the difficulty of showing consistent effects of
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microtubule alterations on anoikis (see Op18 and Tau anoikis results), we concluded

that any effect on anoikis was likely due to alterations of tubulin dynamic
homeostasis. We were unable to find a link between regulation of tubulin dynamics
and the Epithelial-Mesenchymal transition.

A determination regarding the effect of higher or lower ratio of free:

polymerized tubulin and which condition was more favorable to anoikis was unable

to be determined due to difficulty isolating free vs polymerized tubulin forms given
its incredible instability at room temperature. It was anticipated that the direction of
the tubulin effect would be consistent with the direction of the VDAC effect (more free

tubulin=closed VDAC=metabolic effects arising from closed VDAC= cell death). Given

the range of phenotypes that are correlated here, any consistency in these models

proved very difficult to achieve.

While we were able to show a very robust effect of VDAC knockdown on ROS,

this phenotype likely was due to an unconsidered alternative source, as the ROS

decrease was not associated with an accompanying decrease in JC1 or ATP decline in
detached conditions beyond that which occurred the control cells.

In an attempt to evaluate experimentally manipulated tubulin levels effects on

anoikis, we overexpressed both microtubule associated proteins Op18 and Tau. As

discussed previously, our original assumption was that alterations in the free pool of

tubulin via Op18 induced destabilization of microtubules would close VDACs, due to

direct tubulin binding, however, this may not be the case. It is possible that binding

of tubulin dimers in the T2S quaternary complex with Op18 prevents their binding to
VDAC channels, effectively competitively inhibiting free tubulin binding, resulting in
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a paradoxical opening of VDAC channels. Additionally, Op18 overexpression could

potentially result in cell death even if it does cause tubulin-VDAC binding, because
any dysregulation of this tightly controlled program in tubulin dynamics could be

problematic for cells. Op18 may also bind to the tips of protofilaments and directly
destabilize growing microtubules. A final alternative is that Op18 induces
accumulation of free tubulin which is able to close VDACs, and that the effect on

anoikis seen is due to a loss of mitochondrial activity, causing metabolic catastrophe
(see Chapter 2).

VDAC1 is typically the most abundant isoform expressed in cells (27). VDAC1/2

are most sensitive to tubulin induced blockade, while VDAC-3 is expressed in

significantly lower abundance, and is far less affected by tubulin dynamics (28).

Isoform 3 is thought to contribute most to typical mitochondrial membrane potential
in steady state while VDAC1/2 are generally kept closed by endogenous free tubulin.

In suspension, VDAC1/2 may open due to a decrease in free tubulin which would

result in oxidative injury. Effects of VDAC knockdown (~VDAC closure) on anoikis
were largely insignificant and/or inconsistent. We found that knockdown of VDAC1
resulted in small protection from anoikis, whereas VDAC3 depletion had no effect on
anoikis. Interestingly, depletion of VDAC2 sensitized cells significantly.

It was

previously observed that the pro-apoptotic protein, Bak, is sequestered through an

interaction with VDAC2; furthermore, it was demonstrated here that overexpression
of VDAC2 inhibited apoptosis through Bak sequestration (29). Disruption of this
interaction releases Bak through VDAC knockdown likely releases Bak from the

mitochondria inducing apoptosis in detachment, potentially representing an
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interesting area of future research. Given the results presented here, we concluded

that the Tubulin/VDAC/ROS axis was not playing a significant role in the induction
control of mitochondrial function contributing to anoikis in our model.

Figure Legends
Figure 1. a) Western blot showing effect of cell-matrix detachment on tubulin: microtubule
ratios. MCF10aneoT cells were lysed in mitochondrial stabilization buffer in the attached

state or following suspension for the indicated periods of time, fractionated into
free/supernant (F) or microtubule/pellet (M) fractions and analyzed by western blotting for
β-tubulin. b) Effect of EMT on tubulin:microtubule ratios in attached vs detachment

conditions. MCF10aneoT cells shown here either before or after treatment with TGF-β
(resulting in irreversible EMT). p = pellet (insoluble microtubule fraction); s = supernatant
(soluble tubulin dimer fraction)

Figure 2. a) Western blot showing effect of Op18 overexpression in MCF10a PG2 cells

on tubulin: microtubule ratios. Op18 elevated free tubulin: microtubule ratio by

destabilization of polymerized microtubules. b) Op18 constitutive expression was
associated with increased anoikis, assessed by colony formation assay conducted
after suspension in 0.5% methylcellulose containing media in polyHEMA low
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attachment wells for indicated times. c) Tau (MAP4) overexpression in MCF10a PG2

cells resulted in significant sensitization to detachment induced cell death by colony

formation assay as described above. d) Tau overexpression in MDCK cells sensitized
to anoikis (caspase 3/7 activation assay; Promega Caspase-Glo kit). e) Colony

formation assay following suspension in MDCK cells +/- Tau overexpression as
described above.

Figure 3. a) Confirmation of siRNA depletion of specific VDAC isoforms 1 and 2.

Lysates made following single VDAC isoform knockdown (lysates made 72 hrs after
transfection). b) RT-qPCR amplification of 3’UTR of individual VDAC mRNA

transcripts. c) Caspase-3/7 activation assay (Promega) showed increase in anoikis
for VDAC2 knockdown, but VDAC1 knockdown protected from anoikis. d) Relative
caspase activation fold change compared to nontargeting control siRNA for siVDAC

isoforms for two independent experiments. e) Loss of VDAC1, 2, and 3 results in
decrease in ROS burst following detachment (24 hr suspension) as assessed by CM-

H 2 DCFDA staining followed by flow cytometric analysis. f) Relative fold change in ROS
burst (vs siNT control) average values from 2 independent experiments (assessed by

flow cytometry following CM-H 2 DCFDA staining).

Figure 4. a) JC1 (Orange J-aggregate/Green monomer) ratio in MCF10a PG2 cells
depleted of VDAC1 assessed by flow cytometry showing mitochondrial membrane
potential in MCF10A PG2 +/- siVDAC isoforms.
169

Figure 5. a) Graphical overview of potential role of VDAC and regulation on anoikis.
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The EMT has been demonstrated extensively to confer resistance to anoikis. Here, it

was demonstrated that EMT resulted in increased mitochondrial oxidative metabolism
resulting in maintenance of ATP during suspension. Increased oxidative phosphorylation in

mesenchymal cells was accompanied by increased production of mitochondrial superoxide;
however, general ROS was suppressed due to decreased production of hydrogen peroxide
(H 2 O 2 ). We established here that glutamate dehydrogenase 1 (GLUD1) was upregulated

during EMT, resulting in increased production of α-ketoglutarate which was critical for

suppression of H 2 O 2 and protection from anoikis. The work presented here demonstrated

that the wound healing transcription factor GRHL2, through suppression of EMT, sensitizes

cells to anoikis, at least in part through downregulation of GLUD1 resulting in depletion of

α-ketoglutarate and increased production of ROS. Therefore, this thesis has established a

novel pathway for control of anoikis through metabolic alteration and ROS suppression
occurring during the oncogenic EMT, and demonstrated an additional mechanism by which
GRHL2 sensitizes to anoikis.

Warburg metabolism has been extensively studied in the context of tumor cells;

however, these findings are largely context dependent (1, 2). Recent work has demonstrated
that the CSC phenotype is in fact dependent on oxidative phosphorylation (3, 4). Moreover,

oxidative metabolism has been shown to be enhanced in distant metastases, highlighting the
critical importance of a better understanding of how tumor metabolism influences these

metastatic, chemoresistant subpopulations in vivo (5, 6). As discussed previously, the

precise cues inducing cellular migration from the primary tumor are incompletely
understood. What is clear at present is that EMT is a major mechanism by which cells acquire

the (epi)genetic alterations to aid invasion from their primary site, and further, evade anoikis
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during tumor dissemination.

It has been postulated that oncogenic mutations in

subpopulations of tumors may lead to the acquisition of properties that are advantageous to

the growth of tumors in the short term such as those that increase proliferation; however,
these changes are ultimately detrimental in the primary site which may lack the proper
vasculature to support this activity. This can lead to challenges including lack of carbon

source nutrients, hypoxia, and results in reactive oxygen species accumulation. Metabolic
alterations due to oncogenic transformation, EMT or transition to cancer stem cells have
been reported extensively, with unique effects in each system (5, 7-10).

Paradoxically, oxygen deprivation results in the generation and accumulation of

reactive oxygen species (11). HIF1α stabilization due to hypoxic conditions reduces

mitochondrial biogenesis (12), results in the induction of multiple antioxidant genes (11),

and signals EMT via induction of transcription factors including Twist, Snail, and ZEB1 (13,

14). In fact, in our own hands, MSP cells were found to have stabilized HIF1α compared to
parental HMLE cells (unpublished data; refer to Chapter 4). This could potentially, at least
in part, explain the decreased mitochondrial load present in MSP cells (Chapter 2), which are
paradoxically more efficient than those in their epithelial counterparts. Alternatively, HMLE
cells may upregulate production of mitochondria due to their lack of functional activity

compared to mesenchymal cells. The reactive oxygen generated from hypoxic conditions in
some cases leading to the induction of the EMT program is thus the likely culprit of gene

expression changes that ameliorate these toxicities, resulting in a relatively low ROS
environment compared to epithelial cells.

As noted earlier, tumor tissues are known to have high ROS levels relative to “normal”

tissues, and are thought to upregulate antioxidant enzymes in order to keep these harmful
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oxidants within a “non-lethal” threshold limit. The maintenance of ROS within a crucial

range may aid in some cellular processes, acting as a signaling molecule of sorts (15), while

rising beyond that range can be catastrophic. This requires the presence of safeguards such

as robust expression of antioxidant genes. However, it has also been shown that if driven to
critically low levels the result is cell cycle arrest or even apoptosis (16). In fact, ANGPLT4

was reported to protect from anoikis by stimulating ROS of the superoxide variety from the
NOX complex stimulating Src leading to increased activity of PI3K and ERK pro-survival

signaling (17). Note that in our hands (as has been reported elsewhere), ROS suppression,

assessed by CM-H 2 DCFDA detecting H 2 O 2 primarily, protects from anoikis. This discrepancy
may be due to a species or source specific effect or may lie in the fact that short term caspase
activation assays may only show effects of increased caspase activity due to alleviation of

ROS suppressing cysteine active sites of caspases, which is overcome at later time points. In

fact, our findings support that anoikis resistant MSP cells have higher superoxide level
relative to HMLE or MSP+GRHL2 cells (Chapter 2). We interpret this result as a readout of

mitochondrial oxidative phosphorylation generating ROS from complex’s I and III – but
perhaps these cells have some yet unexplored mechanism by which they induced c-SRC

activation through increased superoxide (17). Based on RNA-seq, we found that GRHL2

upregulates ANGPTL4 significantly (3.8 fold) which would support a role in ROS generation,
however in our model, GRHL2 overexpression decreased superoxide level, both from general
sources as well as specifically from mitochondria and increased H 2 O 2 , indicating lack of

generalizability of these previously reported findings to our system.

Another yet unexplored pathway through which GRHL2 may exert regulatory control

over anoikis is through that of the atypical FAT cadherin family of proteins. GRHL2 greatly
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downregulates expression of FAT4 specifically, which is highly upregulated in mesenchymal

cells (Chapter 4). FAT4, the mammalian homologue most closely related to Drosophila fat

(18), has been described to play a role in both regulation of planar cell polarity (PCP) as well
as HIPPO signaling. As extensively described in Chapter 1, YAP and TAZ are pro-survival

factors that mediate Hippo pathway signaling which are critical pro-survival factors with

described roles in anoikis (19, 20). Regulation of the FAT cadherin family members may be
yet another means by which GRHL2 enforces epithelial cell sensitivity to anoikis through
regulation of Hippo signaling, a pathway which merits further study.

Our lab has previously demonstrated that reversal of EMT by GRHL2 suppresses the

oncogenic EMT, enforces the default epithelial cell state, and resulted in reversal of the

cancer stem cell-like state (21, 22). It has been extensively demonstrated that in these
settings, plasticity conferred by EMT benefits small populations of cells, bestowing CSC-like
and chemoresistant properties to these subpopulations that resume growth after a period of

dormancy (23-29). In culture, treatment of HMLE cells with taxol derivatives enriches for

this CSC-like population; conversely, stable expression of GRHL2 significantly sensitizes
these, as well as MDA-MB-231 cells, to this therapy. Critically, ectopically expressed GRHL2

prevents the chemotherapy-induced emergence of this CSC-like population (22). Further,

SUM149 cells subjected to metabolic stress such as glutamine deprivation largely die, but the

rare resistant populations which result are described as a “metabolically adaptable,”
glutamine independent population (30). In addition to having undergone EMT, these cells
now display chemotherapeutic resistance to a multitude of chemotherapeutic agents
including taxol, Erlotinib, doxorubicin, and other targeted and cytotoxic agents. These cells
are reported to have significantly downregulated GRHL2 and upregulated ZEB1 (a finding
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confirmed by our laboratory). Preliminary evidence suggests that re-expression of GRHL2

in this model significantly sensitizes MA cells to chemotherapeutic intervention.

Additionally, significant changes in histone activation marks H3K4 trimethylation and
H3K14 acetylation have been reported to be associated with the drug resistant state (31),
which when reversed using HDAC inhibitor pretreatment, significantly sensitized cells to
chemotherapy (30). This highlights the critical need for a better understanding of how

GRHL2 regulates epigenetic modification of genes to sensitize to chemotherapies.
Prevention of the emergence of CSC-like populations will be a critical step to abrogate
chemo/radiotherapy resistant recurrence or metastases developing after initially successful

treatment of primary disease. As established previously by our lab (22), Wnt and TGF-β
signaling collaborate to coordinately downregulate GRHL2, while inhibition of these
pathways maintains endogenous GRHL2. It was established here that BMP2 was able to
inhibit TGF-β signaling to maintain GRHL2 protein levels.

Combining BMP pathway

activation and Wnt inhibitors with conventional cytotoxic or targeted chemotherapy may

establish a means by which chemotherapy resistant subpopulations are sensitized,
preventing recurrence of disease. A better understanding of the pathways which regulate

endogenous GRHL2 levels is critical to establish a practical means by which to translate this
knowledge to patient care.

The findings presented here establish a role of GRHL2 in anoikis beyond that of

previously described pathways by which EMT influences anoikis. Here, we provided a

mechanism by which EMT decreases ROS as to protect cells against anoikis. Under this
model, GRHL2 reverses EMT, suppressing mitochondrial oxidative function and α-

ketoglutarate level through the repression of the critical enzyme regulating glutaminolysis,
182

GLUD1, resulting in loss of glutamine utilization, increased ROS level, ultimately shifting
metabolism resulting in anoikis sensitivity.
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Epithelial–Mesenchymal Transition and Tumor Suppression
Are Controlled by a Reciprocal Feedback Loop between
ZEB1 and Grainyhead-like-2
Benjamin Cieply1, Joshua Farris1, James Denvir3, Heide L. Ford4, and Steven M. Frisch1,2

Abstract
Epithelial–mesenchymal transition (EMT) in carcinoma cells enhances malignant progression by promoting
invasion and survival. EMT is induced by microenvironmental factors, including TGF-b and Wnt agonists, and
by the E–box-binding transcription factors Twist, Snail, and ZEB. Grainyhead-like-2 (GRHL2), a member of the
mammalian Grainyhead family of wound-healing regulatory transcription factors, suppresses EMT and
restores sensitivity to anoikis by repressing ZEB1 expression and inhibiting TGF-b signaling. In this study,
we elucidate the functional relationship between GRHL2 and ZEB1 in EMT/MET and tumor biology. At least
three homeodomain proteins, Six1, LBX1, and HoxA5, transactivated the ZEB1 promoter, in the case of Six1,
through direct protein–promoter interaction. GRHL2 altered the Six1–DNA complex, inhibiting this transactivation. Correspondingly, GRHL2 expression prevented tumor initiation in xenograft assays, sensitized
breast cancer cells to paclitaxel, and suppressed the emergence of CD44highCD24low cells (deﬁning the cancer
stem cell phenotype in the cell type studied). GRHL2 was downregulated in recurrent mouse tumors that had
evolved to an oncogene-independent, EMT-like state, supporting a role for GRHL2 downregulation in this
phenotypic transition, modeling disease recurrence. The combination of TGF-b and Wnt activation repressed
GRHL2 expression by direct interaction of ZEB1 with the GRHL2 promoter, inducing EMT. Together, our
observations indicate that a reciprocal feedback loop between GRHL2 and ZEB1 controls epithelial versus
mesenchymal phenotypes and EMT-driven tumor progression. Cancer Res; 73(20); 1–11. 2013 AACR.

Introduction
The oncogenic epithelial–mesenchymal transition (EMT)
contributes to tumor progression by enhancing tumor cell
invasiveness and anoikis-resistance, which may enhance the
early steps of metastasis (1–5). Chemo- and radioresistance
also accompany EMT, confounding stable patient responses to
treatment, especially in the claudin-low subclass of breast
cancer, where a frank EMT-like pattern of genes is expressed
(6–9). In certain contexts, EMT also promotes the transition of
tumor cells to cancer stem cell (CSC)/tumor-initiating cells,
although CSCs can arise independently of EMT (10–14).
The transcription factors ZEB1 and ZEB2 (SIP1) are pivotal
activators of EMT. ZEB1 and, subsequently, ZEB2 were iden-
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tiﬁed as the ﬁrst repressors of the mammalian E-cadherin
promoter (15, 16). They are now known to regulate cytoskeletal, cell polarity, cell adhesion, and apoptosis-regulatory genes
that collectively sufﬁce for EMT induction (17, 18). ZEB1 is
induced by transcription factors that include NF-kB, Twist/
Snail (acting in concert), TCF4, and LBX1 (19–22). Conversely,
ZEB1 expression is translationally attenuated by mir-200b/c,
whose expression is, in turn, repressed by TGF-b signaling,
explaining (in part) the engagement of stable autocrine TGF-b
signaling in the maintenance of EMT (23).
Grainyhead-like-2 (GRHL2) is a transcription factor that
regulates the EMT/MET-related processes of wound healing,
epidermal junction assembly, and neural tube closure (24–
27). Previously, we reported that GRHL2 is a generalized
suppressor of oncogenic EMT, through at least two mechanisms – direct repression of ZEB1 expression and inhibition of
the TGF-b pathway (28). Here, we show that GRHL2 inhibited
transactivation of the ZEB1 promoter mediated by the homeodomain proteins Six1, LBX1, and HoxA5. GRHL2 acted as a
tumor suppressor gene, by the criterion of suppressed tumorinitiation frequency. In addition, GRHL2 sensitized tumor
cells to paclitaxel and prevented the emergence of CD44high
CD24low mammary epithelial cells. The combination of Wnt
and TGF-b pathway activation upregulated ZEB1 expression.
ZEB1 reciprocally repressed GRHL2 expression through a
direct interaction with the GRHL2 promoter. These observations reveal a novel GRHL2–ZEB1 reciprocal feedback loop
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that drives EMT versus MET in response to extracellular
signals.

Materials and Methods
Cell lines
HMLE and HMLEþtwist-ER were kindly provided by R.
Weinberg (Whitehead Institute, Cambridge, MA) and the
MDA-MB-231LN by E. Pugacheva (West Virginia University,
Morgantown, WV). Cells were cultured and stable cell lines
were generated via retroviral transduction as described
previously (28) GRHL2 was expressed using either MSCVIRES-puro or MSCV-IRES-GFP (pMIG, Addgene) and mixed
populations or multiple clonal lines were used as indicated.
The b-catenin S33Y mutant (provided by S.P.S. Monga,
University of Pittsburgh, Pittsburgh, PA) was subcloned into
the pMXS-IRES-PURO retroviral vector [contributed by Russ
Carstens, University of Pennsylvania (Philadelphia, PA) inframe with a C-terminal FLAG tag]. The human Six1
sequence was also subcloned into the pMXS-IRES-PURO
vector. ZEB1 shRNA (V3LHS_356186, Open Biosystems) and
ZEB1 cDNA were expressed via the pTRIPZ and pLUT
lentiviral vectors, respectively, as described previously (28).
Human H-rasV12 in MSCV-IRES-Blast (Addgene) was used to
express activated Ras in CD44low (ﬂow-sorted) HMLE cells
for tumor assays. HMLEþRas cells were subjected to stable
GRHL2 knockdown (Open Biosystems RHS4430-99291384)
using pGIPZ, followed by selection for puromycin resistance
and sorting for GFP.
Xenograft assays
MDA-MB-231LN stably expressing either empty-MSCVIRES-Puro or GRHL2-IRES-Puro were trypsinized and resuspended in growth media, and the indicated cell numbers in 0.1
mL were injected into the fourth inguinal mammary fat pad of
female BALB/c nude mice (Charles River) at approximately
four weeks of age. HMLEþRas cells with GRHL2 or control
short-hairpin RNA (shRNA; see earlier) were trypsinized and
suspended in growth medium; the indicated cell numbers were
injected in 0.1 mL into the fourth inguinal mammary fat pad of
female nonobese diabetic/severe combined immunodeﬁcient
(NOD/SCID; Charles River). Assays were carried out for 10
weeks (HMLER) or for indicated times. Tumor volume was
determined using the formula p(L1  L22)/6, where L1 is the
long axis and L2 is the short axis. Tumor burden was monitored
according to the WVU ACUC Tumor Burden Policy. Animal
studies were approved by the West Virginia University Animal
Care and Use Committee.
Western blotting
Electrophoresis, transfer, immunoblotting, and antibodies
used were described (28). Other antibodies used here were:
rabbit anti-vimentin (Cell Signaling Technology), mouse antiFLAG (M2; Sigma), and mouse anti-GAPDH (Thermo Scientiﬁc).
Chemosensitivity assays
MDA-MB-231 cells with stable GRHL2-MSCV-IRES-puro or
empty MSCV-IRES-puro were plated in 96-well dishes at a
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density of 5,000 cells per well and assayed in biological triplicate for cell viability after three days of incubation, with the
indicated concentration of paclitaxel, using Presto-Blue (Invitrogen) according to the manufacturer's protocol. For the
chemo-induced marker analysis, the protocol was modeled
after the study by Gupta and colleagues (38). HMLE cells
expressing empty-MSCV-IRES-GFP or GRHL2–MSCV-IRESGFP were treated with paclitaxel (10 nmol/L) for four days,
followed by seven days of recovery and ﬂow analysis for CD44
using a CD44-PE antibody (BD Biosciences). HMLE induced to
undergo EMT by ectopic twist were used as a positive control
for the CD44high phenotype.
Quantitative reverse transcription PCR analysis of
primary vs. recurrent mouse tumors
RNAs from primary and recurrent tetO-neuNT (n ¼ 5 for
each group; ref. 29) or tetO-Wnt1 (n ¼ 4 for each group;
ref. 30) were provided by L. Chodosh (University of Pennsylvania) or E. Gunther (Penn State University, Hershey, PA)
and analyzed for GRHL2 expression using a b2-microglobulin internal control as described previously (28), using the
primers: mGRHL2-f: caaggacgaccagcgcagca; mGRHL2-r:
ggccctccccctgcttctga; mB2M-f: tggtctttctggtgcttgtc; mB2M-r:
gggtggaactgtgttacgtag.
BIO, TGF-b, and BMP2 treatments
HMLE cells were treated with 5 mM 6-bromo-3-[(3E)-1,3dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro(3Z)-2H-indol-2-one (BIO; ref. 31) and/or TGF-b1 (5 ng/mL) for
four days. BIO was removed and the TGF-b was continued for
another six days; samples were then analyzed by Western blot.
HMLEþtwist-ER were treated with either 50 nmol/L 4-hydroxytamoxifen (4OHT), 0.5 mg/mL BMP-2 (R&D Biosystems), or
both for 7 to 10 days and then analyzed by Western blot.
Reporter assays
Cotransfections, luciferase, and b-galactosidase assays as
well as the GRHL2 expression vector and ZEB1-WT- promoter
reporter were described previously (28); all values represent the
average relative luciferase activity/b-galactosidase activity of
biological duplicates; error bars represent SD from the mean.
The transcription factors used in the cotransfection/reporter
assays were obtained and cloned as follows: hLBX1 was
obtained from D. Haber (Dana–Farber Cancer Center) in
pBABE and cloned into pCDNA3.1. The hHOXA5 was purchased from Addgene and subcloned from pET28B into
pCDNA-3.1. mTwist (pBABE-mTWIST-ER) was purchased
from Addgene and the twist cDNA was subcloned into
pCDNA-3.1 (GC rich Phusion buffer). HA-Snail-pCDNA-3.1 was
purchased from Addgene. The GRHL2 genomic sequence from
625 to þ335 (relative to the transcription start site of the
standard GRHL2 transcript) was subcloned into pGL4.14
using the following primers: Gra-prom-f3: CTCACCTGTTTGAAAATCTG and Gra-prom-r12: TGTTTGATCCAATGAACTTGC, using the Bacterial Artiﬁcial Chromosome clone
2058A8 (Invitrogen) as a template; these coordinates were
based on the GRHL2 transcript NM_024915. The band resulting from this PCR was reampliﬁed with similar primers
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containing NheI (forward) and BglII (reverse) restriction sites,
and subcloned into pGL4.14 (Promega).
The ZEB1 promoters containing a mutant downstream
homeobox site or deleted upstream homeobox site or both
were generated as follows. The downstream site was mutated
by using the mutagenic primers Mut-f3: cgtgcctccctctccccaccagtccgtaggaaaacttttccc Mut-r3: gggaaaagttttcctacggactggtggggagagggaggcacg in the Quickchange-IIXL kit (Agilent) with
the ZEB1 promoter/pGL3basic clone (provided by Antonio
Garcia de Herreros, University of Barcelona) as a template. The
deletion of the upstream site was generated by amplifying
the same template in two separate PCR reactions, using
Ant-f: TAATTTACGCGTCCTTAAGGTCCTGCACGGCG, Antr: TTTAAAAAGCTTCCGCCATGATCCTCTCGC (reaction 1)
and Ant-f2: tatataGCGGCCGCAAGGGAAGGGAAGGGAGTCC,
Ant-r2: TTTAAAGCGGCCGCTTCAATGAGATTGAACTTCA.
Following restriction digestion and isolation from an agarose
gel, fragments were three-way ligated into pGL3basic.
Chromatin immunoprecipitation assays
The protocol for cross-linking, immunoprecipitation, de–
cross-linking, and quantitative PCR (qPCR) analysis was as
described previously (28). For Six1 protein interaction with
the ZEB1 promoter, ﬁve dishes of HMLEþ empty vector
(pMXS-IRES-puro) or FLAG-Six1 were immunoprecipitated
with mouse anti-FLAG-M2-agarose or mouse IgG (Santa Cruz
BioTechnology)-agarose in conjunction with DNA/proteinblocked protein A/G agarose (Pierce/Thermo). Primers to
amplify the ZEB1 promoter were: f: gccgccgagcctccaacttt;
r: tgctagggaccgggcggttt. For interaction of ZEB1 protein with
the GRHL2 promoter, ﬁve dishes of HMLE expressing ZEB1 (in
pLUT vector) were processed. To pull down ZEB1, 1 mg of the
following antibodies (3 mg in total) were used: ZEB1, rb,
Sigma HPA004820; ZEB1, rb, Cell Signaling Technology
3396S; and ZEB1, rb, Santa Cruz Biotechnology SC-25388. The
control antibody was rabbit immunoglobulin G (IgG, 3 mg;
Santa Cruz Biotechnology). Primers to analyze the ZEB1
chromatin immunoprecipitation (chIP) were: positive control:
Ecad-ZEB1-f: ggccggcaggtgaaccctca; Ecad-ZEB1-r: gggctggagtctgaactga; GRHL2 promoter set 1: f: cgccgctccactcgggtaaa;
r: tgcgcgatgattggctgggg; GRHL2 promoter set2: f: tcagctctcacaggctgccg; r: gaggcgcgctcaggtaaggc. The negative control
primer set for all CHIP assays was from an intergenic region
upstream of the GAPDH locus: GAPDH-f: atgggtgccactggggatct; GAPDH-r: tgccaaagcctaggggaaga.
Electrophoretic mobility shift assay
Puriﬁed recombinant Six1 protein was generated as
described previously (32). Puriﬁed recombinant GRHL2 protein was obtained by expressing the GRHL2 coding sequence in
Escherichia coli (E. coli) BL21 using the pGEX-6P3 vector and
purifying the fusion protein as described previously (15). After
binding to the glutathione Sepharose resin (GE Healthcare),
the protein was cleaved free of GST sequence using PreScission Protease, which was then dialyzed against electrophoretic mobility shift assay (EMSA) buffer (see further) using
Slide-A-Lyzer Mini-dialysis Unit (Thermo Scientiﬁc). 2 EMSA
buffer was: 30 mmol/L HEPES pH 7.6, 20% glycerol, 1 mmol/L
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EDTA, 200 mmol/L KCL, 0.5% NP40, 5 mg/mL BSA (added
fresh), 10 mmol/L DTT (added fresh). For 20 mL binding
reactions: 10 mL 2 EMSA bufferþ1 mL poly dIdC (0.5
mg/mL)þ2 mL annealed 100 nmol/L oligonucleotide, and
recombinant protein (as indicated). Oligonucleotides for
EMSA were synthesized with Cy5 groups on both 50 ends
(Operon) and annealed at 10 mmol/L Tris/1 mmol/L EDTA/
100 mmol/L NaCl. Binding reactions were incubated at 4 C for
20 minutes, 15 minutes at room temperature, and analyzed on
6% polyacrylamide/TBE gels in 0.25 TBE buffer (pre-run for
1 hour) at 170V. The ﬂuorescent signals were imaged using
the LiCor Odyssey imaging system.
Oligo sequences (Forward strands) ZEB1-WT-Promoter:
(Cy5)-GGAAGGTGATGTCGTAAAGCCGGGAGTGTCGTAAACCAGGTGCGGTGGG
ZEB1-MT-Promoter: (Cy5)-GGAAGGTGATGTCGTCCCGCCGGGAGTGTCGTCCCCCAGGTGCGGTGGG
GRHL2-Pos-Con: (Cy5)-AACTATAAAACCGGTTTATCTAGTTGG
Six1-Pos-Con: (Cy5)-GGGGGCTCAGGTTTCTGTGGC
Negative control (from E-cadherin promoter): (Cy5)-TGGCCGGCAGGTGAACCCTCAGCCAATCAGCGCTACGGGGGGCGGTGCTCCGGGGCTCACCTGGCTGCAG
Flow cytometry
Trypsinized cells (1  105) were stained with APC mouse
anti-human CD44 (BD 560890) and PerCP-Cy5.5 mouse antihuman CD24 (BD 561647) in 100 uL of PBS containing 2.5
mmol/L EDTA, 10 mmol/L HEPES, and 2% horse serum,
followed by washing and analysis using a FACS-Aria.
Statistical methods
Error bars in graphs represent SDs, using a two-tailed t test. P
values for tumor assays were calculated using the two-tailed
Fisher exact test. Tumors were considered present when the
tumor volume was reported to be greater than 100 mm3. ORs
and P values for tumor incidence were calculated using the
Fisher exact Test as implemented in R v2.15.1 (www.r-project.
org).

Results
GRHL2 inhibits the activation of ZEB1 expression by
homeodomain proteins
Previously, we reported that GRHL2 binds and represses the
ZEB1 promoter so as to suppress EMT (28). To characterize
this transcriptional regulation further, we analyzed the ZEB1
promoter using a transcription factor-binding prediction program (Genomatix) and identiﬁed two tandem homeodomain
consensus binding sites, overlapping with and just upstream of
the putative GRHL2 site. Alignment of this sequence between
several species revealed that both the putative GRHL2 binding
site as well as these homeobox sites were highly conserved
(Fig. 1A). In this light, we tested the effect of two homeodomain
factors that were previously shown to be involved in EMT
induction in breast cancer cells – LBX1 and Six1 – on the
activity of the ZEB1 promoter (22, 33). These factors activated
transcription of the ZEB1 promoter signiﬁcantly; mutation
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Figure 1. Homeodomain proteins LBX1 and Six1 activate ZEB1 expression and are inhibited by GRHL2 protein. A, the region of interest from the ZEB1 promoter
is conserved between various species: Ms, Mus musculus; Hs, Homo sapiens; Bp, Bos primigenius; Dr, Danio rerio. Bold, homeobox consensus sites; italics,
grainyhead consensus sites. B, LBX1 and Six1 activate transcription from the ZEB1 promoter in a GRHL2-sensitive manner. The ZEB1 promoter-luciferase
reporter with wild-type sequence (WT), the 30 homeobox site mutated (MUT), or both the mutation of the latter site plus deletion of the 50 homeobox binding site
(DD) were cotransfected into MSP cells together with the indicated transcription factors; values represent the average of biologic duplicates from one
representative of two experiments. C, Six1 induces the endogenous ZEB1 gene and EMT in unfractionated HMLE cells. HMLE cells expressing vector or
FLAG-Six1 were analyzed for the indicated EMT markers (top) or morphologic changes (bottom).

of the 30 homeodomain binding site substantially diminished transactivation by these factors. The double deletion
totally eliminated it, and, interestingly, GRHL2 cotransfection
inhibited the transactivation by both homeodomain factors
(Fig. 1B).
We then tested the effect of Six1 on endogenous ZEB1
expression. HMLE cells are a mixed population containing
5% to 10% mesenchymal cells in equilibrium with epithelial
cells (11). HMLE cells were infected with Six1 retroviral expression constructs. Interestingly, Six1 by itself upregulated ZEB1,
downregulated GRHL2, and induced EMT (Fig. 1c). Upon
removal of the CD44high subpopulation by ﬂow sorting before
infection with Six1 retrovirus, however, induction of ZEB1 by
Six1 required the concomitant knockdown of GRHL2 through
an shRNA (previously shown to have identical effects with
other shRNAs targeting GRHL2), consistent with the antagonistic effect of GRHL2 on EMT that we observed previously
(Supplementary Fig. S1; ref. 28). Knock-down of the individual
homeodomain proteins examined failed to block ZEB1 induction during EMT, indicating that multiple redundant factors,
likely to include additional, unidentiﬁed factors, activate
ZEB1 (data not shown). In this connection, HoxA5, another
factor that was predicted to bind these two sites, also showed
robust, GRHL2-sensitive ZEB1 activation as well as the ability
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to induce mammosphere formation in HMLE cells, although
frank EMT was not evident (Supplementary Figs. S2 and S3;
data not shown).
We tested Six1 for selective, direct binding to an oligonucleotide corresponding to the conserved sequence of the
ZEB1 promoter. Six1 protein interacted preferentially with
the wild-type, but not the doubly mutated (transcriptionally
inactive), sequence as did the GRHL2 protein (Fig. 2a and b).
The addition of stoichiometric amounts of GRHL2 protein
diminished the Six1–DNA complex dramatically, indicating
either a competition for DNA binding or an inhibitory Six1–
GRHL2 interaction, which the data do not allow us to
distinguish (Fig. 2C). ChIP analysis revealed that Six1 was
recruited to the endogenous ZEB1 promoter, indicating a
direct Six1 protein–ZEB1 promoter interaction (Fig. 2D).
The combined data support a model under which GRHL2
is a general inhibitor of homeodomain protein-induced ZEB1
expression and EMT.
GRHL2 suppresses primary tumor growth and sensitizes
tumor cells to chemotherapy-induced cytotoxicity
Previously, we reported that GRHL2 suppressed or reversed the oncogenic EMT, in part, through the repression of
the ZEB1 gene (28). EMT can increase the frequency of
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Figure 2. GRHL2 and Six1 bind speciﬁcally to sequences in the ZEB1 promoter, and GRHL2 alters this complex. Wild-type (wt) or mutant (mut)
oligonucleotides corresponding to the conserved sequence of interest from the ZEB1 promoter were used to analyze and demonstrate the speciﬁcity of
GRHL2 protein (A) or Six1 (B) protein interactions. C, GRHL2 positive control oligo (GRHL2PC), Six1 positive control oligo (Six1PC), oligo from the
E-cadherin promoter, which neither protein is predicted to bind (NC), and WT ZEB1 promoter oligo were used in an EMSA with the indicated
combinations of GRHL2 and Six1 proteins. D, Six1 protein interacts with the ZEB1 promoter in vivo. Chromatin from HMLE expressing either vector
or FLAG-Six1 were used in a ChIP assay and analyzed by qRT-PCR using ZEB1 promoter primers or GAPDH control primers. Values are the average
of biologic duplicates from one representative of two experiments.

breast CSCs in certain cell lines such as HMLE (12), and
consistent with this, GRHL2 suppressed mammosphere
generation (28). Here, we tested the effects of GRHL2 on
tumor-initiation frequency, a measure of CSC frequency.
HMLER cells are immortalized mammary epithelial cells
that express H-rasV12 ectopically and have not undergone
EMT, but are induced to do so by stable GRHL2 knockdown
using multiple, independently targeting shRNAs (28, 34). As
reported previously, HMLER cells possessed a low tumorinitiation frequency, but this frequency was increased signiﬁcantly by the knockdown of the GRHL2 gene (Fig. 3A).
Correspondingly, the knockdown of GRHL2 increased the
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frequency of CD44highCD24low cells (Supplementary Fig. S4),
which have been correlated with the CSC phenotype in this
cell line previously (12, 28). To extend this to another cell
line, and use the converse approach, the triple-negative
breast cancer line, MDA-MB-231LN was stably transduced
with a GRHL2-expressing retrovirus or with or empty vector
(28) and injected. GRHL2 suppressed the frequency of
tumors signiﬁcantly (Fig. 3b). These data were consistent
with the ability of GRHL2 to suppress the tumor initiationpromoting effect of EMT (11, 12, 35). In conjunction with the
functional assays and clinical correlations – downregulation
of GRHL2 expression in EMT-like tumors – that we
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Figure 3. GRHL2 suppresses tumor-initiation capacity and sensitizes breast cancer cells to chemotherapy-induced cytotoxicity. A, GRHL2 suppresses
tumor initiation (knockdown approach). Immunodeﬁcient mice were injected orthotopically with HMLER cells expressing control shRNA versus GRHL2
shRNA (one of two GRHL2 shRNAs shown previously to suppress EMT in this cell line; ref. 22); individual tumor volumes at 10 weeks are shown. B,
GRHL2 suppresses tumor initiation (overexpression approach). MDA-MB-231LN cells expressing GRHL2 (three individual clones, labeled G1,G2, and G3) or
MDA-MB-231LN cells with empty vector (vec) were assayed at the indicated time points. (Mice bearing vector control tumors were sacriﬁced between
4.5 and 7 weeks due to signs of tumor burden-related illness.) ORs for tumor initiation were 0.0108 and 0.0558 for the early and late time-point data,
respectively. C, GRHL2 is downregulated during the transition from primary to recurrent phenotype in tetO-Wnt1 and tetO-neuNT mouse models; qRT-PCR on
RNAs from independent tumors, normalized against b2-microglobulin, conducted in technical duplicate.

published previously (28), these results identify GRHL2 as a
tumor suppressor gene.
In doxycycline-inducible mouse mammary tumor models,
the expression of neuNT, Wnt1, or c-myc promotes primary
tumors that regress upon the removal of doxycycline. The
tumors recur frequently, and the recurrent tumor cells have
undergone EMT, providing a model for evolution from oncogene/proliferation rate-driven tumors to oncogene-independent, EMT-driven recurrences (29, 30, 36). We analyzed RNA
from the tetO-neuNT and tetO-Wnt1 mouse models for GRHL2
expression by quantitative reverse transcription (qRT)-PCR. In
both cases, GRHL2 expression was greatly reduced in the
recurrent tumor relative to primary (Fig. 3C). These ﬁndings
indicate that GRHL2 is downregulated during tumor evolution
to an EMT phenotype, further supporting the tumor suppressor
function of GRHL2, in a mouse model for disease recurrence.
EMT is associated with chemoresistance (37, 38). We reasoned that the mesenchymal–epithelial transition induced by
GRHL2 would be associated with enhanced sensitivity to the
microtubule-targeting chemotherapy drug, paclitaxel. Ectopic
GRHL2 expression induced dose-dependent cell death in the
otherwise refractory MDA-MB231LN tumor cell line (Supple-
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mentary Fig. S5). HMLE cells contain a subpopulation of
CD44highCD24low cells that is enriched by paclitaxel treatment;
this subpopulation has enhanced tumor-initiation frequency
(11, 38). We conﬁrmed previous reports that, following paclitaxel treatment and recovery, this subpopulation predominated (Supplementary Fig. S5). The paclitaxel-selected cells
also expressed lower levels of GRHL2 than the original population, consistent with their previously reported EMT phenotype. Ectopic GRHL2 expression prevented the chemotherapy-induced emergence of CD44highCD24low cells, indicating
that GRHL2-mediated suppression of this phenotype was
resistant to the effects of challenge with a chemotherapy drug
(Supplementary Fig. S5; ref. 28). The current data did not,
however, allow us to exclude the possibility that paclitaxel
generated a second, as yet uncharacterized, CSC subpopulation from HMLE that was not suppressed by GRHL2.
Based on the extensive data supporting an oncogenic role
for EMT, the suppression of EMT by GRHL2, the effects of
GRHL2 on tumorigenicity and chemosensitivity, and the
downregulation of GRHL2 during EMT in cell culture, patient,
and mouse models, we set out to identify pathways that
downregulate GRHL2 expression.
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Figure 4. Wnt and TGF-b cooperate
to downregulate GRHL2. HMLE
cells treated with the canonical
Wnt pathway agonist BIO (A) or
stably expressing b-catenin S33Y
(B) were assayed for GRHL2
downregulation in response to
TGF-b treatment by Western
blotting; each is one representative
of two duplicate experiments. C,
HMLE cells that stably expressed
Twist-ER protein were treated with
or without 4-OHT (to activate
Twist-ER) in the presence or
absence of the TGF-b pathway
antagonist BMP2, and cell lysates
were assayed for GRHL2 and other
indicated protein expression.
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GRHL2 is downregulated by Wnt and TGF-b
TGF-b is able to induce EMT in only restricted cell
contexts (39). In HMLE cells, TGF-b induced EMT only in
conjunction with Wnt pathway agonists or in cells where
GRHL2 had been knocked down, providing insight into this
restriction (11, 28).
Activation of the Wnt signaling pathway by transient
treatment with the GSK-3 inhibitor, 6-bromo-3-[(3E)-1,3dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro(3Z)-2H-indol-2-one (BIO; ref. 31) or, by stable expression of
the degradation-resistant b-catenin S33Y mutant (40),
downregulated GRHL2 expression only modestly, as did
extended treatment with TGF-b. Coactivation of both pathways, however, caused a dramatic downregulation of GRHL2
expression (Fig. 4A and B), accompanied by upregulation of
the GRHL2-repressed target gene, ZEB1. BMP2, a functional
antagonist of TGF-b signaling and Twist-induced EMT
(11, 41), alleviated both GRHL2 downregulation and ZEB1
induction in response to the activation of Twist-ER protein
by 4-hydroxytamoxifen (Fig. 4C).
These observations signiﬁed that the Wnt and TGF-b pathways collaborated to downregulate GRHL2 as an intermediate step in EMT, correlating with increased ZEB1 expression,
which prompted us to investigate the potential role of ZEB1
in repressing GRHL2.
ZEB1 represses the GRHL2 promoter directly
To test the role of ZEB1 in the downregulation of GRHL2,
HMLE cells with an estrogen-inducible Twist fusion protein
(HMLEþTwist-ER) were induced to undergo EMT by the
addition of 4-hydroxytamoxifen. As we reported previously,
this upregulated ZEB1 and downregulated GRHL2 (28). Suppression of ZEB1 with siRNA, however, largely prevented the
GRHL2 downregulation (Fig. 5A). To test this in a different
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context using a different knockdown reagent, HMLE cells
with doxycycline-inducible ZEB1 shRNA expression or control
cells were induced with the combination of BIO and TGF-b.
Depletion of ZEB1 by ZEB1 shRNA alleviated the downregulation of GRHL2, indicating that the WntþTGF-b–mediated
downregulation of GRHL2 is dependent on ZEB1 expression
(Fig. 5B). Conversely, we expressed ZEB1 ectopically in HMLE
cells using a doxycycline-inducible lentiviral vector. Induction
of ZEB1 downregulated GRHL2 expression as well as the
previously characterized ZEB1 target, E-cadherin (Fig. 5c;
ref. 15). These observations indicated that ZEB1 repressed
GRHL2 expression.
We then explored the possibility that the ZEB1 protein
might repress the GRHL2 gene through direct interaction with
promoter sequences. As an initial test, we subcloned a genomic
fragment containing the sequences from 625 to þ335 (relative to the transcription start site of the standard GRHL2
transcript) into a luciferase reporter vector and assayed this for
transcriptional activity. The transcriptional activity of the
GRHL2 promoter clone was substantially greater in HMLE
cells than in the mesenchymal subpopulation cells (MSP)
derived from HMLE, consistent with the low expression of
endogenous GRHL2 in the latter, validating this promoter
clone (Fig. 5D; ref. 28). Cotransfected ZEB1 repressed the
promoter, nearly to background level. By contrast, two other
E-box binding EMT-related transcription factors, Snail and
Twist, only modestly repressed the promoter. Conversely, the
promoter activity assayed in MSP cells was stimulated by
transfection of ZEB1 siRNA (Fig. 5E).
Inspection of published ZEB1 CHIP-seq data indicated
binding sites positioned near the transcription start site of
GRHL2 (Fig. 6A). By ChIP analysis using an anti-ZEB1 antibody,
we detected an interaction of ZEB1 protein with GRHL2
sequences near the transcription start site, with efﬁciency
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Figure 5. ZEB1 downregulates the GRHL2 promoter. A and B, si/shRNA-mediated knockdown of ZEB1 partially alleviated GRHL2 downregulation
caused by 4-OHT-activated Twist-ER protein (A) or BIO plus TGF-b treatment (B). C, HMLE cells stably expressing a doxycycline-inducible ZEB1
expression construct were induced with doxycycline and lysates were analyzed for ZEB1, GRHL2, E-cadherin, and Akt by Western blotting. D, the
GRHL2 promoter in a luciferase reporter vector was cotransfected with Snail, Twist, or ZEB1 expression vectors in HMLE cells or the promoter was
transfected by itself into MSP cells; normalized luciferase activity values are shown. E, HMLE-MSP transfected with control or ZEB1 siRNA were
transfected with the GRHL2 promoter-luciferase construct; normalized luciferase activity values are shown. Values are the average of biologic
duplicates from one representative of two experiments.

comparable with that of the E-cadherin promoter and significantly stronger than a negative control sequence (the intergenic region upstream of the GAPDH gene; Fig. 6B). When
combined, these data indicated that the ZEB1 protein
represses the GRHL2 promoter directly, establishing that a
mutual antagonism between expression of ZEB1 and GRHL2
directs tumor cells toward epithelial or mesenchymal
phenotypes.

Discussion
Our observations inform a model of reciprocal antagonism
between ZEB1 and GRHL2 as a pivotal mechanism underlying
EMT (Fig. 7). Under this model, GRHL2 and ZEB1 – each
regulated by microenvironmental factors – repress each
other's transcription. GRHL2 represses ZEB1 by inhibiting at
least three activators of the ZEB1 promoter: LBX1, Six1, and
HoxA5.
We focused on these three transcription factors in light
of the functional importance of homeodomain consensus
sites for activity of the ZEB1 promoter (Fig. 1). Although
numerous homeodomain proteins may have partially redundant functions, confounding efforts to show an effect of
knockdown/knockout of an individual factor, their overall
signiﬁcance in diverse cancer types is established (reviewed
in ref. 42). In particular, previous reports have implicated
LBX1 and Six1 in breast-cancer-related EMT (22, 33, 43).
Although Six1 was shown previously to induce ZEB1 expres-
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sion, this was proposed to be posttranscriptional in colorectal cancer cell lines (44), in contrast with our evidence
indicating a direct interaction of Six1 with the ZEB1
promoter.
Importantly, GRHL2 protein, the ﬁrst direct transcriptional
repressor of the ZEB1 gene to be reported (28), interfered with
the transcriptional activation of the ZEB1 promoter by all three
of these factors. Although the GRHL2 protein effectively abolished the Six1 protein–DNA complex on the ZEB1 promoter
oligonucleotide that contained two tandem Six1 binding sites,
there was no effect on Six1 protein binding to a positive control
sequence containing only one binding site (data not shown),
suggesting that GRHL2 selectively affects two Six1 protein
molecules on DNA versus a single Six1 molecule. We were
unable to detect an interaction of GRHL2 with Six1 protein in
cotransfection assays (data not shown), suggesting that they
interact only on DNA.
The antagonistic effects of GRHL2 versus ZEB1, mediated,
in part, by homeodomain activators of ZEB1, may relate
conceptually to previously reported developmental roles of
these genes. GRHL2 is required for neural tube closure, the
stage of development directly preceding delamination. Subsequently, anterior HOX genes (HoxA1 and HoxB1) induce
EMT during delamination of the neural crest, through
activation of Snail and Msx1/2 transcription (45). Speculatively, the homeodomain factors may also activate EMT
factors such as ZEB1, thereby repressing GRHL2 expression,
which would indicate, analogously, functional opposition of
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Figure 6. ZEB1 protein interacts directly with the GRHL2 promoter. A, ChIP–seq data (Encode project; ref. 55) for ZEB1 reveal a potential binding site near the
transcription start site. B, conﬁrmation of ChIP–seq. Chromatin from HMLE expressing tet-ON ZEB1 was subjected to ChIP using ZEB1 antibody and analyzed
by qRT-PCR using the indicated primers. The average of biologic duplicates from one representative of two experiments is shown.

these factors during development that mirrors their respective functions in regulating the oncogenic EMT.
We have now shown the other half of the reciprocal
feedback loop (Fig. 7) as well: ZEB1 is also a direct repressor

of GRHL2 (Figs. 4 and 5). When combined, this represents a
switch that dictates cellular phenotype between epithelial
and mesenchymal states, formally analogous to the relationship between ZEB1 and mir200 (46). Thus, one effect of
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other?
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Figure 7. A reciprocal feedback
loop between Grainyhead-like-2
and ZEB1 controls EMT and tumor
suppression. Details are explained
in the text.
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inducing ZEB1 expression by microenvironmental factors is
to repress GRHL2 expression, stabilizing ZEB1 expression. In
this connection, we found that neither TGF-b nor the
canonical Wnt pathway stimulation was sufﬁcient to induce
ZEB1/downregulate GRHL2; however, the two in conjunction tipped the balance in favor of ZEB1. This ﬁnding is
precisely consistent with those showing that multiple microenvironmental signals are needed to regulate EMT or MET
(10, 47) and may prove to be the underlying mechanism.
Other combinations of factors induce ZEB1 and EMT, at
least in speciﬁc cell contexts, including TGF-bþ FGF2, TGFbþ TNF-a, TGF-bþEGF(R), TGF-bþmechanotransduction
from extracellular matrix, or factors in the "senescent
cell secretory phenotype" (SASP; refs. 19, 48–51). It is also
notable that Six1 expression activates autocrine TGF-b and
Wnt signaling loops, suggesting that it activates ZEB1 both
directly and indirectly (33).
Our results indicate that these combinations of factors
may downregulate GRHL2 as an intermediate step leading to
EMT. Moreover, stable GRHL2 expression suppressed EMT,
decreased tumor frequency, and sensitized tumor cells to the
effects of chemotherapeutic drugs. Thus, factors that downregulate GRHL2 are potential drug targets for novel therapies
acting to enhance chemotherapeuic responses and prevent
disease recurrence. In this connection, it is interesting to note
that the related gene, GRHL3, is a tumor suppressor in squamous cell carcinoma that upregulates PTEN (52, 53). During
development, GRHL2 and GRHL3 regulate some unique and
other common genes (54), suggesting that the biologic functions of GRHL2 should be investigated in the context of other
Grainyhead family members for optimal translational beneﬁt.
Cellular commitment to undergo an oncogenic EMT is
formally analogous to cell-cycle control in that both involve
a transition from dependence on extracellular signals to an
autonomous, stable state. For example, the cell cycle becomes
autonomous beyond the mitogen-driven restriction point,
activation of cyclinD-CDK4/6 complexes, and maintains that

state by a number of mechanisms, including stable activation
of cyclin E expression by free E2F. Similarly, oncogenic EMT is
initiated by microenvironmental factors, for example, TGF-b
and Wnt agonists. We propose that the transition to an
autonomous state is deﬁned, in part, by downregulation of
GRHL2, stabilizing autocrine signaling through ZEB1, TGF-b,
Wnt, and other factors. Thus, GRHL2 downregulation is an
"oncogenic EMT restriction point."
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Abstract
Developmental morphogenesis and tumor progression require a transient or stable
breakdown of epithelial junctional complexes to permit programmed migration, invasion and
anoikis-resistance, characteristics endowed by the Epithelial-Mesenchymal Transition. The
epithelial master-regulatory transcription factor Grainyhead-like 2 (GRHL2) suppresses and
reverses EMT, causing a mesenchymal-epithelial transition to the default epithelial phenotype.
Here, we investigated the role of GRHL2 in tubulogenesis of Madin-Darby Canine Kidney
(MDCK) cells, a process requiring transient, partial EMT. GRHL2 was required for
cystogenesis, but it suppressed tubulogenesis in response to Hepatocyte Growth Factor (HGF).
Surprisingly, GRHL2 suppressed this process by inhibiting the histone acetyltransferase coactivator, p300, preventing the induction of matrix metalloproteases and other p300-dependent
genes required for tubulogenesis. A thirteen amino acid region of GRHL2 was necessary and
sufficient for the inhibition of p300, the suppression of tubulogenesis and the interference with
EMT. The results demonstrate that p300 is required for the partial or complete EMT occurring
in tubulogenesis or tumor progression, and that GRHL2 suppresses EMT in both contexts,
through inhibition of p300.
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INTRODUCTION
p300 is a co-activator of transcription that interacts with at least four hundred DNAfactors to activate transcription from thousands of enhancers/promoters, mostly contingent upon
its intrinsic histone acetyltransferase (HAT) activity. In this context, it is viewed as an
“integrator” factor that serves as a nexus among multiple signaling pathways and programs of
gene expression (Yao et al.; Kamei et al., 1996; Vo and Goodman, 2001; Bedford et al., 2010).
Accordingly, p300/CBP null mice die at E9.5-11.5 with massive deficits of mesenchymal cells
and erythroid cells, as well as defects in neurulation and heart development (Yao et al.; Oike et
al., 1999). p300 is essential for the differentiation of muscle, erythroid lineages, osteoblast,
oligodendrocytes, and stem cells (Puri et al., 1997; Oike et al., 1999; Blobel, 2000; Polesskaya et
al., 2001; Narayanan et al., 2004; Teo and Kahn, 2010; Zhang et al., 2016). A recent study has
demonstrated p300 is a marker for super-enhancers, positioning it to control cell state transitions
(Witte et al., 2015).
Grainyhead-like 2 (GRHL2) is one of the three genes comprising a family of mammalian
transcription factors related to Drosophila Grainyhead, the first zygotically encoded transcription
factor expressed during the maternal to zygotic transition (the MZT) (Harrison et al.). GRHL2 is
important for epithelial barrier assembly in, for example, the morphogenesis of kidney collecting
ducts, placenta, lung alveoli and the mammary gland ductal system (through OVOL2, a GRHL2
target gene) (Gao et al., 2013; Watanabe et al., 2014; Aue et al., 2015; Walentin et al., 2015).
Grainyhead factors are also critical for diverse developmental events that involve the formation
of epithelial barriers, including epidermal assembly, neural crest formation, and, in the adult,
wound-healing (Wilanowski et al., 2002; Gustavsson et al., 2008; Wang and Samakovlis, 2012;
Mlacki et al., 2015). GRHL2 activates the expression of multiple genes encoding epithelial cell
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adhesion molecules (e.g., E-cadherin, desmosomal proteins, tight junction proteins), and due to
its widespread expression, may be generally important for enforcing an epithelial phenotype
(Rifat et al.; Senga et al.; Wilanowski et al., 2002; Ting et al., 2003; Ting et al., 2005; Auden et
al., 2006; Werth et al., 2010; Boglev et al., 2011; Cieply et al., 2012; Tanimizu and Mitaka,
2013; Aue et al., 2015). Correspondingly, the GRHL2 expression plays an important role in
suppressing the oncogenic EMT, thereby functioning as a tumor suppressor that enhances
anoikis-sensitivity (Cieply et al., 2012; Cieply et al., 2013; Mlacki et al., 2015); in fact, the gene
most tightly correlated with E-cadherin expression in human tumors was GRHL2 (Kohn et al.,
2014).
The opposing roles of GRHL2 in establishing the epithelial state vs. p300 in differentiation - including EMT -- motivated us to investigate a potential role for GRHL2 in inhibiting p300
function. Kidney tubulogenesis is contingent upon temporal and spatial regulation of epithelial
cells, in which GRHL2, which is expressed in the ureteric buds of the developing kidney plays a
critical organizing role (Schmidt-Ott et al., 2005; Aue et al., 2015; Walentin et al., 2015).
Madin-Darby Canine Kidney (MDCK) tubulogenesis in response to Hepatocyte Growth Factor
(HGF) models some aspects of kidney collecting duct tubulogenesis in vivo and requires a
transient, partial EMT (pEMT) (Pollack et al., 1998; O'Brien et al., 2002; Pollack et al., 2004;
Leroy and Mostov, 2007; Hellman et al., 2008; Jung et al., 2012; Zhang et al., 2014). HGF
causes MDCK cells to undergo cell scattering in two-dimensional culture, and induces
tubulogenesis of MDCK cysts that form in a three-dimensional collagen gel (Wang et al.,
1990,1991 #4686; Pollack et al., 2004). Induction of MMP1 and MMP13 by HGF through
AP1/p300 complexes is a required for tubulogenesis in the MDCK model (Benbow and
Brinckerhoff, 1997; Clark et al., 2008; Hellman et al., 2008; Chacon-Heszele et al., 2014).
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Targeted knockout studies indicate a role for HGF/Met in kidney development, and, relatedly,
HGF/Met signaling is a potent stimulator of Wnt signaling, a crucial signaling pathway in this
process, validating the in vivo relevance of this approach (Monga et al., 2002; Bridgewater et al.,
2008; Ishibe et al., 2009).
Herein, we report that GRHL2 promoted cystogenesis but suppressed tubulogenesis. GRHL2
protein interacted functionally with p300, inhibiting its HAT activity and transcriptional
activation of target genes, including matrix metalloproteases. A small (thirteen amino acid)
sequence of GRHL2 was important for inhibition of p300, suppression of tubulogenesis and the
reversal of EMT. These results mechanistically position GRHL2, an enforcer of the epithelial
default phenotype, as an antagonist of p300, a co-activator of differentiation-specific genes, with
important ramifications for developmental and tumor biology.

RESULTS
GRHL2 suppresses cell scattering and tubulogenesis
In light of the epithelial programming role of GRHL2, we tested the effect of HGF on
GRHL2 levels in MDCK cells. Interestingly, we found that HGF down-regulated the expression
of endogenous GRHL2 protein levels at early time points (figure 1A). When constitutively
expressed in MDCK cells, GRHL2 significantly inhibited HGF-induced cell scattering compared
to vector control cells (figure 1B). Conversely, MDCK cells with GRHL2 shRNA knockdown
demonstrated enhanced HGF-induced cell scattering; retention of E-cadherin expression showed
that EMT did not occur in response to the knockdown of GRHL2 alone (figure 1C and see video
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in supplemental figure S1). GRHL2 had only modest effects on the phosphorylation status of
two established HGF/Met signaling mediators, Erk and Akt (figure S2).
We then examined the effects of GRHL2 on HGF-induced tubulogenesis in the threedimensional collagen model. GRHL2 expression caused the formation of larger cysts compared
to vector control cells, consistent with previous reports in hepatic bile duct cells (figure 1D)
(Tanimizu and Mitaka, 2013). GRHL2 significantly suppressed tubulogenesis/branching
morphogenesis following HGF treatment (figure 1D); a similar effect of murine Grhl2 was
observed in mouse inner medullary collecting duct cell line (figure S3A), indicating the
important role of GRHL2 down-regulation in tubulogenesis. Conversely, the stable knockdown
of GRHL2 prevented cystogenesis (figure S3B), presumably by down-regulating epithelial
adhesion molecules (Senga et al.; Werth et al., 2010). Transient knockdown of GRHL2
following cyst formation using a doxycycline-induced shRNA vector, however, clearly indicated
that the loss of GRHL2 promoted tubulogenesis (figure S4A). There was no effect of the
GRHL2 shRNA on cell proliferation (figure S4B). These results indicated that GRHL2
suppressed HGF-activated cell scattering and tubulogenesis.
GRHL2 suppresses the expression of matrix metalloproteases
To identify GRHL2 target genes responsible for the attenuation of cellular responses to
HGF/Met signaling, RNA-Seq was used to compare MDCK cells with constitutive GRHL2
expression vs. GRHL2 depletion, either with no treatment or with HGF induction (24 hours).
This experimental scheme allowed for two distinct comparisons: genes regulated by HGF in the
absence vs. presence of GRHL2, and genes regulated by GRHL2 with vs. without HGF
induction. GRHL2 down-regulated several known matrix metalloproteases (MMP) family
members (Table 1, confirmed by qPCR in figure 2A). In light of the established importance of
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specific MMPs for tubulogenesis in the MDCK and mIMCD-3 cell culture models (Hotary et al.,
2000; Jorda et al., 2005; Hellman et al., 2008; Chacon-Heszele et al., 2014), we verified their
importance for branching tubulogenesis in embryonic kidneys cultured ex-vivo using the
generalized MMP inhibitor, batimastat (figure S5). The down-regulation of MMPs by GRHL2
could contribute significantly to the tubulogenesis-suppressing effect of constitutive GRHL2
expression, although additional contributions from EMT/MET-related GRHL2 genes are likely.
To investigate the transcriptional mechanisms of MMP gene regulation by GRHL2,
MMP1 and MMP14 promoters were assayed as luciferase reporter constructs by cotransfection
in HT1080 fibrosarcoma cells, in which the endogenous MMPs are expressed constitutively
(Tang and Hemler, 2004; Nonaka et al., 2005). GRHL2 was found to suppress MMP1 and
MMP14 promoters using adenovirus E1a protein, a known repressor of MMP genes, as a positive
control (figure 2B). These results demonstrated that GRHL2 repressed MMP1 and MMP14
promoters; however, examination of the promoter sequences utilized in our reporters constructs
did not indicate the presence of GRHL2 DNA binding consensus sites (Wilanowski et al., 2002;
Gao et al., 2013; Aue et al., 2015; Walentin et al., 2015), suggesting a more subtle mechanism
for repression not involving direct DNA binding.
GRHL2 inhibits p300 function
The AP-1 transcription factor family is important in the regulation of most MMP genes
(Clark et al., 2008). GRHL2 significantly suppressed AP-1 activity on minimal reporter
constructs in HT1080 and 293 cells (figure 3A). GRHL2 did not appear to affect the expression
of FOS or JUN family members following HGF induction (figure S6).
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In light of the functional similarities between adenovirus E1a and GRHL2 (see
Discussion), we compared a published list of genes that E1a down-regulated through p300
interaction (Ferrari et al., 2014) against our list of GRHL2-downregulated genes; this latter list
was derived from the RNA-seq analysis that we performed on GRHL2-expressing human
mesenchymal subpopulation cells (MSP), reported in (Farris et al., 2016) (as comparison of
canine vs. human gene lists proved uninformative for technical reasons). About 43.5% of the
genes that E1a repressed through p300 were also repressed by GRHL2 (figure 3B). Downstream
Effector Analysis/Ingenuity Pathway analysis revealed that the expression of GRHL2 suppressed
the regulation of numerous p300-associated genes that were up-regulated or down-regulated by
HGF in the absence of GRHL2 expression (figure 3C and figure S7). These results suggested
that GRHL2 could potentially inhibit p300 function.
To investigate this, the effect of GRHL2 upon the activity of a GAL4-DNA binding
domain-p300 fusion protein was assayed by transient transfection using a GAL4-responsive
luciferase promoter, an established method for testing p300 coactivator function without
confounding effects from primary DNA binding activator proteins (Snowden et al., 2000).
Adenovirus E1a protein repressed the AP-1 and GAL4/GAL4-p300 reporter activities, but a
p300-non-binding mutant of E1a (Ferrari et al., 2014) failed to do so (figure S8), validating the
p300-dependence of transcription in these assays. GRHL2 inhibited the co-activator function of
p300 in this assay (figure 3D). As additional negative controls, GRHL2 did not affect the ability
of a p300-independent GAL4-activator fusion protein (VP16-GAL4; (Kutluay et al., 2009)) to
activate the same reporter; another transcription factor unrelated to GRHL2, c-Myc, failed to
inhibit GAL4-p300 function in this assay (figure S9). These results indicated that GRHL2 was a
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potent suppressor of p300 function. The highly related GRHL1 and GRHL3 proteins were found
to have similar effects in the reporter assay (figure S10).
GRHL2 inhibits the histone acetyltransferase (HAT) activity of p300
The HAT domain of p300 acetylates numerous substrates, including lysines 18 and 27 in
the N-terminal tail of histone 3 (H3) (Ogryzko et al., 1996; Kasper et al., 2010; Jin et al., 2011).
Using recombinant proteins, GRHL2 inhibited acetylation of H3K27 by p300 in a dose
dependent manner in vitro (figure 4A). Similar results were obtained using the p300 HAT
domain alone (amino acids1283-1673) rather than full-length p300 (figure S11). Recombinant
GRHL1 and GRHL3 proteins also inhibited the HAT activity of p300 (figure S12).
To confirm these in vitro effects in cells, we analyzed histone acetylation by CHIP-qPCR
using the human cell line, HT1080 (as Encode reference data reporting histone acetylation are
available for the human genome.) Consistent with the in vitro results, the acetylation of H3K27
was inhibited in HT1080 cells expressing GRHL2 constitutively, specifically on promoters that
GRHL2 repressed, including MMP1, MMP14, MMP2, and ZEB1; acetylation of GRHL2upregulated gene promoter-associated H3K27 was either not affected (CDH1, ESRP1) or upregulated (RAB25) (figure 4B). Unlike the effect of E1a on p300, there was neither an effect of
GRHL2 on global H3 acetylation nor global chromatin condensation, assayed by Western
blotting (figure 4B) or by immunofluorescent localization of a LacI-mCherry-GRHL2 protein
(Ferrari et al., 2014), respectively (figure S13).
GRHL2 interacted with p300 by the criteria of co-immunoprecipitation of transiently cotransfected genes, or of endogenous proteins (figure 4C). The recombinant proteins interacted
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only weakly, however (figure S14) suggesting that the interaction is transient or requires posttranslational modifications absent from our recombinant proteins.
GRHL2 inhibits the C-terminal transactivation domain of P300
Multiple domains of p300 can co-activate transcription independently. One of these is
the C-terminal domain (1665aa-2414aa) which interacts with the p160 family of co-activators
(Stiehl et al., 2007). Previous reports suggested that the activity of the C-terminal domain is
stimulated by auto-acetylation, catalyzed by the p300 HAT domain (Stiehl et al., 2007). In light
of the HAT-inhibitory effect of GRHL2 described above, we hypothesized that GRHL2 inhibited
the C-terminal domain through this mechanism. We confirmed that transcriptional activation by
the C-terminal domain, assayed as a GAL4-C-term fusion protein, was stimulated by a cotransfected p300 HAT domain, and that the latter domain had no detectable ability to activate
transcription independently (figure 5A). GRHL2 inhibited the enhanced transactivation by the
p300 C-terminal domain in the presence of co-transfected p300 HAT (figure 5B). Embedded
within the C-terminal domain is a small sub-domain called the IRF-3 Binding Domain (IBID;
amino acids 2050-2096) that mediates the interaction with the p160 co-activator family,
including the family member Steroid Receptor Coactivator-1 (SRC-1) (Sheppard et al., 2001).
While neither the IBID domain of p300 nor SRC-1 alone activated transcription efficiently, the
combination of both activated transcription, as reported previously (figure 5C) (Sheppard et al.,
2001). GRHL2 potently inhibited transcription that was driven by the complex of p300-IBID
and SRC-1 (figure 5D). Interestingly, mutation of the two lysines (K2086 and K2091) of the
IBID domain that are acetylated in vivo abrogated the ability of the p300-IBID/SRC1 complex to
activate transcription (figure 5E). These results indicate that the transcriptional activation by the
p300 C-terminus -- which is supported by SRC-1 and abrogated by GRHL2 – depends upon
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acetylation of at least these (and probably other) lysines by p300 HAT, or perhaps other GRHL2sensitive HATs that remain to be determined.
A small region of GRHL2 inhibits p300 and is critical for suppressing tubulogenesis and EMT
To identify the region of GRHL2 responsible for p300 inhibition, whole domains of
GRHL2 were deleted initially (figure 6A) and assayed for inhibition of HAT activity and
transcriptional activation by GAL4-p300. In light of the lack of GRHL2 binding sites in most
GRHL2-repressed promoters (data not shown), the surprising result was that the DNA binding
domain (amino acids 245-494) was critical for inhibition (figure S15, S16). GST-GRHL2
protein sub-fragments derived from the DNA binding domain were assayed for HAT inhibition
(figure 6B). The region 325-475aa, and within that, the thirteen amino acid sequence 425-437aa,
inhibited HAT activity potently (figure 6C), and a synthetic peptide (aa420-442) was also able to
inhibit p300 HAT activity (figure S15C). The 425-437 fragment (IRDEERKQNRKKG) is an αhelix conserved amongst GRHL1, GRHL2, and GRHL3 (Kokoszynska et al., 2008). A GRHL2
∆425-437 construct (with a synthetic nuclear localization signal) was unable to repress an AP-1promoter, GAL4-P300 transactivation (assayed on a GAL4-Luc reporter), the MMP1 promoter
or the MMP14 promoter (figure 6D). We recently reported that GRHL2 repressed the expression
of the glutamate dehydrogenase-1 gene (GLUD1), with important consequences for metabolism
and anoikis (Farris et al., 2016). Interestingly, GRHL2 also repressed this promoter in a manner
that required amino acids 425 to 437 (figure S17). GRHL2 ∆425-437 was still able to interact
with p300 in a co-transfection assay, however (figure S18).
We hypothesized that the inhibition of p300 function could provide a mechanism for
some aspects of transcriptional reprogramming by GRHL2. Consistent with the inability of the
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GRHL2 ∆425-437 to repress the AP1-dependent promoters MMP1 and MMP14 (figure 6C), this
mutant was unable to suppress HGF-induced tubulogenesis in MDCK cells (figure 7A).
Moreover, wild-type GRHL2 reverses EMT in Mesenchymal Subpopulation (MSP) cells, a
cancer stem cell-like subpopulation derived from the mammary epithelial cell line HMLE
(Cieply et al., 2012; Cieply et al., 2013). The GRHL2 ∆425-437 mutant failed to reverse EMT,
by the criteria of cell morphology as well as EMT marker protein and mRNA expression (figure
7B). These results indicated that the inhibition of p300 by GRHL2 contributes significantly to
transcriptional reprogramming involved in both tubulogenesis and EMT (figure 8).
DISCUSSION
Previously, we proposed that the epithelial cell is the default phenotype from both
developmental and cancer biologic points of view. Under this hypothesis, the epithelial
phenotype is adopted automatically by a cell in the absence of genomic/epigenetic alterations or
inductive differentiation signaling (Frisch, 1997). Consistent with this idea, E-cadherinexpressing cells are the first to emerge at the late two cell stage; these eventually give rise to all
differentiated cell types of the adult organism (Hyafil et al., 1980; Vestweber and Kemler, 1985;
Fleming et al.,1989; Larue et al., 1994). The adenovirus-5 E1a protein, which interacts with and
negatively modulates p300, enforces an epithelial phenotype, suppresses EMT, enhances anoikis,
suppresses MMP expression, and exerts a ubiquitously acting tumor suppression effect in human
tumor cells (Frisch and Mymryk, 2002).
The default idea has been invoked in recent studies from other laboratories, to explain,
for example, the mesenchymal-epithelial transition (MET) occurring at metastatic sites (Thiery
and Sleeman, 2006; Polyak and Weinberg, 2009; Tam and Weinberg, 2013). The default
hypothesis could be explained molecularly if critical co-activators such as p300 were required
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for differentiation-specific but not epithelial-specific gene expression (Frisch, 1997).
Accordingly, we reported previously that GRHL2, shown here to antagonize the co-activator
p300, inhibits and reverses the oncogenic EMT, suppressing tumor initiation, drug-resistance and
anoikis-resistance (Cieply et al., 2012; Cieply et al., 2013).
The novel observation that GRHL2 antagonizes p300-dependent pathways in the context
of tubulogenesis provides a potentially unifying mechanism for both the developmental and
oncologic effects of GRHL2. GRHL2 probably regulates tubulogenesis by additional, p300independent mechanisms. For example, cells which fail to down-regulate GRHL2 appropriately
may fail to down-regulate cell adhesion molecules in response to morphogenic factors (Werth et
al., 2010; Senga et al., 2012). For example, E-cadherin relocalizes from cell junctions to diffuse
membrane pattern in protrusive cell extensions during tubulogenesis; this relocalization might be
envisioned to require GRHL2 down-regulation and subsequent loss of junctional complex
components in these specific cells (Pollack et al., 1998).
p300 contributes to tubulogenesis and cancer-related EMT in multiple important ways
providing a mechanism for GRHL2, via inhibition of p300, to suppress these processes. With
regard to cancer, transcription factors that utilize p300/CBP and additional coactivators that
interact with p300/CBP have been implicated in the oncogenic EMT, tumor drug-resistance and
tumor recurrence (Matthews et al., 2007; Qin et al., 2009; Santer et al., 2011; Zhou et al., 2012;
Delvecchio et al., 2013; Ringel and Wolberger, 2013; Yang et al., 2013; Xu et al., 2014; Cho et
al., 2015). The upregulation of matrix metalloproteases (MMPs) associated with the oncogenic
EMT requires AP-1, Ets and other p300-dependent factors (Westermarck and KÄHÄRi, 1999;
Sun et al., 2004; Chou et al., 2006; Clark et al., 2008; Lee and Partridge, 2010; Santer et al.,
2011).
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With regard to tubulogenesis, the p300-dependent Ets family transcription factors Etv4
and Etv5, are key transcriptional regulators of this developmental process (Yang et al., 1998;
Jayaraman et al., 1999; Goel and Janknecht, 2003; Foulds et al., 2004; Lu et al., 2009; Oh et al.,
2012; Wollenick et al., 2012). In addition, the family of p300-dependent TCF/β-catenin
transcription complexes is a central hub for Wnt signaling, crucial for nephron induction (Li et
al., 2007; Bridgewater et al., 2008; Miller and McCrea, 2010; Ma et al., 2012).
p300 activates transcription through an array of mechanisms; acetylation of histones,
acetylation of transcription factors, the binding of the p300 bromodomain to acetylated histones to
promote transcriptional activity, and recruitment of histone methyltransferases (e.g., Set1b
complex) (Mizzen and Allis; Ogryzko et al., 1996; Gu and Roeder, 1997; Ito et al., 2001; Wolf et
al., 2002; Stiehl et al., 2007; Chen et al., 2010; Tang et al., 2013). By inhibiting the p300 HAT
activity, GRHL2 could enforce an inactive state on p300 in at least two ways. First, p300 HAT
activity is substantially increased by auto-acetylation of an autoinhibitory loop on the HAT
domain, which GRHL2 would suppress, stably inhibiting the enzyme (Thompson et al., 2004).
Secondly, the p300 HAT domain potentiates p300 C-terminal domain (1665aa-2414aa)
transactivation (Stiehl et al., 2007), which GRHL2 blocked. The minimal domain for p300 Cterminal transactivation is amino acids 2000-2180 which include the IRF-3 binding domain (IBID)
(Lin et al., 2001; Matsuda et al., 2004). The p300 IBID domain cooperates with SRC1, a
p160/steroid receptor coactivator family member, to activate transcription (Sheppard et al., 2001).
By inhibiting the HAT activity of p300, GRHL2 suppressed co-activation by the p300-IBID
complex, which was highly dependent upon the two known acetylation sites, K2086 and K2091
for activity. Interestingly, SRC1-p300 has been shown previously to induce TWIST expression
and EMT in breast cancer (Qin et al., 2009), and GRHL2 is a potent EMT suppressor.
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Although more than four hundred DNA binding proteins interact with p300 and utilize it
as a co-activator, the inhibitory effect of GRHL2 on p300 is nearly unique, shared by only one
other family of proteins called the E1a-like inhibitor of differentiation (EID) proteins. EID1
inhibits p300 HAT activity (MacLellan et al., 2000) and EID3 blocks the SRC-1/CBP interaction,
while the mechanism of EID2 is controversial (Ji et al., 2003; Miyake et al., 2003; Båvner et al.,
2005). The effects of EID proteins upon EMT or tubulogenesis have not yet been investigated to
our knowledge.
GRHL2 regulates intracellular metabolism and this could indirectly affect p300 by altering
the levels of the co-factors for p300 HAT, acetyl-CoA or crotonyl-CoA (Li and Li, 2015; Farris et
al., 2016). This may provide an additional, more indirect mechanism for GRHL2 to affect p300
function.
In summary, p300 and related co-activators are crucial for cells to differentiate. Under the
default-phenotype hypothesis, this can be extended to critical roles in EMT, in contexts such as
tubulogenesis and oncogenesis. The inhibition of p300 by GRHL2 provides a mechanism for
GRHL2 to enforce the default epithelial phenotype.

MATERIALS AND METHODS
Cell lines
293 HEK cells without T antigen (Doug Black, UCLA, Los Angeles), MDCK cells (Clone M8
described previously in Frisch et al. (Frisch and Francis, 1994), and HT1080 cells (ATCC) were
cultured in advanced Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) with 10% fetal
bovine serum (Hyclone) and 1x penicillin-streptomycin-glutamine (PSG) (Invitrogen). miMCD-
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3 cells (ATCC) cultured in advanced DMEM:Ham’s F12 (Gibco) with 10% fetal bovine serum
and 1x PSG. HMLE and HMLE MSP cells were described previously (Cieply et al., 2013).
Generation of stable cell lines by retroviral transduction and lentiviral transduction
Full-length GRHL2/pMXS-IRES-Puro and retroviral packaging protocol were described
previously (Farris et al., 2016). GRHL2 ∆425-437 was subcloned into pMXS-IRES-Puro from
GRHL2 ∆425-437-NLS-3xFLAG/pCDNA3.1+. GRHL2 shRNA/pGipZ and scramble control
shRNA/pGipz were obtained from Open Biosystems and packaged as previously described
(Cieply et al., 2012). The shRNA construct in pTRIPZ was made by subcloning a MluI-XbaI
fragment from pGIPZ.
Cell Scattering Assays
MDCK cells were plated on collagen coated 6 well dishes to give 25% cell confluency on HGF
induction. Cells were treated with 60ng/ml recombinant human HGF (RD Systems) in DMEM
media or fresh DMEM media for the time periods indicated. The cells were imaged and then
harvested for protein or RNA analysis. Images were obtained using a Zeiss Axiovert 200M,
Axiocam MRM camera, Phase 20x/0.55, RT, Axiovision Rel. 4.8 software. Cell scattering time
lapse movies were taken every 15 minutes over a 24 hour period. Time lapse images were
obtained using a Nikon Eclipse TE2000-E with Photometrics CoolSNAP HQ2 Monochrome
CCD with Phase 40x/0.75 objective using Bioptechs Delta T4 Culture Dish Heater, Prior
ProScan II Encoded Motorized Stage, and OKO LABS Digital Stage Top Incubator (37 degrees
and 5% CO 2 ). For each data point, four 40x images were stitched together using 10% overlap
with background correction in NIS-Elements AR Nikon.
Western Blotting
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Protein lysates were incubated at 95 degrees for 5 minutes in 1X SDS lysis buffer (125mM TrisHCl, pH 6.8, 0.04% SDS, 0.024% bromophenol blue, 5% β-mercapatoethanol, and 20%
glycerol). SDS-Page was run in 4%-20% gradient Novex Tris-Glycine gel (Invitrogen).
Proteins were electrophoretically transferred to a polyvinylidene difluoride membrane
(Immobilon) in Tris-Glycine buffer with 5% methanol. Membranes were blocked for 1 hour in
1xTBS+ 5% nonfat milk. Primary and secondary antibodies were incubated in 1xTBS+5%
nonfat milk+ 0.1% Tween-20. Primary antibodies were incubated for 2hour/RT or overnight/4
degrees at 1:1000 dilution. Primary antibodies used were: GRHL2, rb (Sigma); β-actin, ms
(Thermo-pierce); Fibronectin, ms (BD Biosciences); Vimentin, ms ((Santa Cruz Bio-tech
[SCBT]); β-actin, ms (Sigma); E-cadherin, ms (BD Biosciences); β-catenin, ms (BD
Biosciences); GAPDH, ms (Origene); acetyl-lysine, rb (Millipore); H3K18AC, rb (Cell
Signaling [CS]); H3K27AC, rb (CS); total H3, rb (CS); GST, ms (Thermo-pierce); p300,rb
(SCBT sc-584); p300, rb (SCBT sc-585); FLAG, ms (Sigma); GAL4, rb (SCBT). Goat antirabbit or anti-mouse horseradish peroxidase conjugated secondary antibodies (Bio-rad) were
used at 1:3000 dilution and incubated for 1hour/RT. Western blot membranes were developed
using ECL-West Pico (Pierce) and analyzed using standard chemiluminescence techniques.
MDCK Tubulogenesis assay
MDCK Tubulogenesis assay was performed as previously described (Elia and LippincottSchwartz, 2001). Briefly, collagen matrix was made by mixing 10x MEM (Invitrogen), 100x PSG,
23.5g/L NaHCO 3 (Invitrogen), sterile water, and HEPES (Invitrogen) to working concentrations.
Vitrogen Bovine Collagen (Advanced Biomatrix 5005-b) was added to a final concentration of
2mg/mL. NaHCO 3 was used to bring the solution to pH 7.3 via pH strip indicator (Elia and
Lippincott-Schwartz, 2001). In a 24-well plate, 100µl of working collagen solution was placed in
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a 1.0 micron pore cell culture insert (Falcon) and allowed to solidify for 3 hours in tissue culture
incubator. Sub-confluent MDCK cells were trypsinized and counted using Countess Cell counting
machine (Invitrogen). Cells were pipetted into the working collagen solution to give a final
concentration of 5,000 cells/ml. Then, 250µl of cell/collagen solution was pipetted onto the presolidified collagen matrix in the cell culture insert. The cell-collagen matrix was allowed to
solidify for 2 hours at 37 degrees and 5% CO 2 and then 250 µl and 500µl of media were place on
cell-collagen matrix cell culture insert and in 24 well the, respectively. Media were changed every
3 days. After 6 days, 60 ng/ml recombinant human HGF was added to indicated wells, and
branching morphogenesis was monitored by microscopy. MDCK cyst staining was performed as
previously described (Elia and Lippincott-Schwartz, 2001), with the only modification being the
substitution of 7mg/mL fish skin gelatin for Triton X-100 in permeabilization buffer. Cysts were
stained with Alexa Fluor 488 Phalloidin (Molecular Probes) and Hoescht 33258 (Molecular
Probes). Representative 2 day post-HGF images were obtained using a Zeiss 710 Confocal with
Airyscan, Apochromat 40x/1.2 W Autocorr M27, RT, AxioObserver.Z1 software, and Diode 405
and Argon 488 lasers. Images were processed in Adobe Photoshop. Tubulogenesis was observed
by day 2 post-HGF addition and quantified on day 5 post-HGF addition.
RNA-Seq Assay
MDCK+GRHL2/pMXS and MDCK+shGRHL2/Gipz cells were plated in collagen coated
60mm2 dishes to obtained 25% confluency upon HGF treatment. Cells were treated with either
60ng/ml HGF in DMEM complete or DMEM complete media alone for 24 hours; RNA was
isolated from all four treatment conditions in triplicate using the RNeasy Plus Kit (Qiagen) and
quantified using Nandrop (Fischer). Raw data were aligned to the CanFam3 reference genome
using TopHat2 (Kim et al., 2013). For each sample and each gene, the number of reads
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generated from that sample and mapping to that gene were counted using RSamtools. Genes
were as defined in the ensembl database v82 (Cunningham et al., 2015). The resulting count
table was analyzed using DESeq (Anders and Huber, 2010), performing two independent
comparisons: samples with HGF compared to those without, with GRHL2 overexpressed, and,
samples with HGF compared to those without, both expressing GRHL2 shRNA. Genes were
considered differentially expressed if they showed a false discovery rate of 0.05 or less and a
fold change of 1.5 or higher in either direction. Genes found to be regulated by HGF with
shRNA against GRHL2, but not found to be regulated by HGF with GRHL2 overexpressed were
uploaded to Ingenuity Pathway Analysis (Qiagen), where a Core Analysis was performed using
default settings.
Quantitative reverse transcription PCR analysis
MDCK parent, GRHL2/pMXS, and shGRHL2/pGipZ cells were plated on collagen coated
60mm2 dishes and treated as indicated. Cells were harvested using RNAeasy Plus mini kit
(Qiagen), analyzed using Nanodrop, and converted to cDNA using SuperScript III First-Strand
Synthesis SuperMix (Invitrogen) with oligo dT primers and 1ug of RNA. cDNA was analyzed
using SYBR Green PCR Master Mix on an Applied Biosystems 7500 Real Time PCR System.
Values reported were determined using the delta delta CT method using canine CBX1 as internal
control. Primers were as follows: CBX1-F (AAGTATTGCAAGGCCACCCA), CBX-R
(TTTTCCCAATCAGGCCCCAA), GRHL2-F (TTCCTCCCCAGGAGAGATGG), GRHL2-R
(GGCCCAACACACGGATAAGA), MMP1-F (TGACTGGAAAGGTCGACACG), MMP1-R
(GACCTTGGTGAAGGTCAGGG), MMP3-F (CTGACCCTAGCGCTCTGATG), MMP3-R
(GTCCTGAGGGATTTTCGCCA ), MMP13-F (GGACTTCCCAGGGATTGGTG), MMP13-R
(ATGACACGGACAATCCGCTT), MMP14-F (CCCAGAGGAGGGCATGTTTT), MMP14-R
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(GACTCCCCACCCTTCCAATG), FOS-F (GGGAGGACCTTATCTGTGCG), FOS-R
(ACACACTCCATGCGTTTTGC), FOSL1-F (ACACCCTCCCTGACTCCTTT), FOSL1-R
(CTGAAGAGGGCATGGGATTA), FOSB-F (GGAGAAGAGAAGGGTTCGCC), FOSB-R
(CACAAACTCCAGACGCTCCT), JUN-F (GACCTTCTACGACGATGCCC), JUN-R
(TTCTTGGGGCACAGGAACTG), JUNB-F (GTGAAGACACTCAAGGCCGA), and JUNB-R
(AGACTGGGGGAATGTCCGTA).
Luciferase Reporter Assays
HT1080 or 293 NOT cells were transiently transfected using Lipofectamine 2000 (Invitrogen) at
a 1µg DNA: 3µl Lipofectamine ratio. After 20 minute incubation in 300µl of Opti-MEM
(Invitrogen), a total of 1.0µg of DNA was transfected into a 12 well with DMEM media and
refeed 4 hours later with DMEM media. After 28-36 hours post-transfection, the cells were
washed twice with cold PBS, lysed in 200µl of 1x Cell Culture Lysis Buffer (Promega), frozen
for at least 1 hour at -80 degrees, thawed on ice, and centrifuged at 13,200rpm. The supernatants
were assayed for luciferase activity (Promega) and β-galactosidase activity as internal control
(2x β-galactosidase assay reagent, 200mmol/l sodium phosphate, pH 7.3, 2mmol/L MgCl 2 ,
100mmol/L 2-mercaptoethanol, and 1.33mg/mL o-nitrophenylgalactoside). MMP1 promoter (1200 to +60) and MMP14 promoter (-1114 to -242) luciferase reporter plasmids were generated
by subcloning the promoter from genomic DNA using PCR into the pGL3-basic luciferase
reporter plasmid. Primer sequences were: MMP1prom-F
(TTATTACTCGAGCCCTCCCTCTGATGCCTCTGA), MMP1prom-R
(TATATAAAGCTTCTCCAATATCCCAGCTAGGAA), MMP14prom-f
(TTATTACTCGAGCCCTTTCTCACGGTCAGCTT), MMP14prom-R
(TATATAAAGCTTTCTCGCTCTCTCCTCTGGTC). GRHL2/pcDNA3.1, TK-LacZ and
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E1a/pCDNA3.1 plasmids were described previously (Grooteclaes and Frisch, 2000; Cieply et al.,
2012). E1A p300 binding mutant was a generous gift from Arnold Berk (UCLA, Los Angeles,
California) subcloned into pCDNA3.1+. GRHL2 ∆425-437 was generated by cloning GRHL2
1-424aa and GRHL2 438-625aa fragments and ligating together with Bglll and then ligating into
pCDNA3.1+ using BamHI and Sal1. Primers used were GRHL2-1-424-F
(TATATAGGATCCATGTCACAAGAGTCGGACAA), GRHL2-1-424-R
(ATATAAAGATCTTTTTCTTTCTGCTCCTTTGT), GRHL2-438-625-F
(TAAATTAGATCTAAAGGCCAGGCCTCCCAAAC), GRHL2-438-625-R
(TTATATGTCGACCTAGATTTCCATGAGCGTGA). pGL4.44[luc2P/AP1 RE/Hygro]
(Promega) was used to assay for AP-1 responsive promoter activity and control plasmid was
pGL4.27 (Promega). Phorhol 12-myristate 13-acetate (PMA) induction (10ng/mL)
(ThermoFisher) was used for assaying AP-1 activity in tranfected 293 cells. Full length p300GAL4/VR1012 and EV-GAL4/VR1012 were generous gifts from Neil Perkins (Newcastle
University, UK); they were assayed on the GAL4 responsive reporter pG5-Luc (Promega).
GAL4- p300 HAT (1283-1674aa), GAL4- p300C-terminus (1665-2414aa), and GAL4- p300
IBID (2050-2096) were generated by subcloning PCR fragments (MluI-NotI) into pBIND
(Promega). Primer sequences were: p300 c-terminal-F
(TATATAACGCGTATCGCTTTGTCTACACCTGCAAT), p300 c-terminal-R
(TTTAAAGCGGCCGCCTAGTGTATGTCTAGTGTAC), p300 HAT-F
(TATATAACGCGTATAGGAAAGAAAATAAGTTTTCT), p300 HAT-R
(TTTAAAGCGGCCGCCTAGTCCTGGCTCTGCGTGTGCAG), p300 IBID-F
(TATATAACGCGTATGCCTTACAAAACCTTTTGCG), and p300 IBID-R
(TTTAAAGCGGCCGCCTAATTAGAGTTGGCATACTTGG). To generate the p300-IBID

71

Mutant (K2086A and K2091A), the p300 IBID lysine nucleotide sequences were mutated to
alanine and flanking Mlu1 and Not1 restriction enzyme were added to the 5’ and 3’ ends,
respectively. The sequence was then generated as a gBlock gene fragment (IDT). The p300
mutant sequence was 5’ CACAACCAGG ATTGGGCCAG GTAGGTATCA GCCCACTCGC
ACCAGGCACT GTGTCTCAAC AAGCCTTACA AAACCTTTTG CGGACTCTCA
GGTCTCCCAG CTCTCCCCTG CAGCAGCAAC AGGTGCTTAG TATCCTTCAC
GCCAACCCCC AGCTGTTGGC TGCATTCATC GCGCAGCGGG CTGCCGCGTA
TGCCAACTCT AATCCACAAC 3”. The IBID mutant fragment was digested and ligated into
pBIND vector. HA-SRC1/pACTAG was a generous gift from Timothy Beischlag (Simon Fraser
University, Canada).
Immunoprecipitation
GRHL2-STAP contained full-length human GRHL2 fused to a C-terminal myc-Streptavidin
Binding Peptide-S-Tag sequence derived by ligating a synthetic oligonucleotide containing the
S-tag to a PCR product containing the myc-SBP tags from the pCeMM-CTAP vector described
(Burckstummer et al., 2006). 293 NOT cells were plated on collagen coated 6 well dishes and
transfected using 1µg of empty vector/pCDNA3.1+ or GRHL2-S-TAP/pCDNA3.1+ and 1ug of
empty vector/VR1012 or p300/VR1012) with 6ul of lipofectamine (Invitrogen) in 300ul of OptiMEM (Invitrogen). Cells were incubated for 4-6 hours with DMEM media, and then refed with
DMEM media. After 28 hours post-transfection, cells were lysed in 600µl of cold p300 Lysis
Buffer (25mM Tris-HCl pH8, 75mM NaCl, 0.5mM EDTA, 10% glycerol, 0.1% NP40, and
protease inhibitor tablet (Roche)). Sample lysates were passed through 1ml syringe with 27g
needle 3 times and precleared in 4 degree microcentrifuge at 13,200rpm for 10 minutes. Total
lysate samples were obtained, mixed 1:1 with 2X SDS Lysis buffer (250mM Tris-HCl, pH 6.8,
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0.08% SDS, 0.048% bromophenol blue, 10% β-mercapatoethanol, 40% glycerol) and heated for
5 minutes at 95 degrees. Lysates were precipitated for 2 hours with 40ul of a 50% of S proteinagarose (EMD Millipore) which had been pre-equilibrated with p300 lysis buffer containing
10mg/ml BSA. Immunoprecipitation lysates were washed three times with p300 lysis buffer,
diluted with 2X SDS lysis buffer, and heated for 5 minutes at 95 degrees. Lysates were
processed using previously described western blotting methods. For Endogenous p300 and
Ectopic GRHL2 co-immunoprecipitation, MSP cells with empty vector/pMXS or GRHL2/pMXS
were used in the experiment. For endogenous p300 and endogenous GRHL2 coimmunoprecipitation, parental HMLE cells were used in the experiment. The coimmunoprecipitation method was identical between the different cell lines. For each cell line, 2
100mm dishes were grown to 80% confluency, washed twice with cold PBS, lysed in 1mL of
p300 lysis Buffer with protease inhibitors, and passed through 27g needle three times. After
lysates were precleared at 13,200rp, 10µg of p300 antibody (SCBT, SC-584) or rabbit IgG
(Jackson) was added to lysates and incubated overnight on 4 degree wheel. Pre-equilbrated
Protein A-Sepharose (45µl) (GE Healthcare) was added and incubated for 90 minutes. Samples
were washed 3 times in p300 lysis buffer, added 45ul of 2X SDS lysis buffer, and heated at 95
degrees for 5 minutes. Lysates were processed using previously described western blotting
methods.
Histone Acetylation Assays
Histone acetylation reactions contained indicated amounts of recombinant baculovirus flagtagged p300 (37.5ng) (Active Motif) or baculovirus p300 HAT (1283-1673) (Sigma), 250ng of
H3 (Cayman), 100 µM acetyl-CoA (MP Biomedical), and indicated amounts of prescission
cleaved GRHL2, GST-GRHL2 or GST alone in 30µl of p300 acetylation buffer (50mM Tris73

HCl pH 8.0, 1mM DTT, 0.1mM EDTA, 10% glycerol and protease inhibitor). Acetylation
reactions were incubated for 15 minutes at 30 degrees on heat block. Reactions were diluted
with 2x SDS Lysis buffer and incubated for 5 minutes at 95 degrees. Lysates were processed
using previously described western blotting methods.
Recombinant protein purification
Full length GRHL2 was subcloned into pGEX-6P-3 vector (GE Healthcare) and transformed in
to BL21 bacteria (Invitrogen). GRHL2 fragments were subcloned into pGEX-6p-3 using
BamH1 and Sal1. A colony was selected and grown in 20mL of LB+amp overnight at 37
degrees. The following day, 10 mL of culture was inoculated into 500 mL of LB+amp and
incubated for approximately 2 hours at 37 degrees with shaking until OD~ 0.6 was obtained.
IPTG was added to final concentration of 0.1mM and incubated overnight on shaker at room
temperature. The bacteria were spun in chilled centrifuge for 10 minutes at 5000rpm. Bacterial
pellet was resuspended in 10 mL of BL21 lysis buffer (1xPBS, 1% Triton-100, 1mM DTT, 0.4%
lysozyme and protease inhibitor tablet), incubated for 10 minutes, and sonicated twice for 30
seconds. The suspension was cleared at 13,000 rpm for 10 minutes. To the supernatant, 150µL
of 50% glutathione-sepharose beads (GE Healthcare) was added and incubated for 2 hours with
rotation at 4 degrees. Glutathione-sepharose beads were washed three times with glutathione
washing buffer (1xPBS, 1mM DTT and 0.1% Triton-X) and eluted for 30 minutes with
glutathione elution buffer (100mM Tris pH 8, 150mM NaCl, 20mM Glutathione, and protease
inhibitors). Alternatively, glutathione-sepharose beads with GRHL2 protein attached were
washed 3 times in PreScission cleavage buffer (50mM Tris-HCl, 150mM NaCl, 1mM EDTA,
1mM DTT, pH 7.0). The GST-GRHL2 on glutathione-sepharose beads was cleaved by adding
80ul of Prescission Protease (GE Healthcare) per mL of PreScission cleavage buffer at 5 degrees
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overnight. The sample was spun at 2,000rpm and the supernatant with the GST cleaved GRHL2
was obtained. Proteins were dialyzed against p300 acetylation buffer overnight at 4 degrees
using 20,000 MWCO Slide-A-Lyzer MINI Dialysis Unit (Thermo-Scientific). Protein was
analyzed on SDS-PAGE by Coomassie Blue staining and quantified by comparison of
Coomassie staining to a BSA standard and/or a BCA assay. Synthetic peptides were purchased
from ThermoFischer Scientific with n-terminus acetyl group and c-terminus amidation: GRHL2
420-442aa (GAERKIRDEERKQNRKKGKGQAS) and scramble (IDEKNKGRERQRK)
Chromatin Immunoprecipitation (ChIP)
For ChIP assay, HT1080 cell lines expressing empty vector/pMXS or GRHL2/pMXS cells were
used, and chromatin generated as described previously with the following modifications (Kumar
et al.): (i) Immunopreciptation was performed with 3ug of H3K27-Ac antibody (Cell Signaling)
or rabbit IgG (Jackson) to 3.3x106 cell-equivalents in ChIP RIPA buffer. (ii) Protein A-sepharose
was used instead of FLAG-agarose beads. (iii) qPCRs were performed using 2X SYBR green
master mix (Applied Biosystems; 10 uL), 0.08 uL of 100 micromolar primer, 1 uL ChIP DNA in
a 20 uL reaction. Primer sequences were as follows: MMP1-1-F
(AACCTCAGAGAACCCCGAAG), MMP1-1-R (TACTAACACTGCGCACCTGA) MMP1-2F (CAGAGTGGGGCATGAGTAGG), MMP1-2-R (TGTCTTCGGTACTGGTGACC),
MMP14-F (AAGTAAGTGAGCTTCCCGGC), MMP14-R (GGAGTTCGCCCCAGTTGTAA),
MMP2-F (TCGCCCATCATCAAGTTCCC), MMP2-R (CCCCCAAGCTGTTTACCGAA),
ZEB1-1-F (GCGAGGCGTGGGACTGATGG), ZEB1-1-R (AAAGTTGGAGGCTCGGCGGC),
ZEB1-2-F (CTGCACGGCGATGACCGCT), ZEB1-2-R (TTCCGCTTGCCAGCAGCCTC),
CDH1-F (ACTCCAGGCTAGAGGGTCACC), CHD1-R
(CCGCAAGCTCACAGCTTTGCAGTTCC), ESRP1-F (GGGAGCTTGGTCAAGTCAAC),
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ESRP1-R (TCTTAAATCGGGCCACGCAG), RAB25-F (AGGTCCTGTCCCTTTTTCGC),
RAB25-R (TTGGGGGTAAGGGGACTTCT), GAPDH-F (ATGGTTGCCACTGGGGATCT),
and GAPDH-R (TGCCAAAGCCTAGGGGAAGA). Results were normalized to GAPDH
values.
Ex Vivo Kidney Culture
All experiments involving mice were approved by WVU IACUC. Hoxb7creEGFP transgenic
mice and ex vivo kidney culture method were described previously (Zhao et al., 2004). We
removed embryonic kidney at E13.5 and the kidneys were cultured in 1uM batimastat (Tocris) or
vector in culture media for 48 hours. Images were taken of GFP ureteric buds on Olympus
MVX10 Macro Zoom, ORCA-Flash 4.0 Monochrome camera, Objective 2x, Zoom 4x, FITC,
and using CellSen Imaging Software. Ureteric buds were counted for quantification.
Confocal microscopy of transfected RRE.1 cells
RRE.1 cells, wt e1a-NLS-LacI-mCherry, and empty vector NLS-LacI-mCherry were
generous gift from Arnold Berk (UCLA, Los Angeles) and experiment was performed as
previously described (Verschure et al., 2005; Ferrari et al., 2014). GRHL2 was subcloned into
empty vector NLS-LacI-mCherry using Sal1. Images were taken on Zeiss Axiolmager Z1
microscope LSM 510 Confocal, 63x/0.75 LDPlan-neofluar, DAPI and Rhodamine, and Zeiss
Zen Software. Images were quantified using mean area on Image J.
Statistical Analysis
Error bars in graphs represent standard deviation. P-values were calculated using a
Student’s two-tailed t-test.
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Table 1.

Genes regulated by GRHL2
Gene ID

Fold Change

Significance

(shGRHL2+HGF/GRHL2+HGF)
MMP-1

Interstitial collagenase, necessary for MDCK

31.7

tubulogenesis, p300-dependent expression
MMP-9

Gelatinase B, p300-dependent cancer

5.8

invasiveness, upregulated in EMT
MMP-13

Collagenase 3, Necessary for MDCK

15.1

tubulogenesis, p300-dependent expression
MMP-14

Membrane-type matrix metalloprotease, involved

5.82

in EMT regulation and invasiveness phenotype
MMP-19

3.5

MMP-24

9.6

Increases invasion in multiple cancers

Table 1- HGF-induced MMPs expression in absence of GRHL2 compared to the presence of
GRHL2
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Figure Legends

Figure 1. GRHL2 suppresses HGF-induced cell scattering and tubulogenesis, and is downregulated by HGF. A. HGF induction downregulates endogenous GRHL2 protein. Western blot
and densitometric quantitation of HGF treatment time course in MDCK cells are shown. HGF
induction downregulates endogenous GRHL2 mRNA in MDCK cells; qPCR results expressed as
ratios compared to vector control. B. Constitutive GRHL2 expression in MDCK cells suppresses
HGF-induced cell scattering; images represent representative morphologies of cells treated for
42 hours. C. GRHL2 knockdown in enhanced HGF-induced cell scattering (16 hours), but
MDCK shGRHL2 cells did not undergo an EMT phenotypic change when EMT markers were
examined via western blotting. D. Constitutive GRHL2 expression in MDCK cells prevents
tubulogenesis (blue-nuclei and green-actin). Scale bar equals 20 microns. Graph represents
quantification of percentage of cysts that demonstrated tubulogenesis.
Figure 2. GRHL2 suppresses the induction of MMP genes and MMP promoters by HGF.
A. GRHL2 suppresses the induction of MMP genes (qPCR analysis; EN: endogenous GRHL2,
CE: constitutively expressed GRHL2, KD: GRHL2 shRNA knockdown). B. GRHL2 suppresses
the induction of MMP promoters by HGF. HT1080 cells were cotransfected with either MMP1
or MMP14 promoter-luciferase reporter constructs and GRHL2, E1A, or empty expression
vectors. Values represent relative luciferase activity normalized to TK-β-galactosidase control.
Figure 3. GRHL2 suppresses AP-1 and p300 function. A. GRHL2 suppresses AP1 function.
HT1080 and 293T cells were cotransfected with AP-1 response element- luciferase reporter
construct and GRHL2 expression vector or empty vector. Phorhol 12-myristate 13-acetate
(PMA) was used to induce AP-1 signaling in 293T cells. Values represent relative luciferase
activity normalized to TK-β-galactosidase control. B. Venn diagram comparing GRHL2-
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repressed genes (Farris et al., 2016) vs. p300 target genes identified via E1a (Ferrari et al., 2014).
C. GRHL2 suppresses the p300 pathway. p300 effector and target genes induced by HGF in
MDCK cells with GRHL2 shRNA vs. cells with constitutive GRHL2 determined by IPA
analysis quantitation of the number of unregulated, HGF up-regulated or HGF down-regulated
genes for both cell lines is shown in the graph. The p300 interactome diagram on which this is
based is shown in figure S7. D. GRHL2 suppresses p300 function. GAL4-minimal promoterluciferase activation by a co-transfected GAL4-p300 was assayed in HT1080 cells in the
presence or absence of cotransfected GRHL2 expression vector; values represent relative
luciferase activity normalized to TK-β-galactosidase control.
Figure 4. GRHL2 suppresses the HAT activity of p300. A. In vitro HAT assays with
recombinant H3, p300 and GRHL2 proteins. Coomassie stains to assess the quality of
recombinant proteins used throughout this study are shown in figure S19. B. GRHL2 inhibits the
acetylation of H3 on GRHL2-repressed but not GRHL2-induced promoters in vivo (ChIP assay).
Crosslinked chromatin from HT1080+vector HT-1080+GRHL2 cells immunoprecipitated with
H3K27-Ac or rabbit IgG; the indicated promoters were assayed for H3K27Ac by qPCR using the
primers in Materials and Methods. * indicates p values of < 0.05. GRHL2 does not affect global
histone H3K18-Ac or H3K27-Ac (western blotting of total histones). C. GRHL2 interacts with
p300. (left panel): co-transfection of indicated expression constructs, followed by coimmunoprecipation/western blotting; (middle panel): co-immunoprecipitation of retrovirally
expressed S-tagged GRHL2 with endogenous p300; (right panel): co-immunoprecipitation of
endogenous GRHL2 and endogenous P300.
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Figure 5. GRHL2 inhibits the C-terminal transactivation domain of p300. A. The p300 HAT
domain stimulates transactivation by the p300 C-terminus (co-transfection in HT1080 cells). B.
GRHL2 inhibits transactivation by the p300 C-terminus. HT1080 cells were cotransfected with
GAL4 response element luciferase reporter in the presence of the indicated expression
constructs. C. The IBID domain of p300 and the co-activator SRC-1 synergize to activate
transcription. HT1080 cells were cotransfected with GAL4 response element luciferase reporter I
in the presence of the indicated expression constructs. D. GRHL2 inhibits transactivation by the
IBID-SRC-1 complex. HT1080 cells were cotransfected with GAL4 response element luciferase
reporter in the presence of the indicated expression constructs. E. Transactivation by the IBIDSRC-1 complex is contingent upon lysines 2086 and 2091. HT1080 cells were cotransfected
with GAL4 response element luciferase reporter in the presence of the indicated expression
constructs. (a-e):Values represent relative luciferase activity normalized to TK-β-galactosidase
control. F. Schematic of p300 domains. KIX- CREB-binding domain, Bd- bromodomain, HAThistone acetyltransferase domain, and IBID- IRF-3 binding domain.

Figure 6. A small region within the DNA binding domain of GRHL2, amino acids 425-437,
inhibits p300. A. Schematic of GRHL2 domains. TAD- transactivation domain , DBD- DNA
binding domain, and DD- dimerization domain. B. HAT assays using the indicated GRHL2
fragments, assayed as GST-fusion proteins C. GRHL2 aa425-437 inhibits p300 HAT activity.
The indicated fragments derived from GRHL2 were assayed as GST-fusions (left panels) or as
recombinant peptides (right panel) for inhibition of HAT activity. D. GRHL2 amino acids 425437 are required for inhibition of an AP-1 reporter, GAL4 reporter in conjunction with GAL4-
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p300, MMP1 reporter or MMP14 reporter. Values represent relative luciferase activity
normalized to TK-β-galactosidase control.
Figure 7. The p300-inhibitory domain of GRHL2 is important for the suppression of
tubulogenesis and reversion of EMT. A MDCK cells expressing GRHL2 wild-type or GRHL2
∆425-437 were assayed for tubulogenesis (blue-nuclei and green-actin). Scale bar equals 20
microns.; quantitation is shown in the middle panel and Western blot confirmation of protein
levels in the right panel. B. MSP cells expressing GRHL2 wild-type or GRHL2 ∆425-437 were
assayed for reversion of EMT, by western blotting for EMT markers (left panel), cell
morphology (middle panel), or qPCR (right panel).
Figure 8. GRHL2 suppresses tubulogenesis and EMT by inhibition of p300.
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Supplemental Figure Legends

Figure S1. GRHL2 shRNA accelerates HGF-induced cell scattering (videomicroscopy).
Cell scattering time lapse movies were taken every 15 minutes over a 24 hour period. Time
lapse images were obtained using a Nikon Eclipse TE2000-E with Photometrics CoolSNAP HQ2
Monochrome CCD with Phase 40x/0.75 objective. (left panel): MDCK + vector; (right panel):
MDCK+GRHL2 shRNA
Figure S2. GRHL2 did not affect Erk or Akt signaling downstream of HGF/Met. Lysates
from HGF induction time course using the indicated cell lines was analyzed by western blotting
using the indicated antibodies. Densitometry data represent ratios of phospho-Akt or phosphoERK to the corresponding total protein levels.
Figure S3. Effect of GRHL2 on cyst formation. A. Constitutive GRHL2 expression in
mIMCD-3 cells prevents tubulogenesis. B. Knockdown of GRHL2 prevents cyst formation in
MDCK. (left panel) GRHL2 knockdown by western blotting. (middle panel) Quantification of
cysts per well. (right panel) Representative images from MDCK collagen cysts
Figure S4. Knockdown of GRHL2 following cyst formation (inducible shRNA) promotes
tubulogenesis. A. MDCK cells with doxycycline inducible GRHL2 shRNA were induced with
HGF in the presence or absence of doxycycline to induce GRHL2 shRNA. Cyst extensions were
quantified 24 hours after HGF induction. Quantification indicates the number of cysts that did
not have extensions at 24 hours. B. GRHL2 does not alter proliferation in MDCK cells. The
indicated cell lines were plated at equal density and counted in triplicate wells at three days postplating.
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Figure S5. MMPs are important for kidney tubulogenesis. E13.5 ex vivo mouse kidney
cultures were grown for 48 hour with batimastat or solvent control and imaged. Ureteric buds
were counted for quantification.
Figure S6. GRHL2 did not affect FOS or JUN family members. FOS, FOSL1, FOSB, JUN,
and JUNB mRNA expression levels were determined in the indicated cell lines at one or four
hours post-HGF induction via qPCR.
Figure S7. GRHL2 suppresses the p300 pathway. p300 effector and target genes induced by
HGF in MDCK cells with GRHL2 shRNA vs. cells with constitutive GRHL2 determined by IPA
analysis quantitation of the number of unregulated, HGF up-regulated or HGF down-regulated
(red=up-regulated, green=down-regulated, and grey=unregulated)
Figure S8. Validation of p300-dependence of reporter assays using WT vs. p300-nonbinding mutant of E1A. HT1080 cells were cotransfected with the indicated reporters and
expression constructs. Values represent relative luciferase activity normalized to TK-βgalactosidase control.

Figure S9. Further validation of reporter assays: A. c-Myc did not inhibit GAL4-p300 pG5
assay. B. GRHL2 did not inhibit GAL4-VP16 activation of GAL4- responsive element.
HT1080 cells were transfected with the indicated reporters and expression constructs. Values
represent relative luciferase activity with GRHL2 present compared to empty vector alone
normalized to TK-β-galactosidase control.

104

Figure S10. GRHL1 and GRHL3 inhibit transactivation by p300. HT1080 cells were
cotransfected with the indicated reporters and expression constructs. Values represent relative
luciferase activity normalized to TK-β-galactosidase control.
Figure S11. GRHL2 suppresses activity of the HAT domain (alone) of p300. Recombinant
GRHL2 inhibits recombinant p300 HAT (1283-1673) acetylation of H3K27 in a dose dependent
manner in the H3 acetylation assay. Coomassie stains to assess the quality of recombinant
proteins are shown in figure S19.
Figure S12. GRHL1 and GRHL3 inhibit p300 HAT activity. Recombinant GRHL1 and
GRHL3 inhibit p300’s acetylation of H3K27 in H3 acetylation assay. Coomassie stains to assess
the quality of recombinant proteins are shown in figure S19.
Figure S13. GRHL2 did not cause global changes in heterochromatin condensation like
E1A. (left panel) GRHL2-lacI-mCherry, E1a-lacI-mCherry or lacI-mCherry expression
constructs were transfected into RRE cells and confocal microscopic images of chromatin
condensation were quantitated.
Figure S14. Recombinant GRHL2 and p300 pulldown interaction. Recombinant GRHL2
and p300 were assayed for interaction by p300 IP/GRHL2 western blot.
Figure S15. Mapping of GRHL2 domains involved in inhibiting HAT activity in vitro. A.
Recombinant GST-GRHL2 fragments were generated without the GRHL2 transactivation
domain (136-625), DNA binding domain (∆245-494), or dimerization domain (1-520) and
assayed for inhibition of p300 HAT activity. B. Recombinant GST-GRHL2 fragments were
generated within the GRHL2 transactivation and assayed for inhibition of p300 HAT activity.
Coomassie stains to assess the quality of recombinant proteins are shown in figure S19. C.
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Synthetic peptide (aa420-442) and scramble peptide were assayed for inhibition of p300 HAT
activity. (right panel) Quantification of H3K27-Ac levels compared to no peptide control.
Figure S16. Mapping of GRHL2 domains involved in inhibiting transactivation by GAL4p300 in reporter assays. HT1080 cells were cotransfected with the indicated reporters and
expression constructs. Values represent relative luciferase activity normalized to TK-βgalactosidase control.
Figure S17. GRHL2 aa 425-437 important for repressing GLUD1 promoter through p300.
HT1080 cells were cotransfected with the indicated reporters and expression constructs. Values
represent relative luciferase activity normalized to TK-β-galactosidase control.
Figure S18. GRHL2 ∆425-437 interacts with p300 in a co-transfection assay. p300 and wt
GRHL2 or GRHL2 ∆425-437 expression vectors were transfected into 293 cells. Lysates were
immunoprecipitated with p300 antibody and probed for GRHL2 interaction.
Figure S19. Confirmation of recombinant proteins (Coomassie blue staining). A.
Prescission cleaved GRHL2 for figure 4A H3 acetylation assay. B. GST-GRHL1 and GSTGRHL3 for figure S12 H3 acetylation assay. C and D. GST-GRHL2 fragments for figure S15
H3 acetylation assay. E. GST-GRHL2 fragments for figure 6A H3 acetylation assay. F. GSTGRHL2 fragments for figure 6B H3 acetylation assay.
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